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Cardiovascular disease (CVD) is the leading cause of death among women in the US.  CVD is 
still thought to be a “man’s disease” and remains underappreciated by the public and under 
treated by health-care providers.  Yet, unlike men, a large proportion of deaths attributable to 
CVD occur in asymptomatic women, making early detection and diagnosis difficult.  Therefore, 
both the development of primary CVD prevention strategies to decrease the risk of CVD and 
screening tools that will aid in the early detection of women who are at increased risk for CVD 
has major public health implications.   
Hormone therapy (HT) has been shown to beneficially affect adverse changes to CVD 
risk factors that occur during menopause; however, HT is no longer indicated for general CVD 
prevention.  Increased physical activity (PA) levels, either separately or as part of a lifestyle 
intervention, may decrease CVD risk in women; however, previous reports have not adequately 
accounted for concurrent changes in HT status. 
Strategies for primary CVD prevention and early detection in postmenopausal women 
were examined using 508 women from the Woman on the Move through Activity and Nutrition 
(WOMAN) study.  At baseline, PA was found to be related to more favorable lipid and 
lipoprotein subclass levels; however, some of these associations were influenced by current HT 
use.  Results at 18 months suggested that a lifestyle intervention was effective for general CVD 
risk factor reduction regardless of HT continuation or discontinuation.  Additionally, lifestyle 
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 appeared to attenuate increases in lipid levels that resulted from discontinuing HT.  Finally, a 
simple walking endurance test may provide supplemental information when ascertaining CVD 
risk in women.   
In the post-WHI era, concern and confusion about the risks associated with HT has left 
women and health-care providers searching for alternative means to decrease risk of CVD.  
Findings from the current report suggest that a non-pharmacological approach for CVD risk 
factor reduction is both safe and effective for primary CVD prevention in postmenopausal 
women.  In light of the current controversies surrounding the use of HT, the promotion of 
healthy lifestyle behaviors for CVD risk factor reduction has important public health 
implications.    
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 1 INTRODUCTION 
1.1 MENOPAUSE AND CARDIOVASCULAR DISEASE RISK 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality among women in 
westernized countries.  In the United States (U.S.) alone, more than half a million women die 
each year as a result of CVD and CVD mortality rates continue to rise4.  In addition, a large 
proportion of deaths attributable to CVD occur in women with no previous symptoms, making 
early detection and diagnosis difficult1, 2.   
The escalating rates of CVD observed in older, postmenopausal women may be related to 
the substantial adverse cardiovascular changes that occur as a woman transitions from pre- to 
post-menopausal status.  In many women, CVD risk factors, including dyslipidemia, 
hypertension, abdominal adiposity, and insulin resistance develop during the menopausal 
transition5, 6.  The alterations in lipid metabolism caused by estrogen deficiency are thought to be 
a substantial component of CVD development in postmenopausal women.  In addition to the 
adverse changes in CVD risk factors, detrimental lifestyle changes, such as an increase in 
sedentary behaviors, that are common as one ages have been suggested to play a critical role in 
CVD development 3, 7-10.   
  1
 1.2 HORMONE THERAPY AND CARDIOVASCULAR DISEASE   
Results of past observational epidemiological studies suggested that postmenopausal women 
taking hormone therapy had a 40-50% reduction of CVD when compared to non-hormone 
therapy users 11.  However, recent evidence from randomized clinical trials has failed to validate 
the proposed cardio-protective benefits of hormone therapy.  The Heart and Estrogen/progestin 
Replacement Study (HERS), found that among postmenopausal women with documented CVD, 
there was an increased risk of future CVD events within the first year of study randomization 
among hormone therapy users 12.  Similar findings were observed in the Women’s Health 
Initiative (WHI).  The WHI consisted of three separate study arms: 1) low-fat dietary pattern, 
calcium and vitamin D supplementation, 2) combined estrogen and progestin, and 3) estrogen 
only.  In 2002, the combined estrogen and progestin arm was terminated early due to growing 
evidence that women without previous CVD who were randomized to receive the combined 
hormone therapy had an increased risk of CVD, stroke, pulmonary embolism, and breast cancer 
13.  In 2004, the estrogen alone arm was discontinued as well because results suggested that 
estrogen therapy increased the risk of stroke and did not appear to reduce the risk of CVD14.  
Findings from these studies have culminated in changed recommendations for prescription and 
distribution of hormone therapy in postmenopausal women 15, 16.  Current guidelines recommend 
against the routine use of combined estrogen and progestin or unopposed estrogen for the 
prevention of cardiovascular disease in postmenopausal women 17. 
Beyond CVD incidence, hormone therapy has also been shown to impact a number of 
CVD risk factors.  In general, hormone therapy has been suggested to alter the lipid profile in 
postmenopausal women.  When compared to non-hormone therapy users, women taking 
hormone therapy consistently had decreased LDL and increased HDL and triglyceride levels as 
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 measured by traditional measures3, 7, 9, 18, 19.  All can be considered beneficial changes with the 
exception of elevated triglycerides.  Additionally, results from the combined estrogen and 
progestin arm of the WHI study suggested that women randomized to hormone therapy had 
greater reductions in both insulin and glucose levels.  However, systolic blood pressure among 
the group receiving combination therapy was 1 mmHg higher at the first year follow-up visit and 
remained 1 to 2 mmHg higher at subsequent follow-up visits.  Diastolic blood pressure did not 
differ between groups 20.  This recent evidence from randomized clinical trials has failed to 
validate the cardio-protective benefit of hormone therapy.  Therefore, other strategies need to be 
pursued in order to decrease CVD risk in women.   
1.3 PHYSICAL ACTIVITY LEVELS IN POSTMENOPAUSAL WOMEN 
One possible strategy for CVD prevention among older women may be to increase physical 
activity levels.  Participation in regular amounts of physical activity has been demonstrated to 
play a vital role in the health and well-being of individuals of all ages 21.  Regular physical 
activity levels may help prevent or control many chronic diseases such as cardiovascular disease 
22-24, diabetes 25-28, cancer 29, 30, depression 31, 32, and functional decline 33, 34.   
Despite the well established benefits, only 38.6% of adults reported being physically 
inactive during their leisure time, defined as never engaging in any light, moderate, or vigorous 
leisure time physical activity.  Additionally, over 68% of Americans did not meet the current 
minimum physical activity guidelines 35, defined as 30 minutes of moderate intensity activity, 
such as that of a brisk walk, on most if not all days of the week 21.   
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 Specific subgroups of the population, such as women, minorities, and the elderly are less 
likely to participate in regular amounts of physical activity 35.  Older, postmenopausal women are 
among the least active subgroups in America 35.  Higher rates of physical inactivity are 
particularly alarming due to the demonstrated beneficial link between physical activity and a 
number of conditions that affect older women.   
Previous reports suggest that individuals with regular physical activity levels have a 
reduced risk of developing CVD21-24, 36.  Inactive individuals are considered twice as likely to 
develop CVD as their active counterparts36.  The inverse association between physical activity 
and CVD development may be due in part to the beneficial role of physical activity on the 
underlying etiology of cardiovascular risk factors6, 37.  As a result, physical inactivity has been 
identified as a major modifiable risk factor for CVD development due in part to numerous 
associated physiological benefits 38.   
In general, physical activity has been shown to improve myocardial contraction, decrease 
resting heart rate, and increase stroke volume39, 40.  Additionally, there is improvement in 
endothelial function and flow-mediated dilation, increase in coronary artery formation and a 
decrease in clotting as a result of physical activity40-42.  Most of the past studies suggesting an 
inverse relationship between physical activity and CVD risk, many earlier studies were 
performed in men.  The assumed benefit of physical activity on CVD development in women 
was extrapolated from such data 43.  Only recent investigations on the relationship between 
physical activity and CVD development have specifically targeted older women.  Current 
evidence suggests that there is, in fact, a beneficial relationship between physical activity and 
CVD development among older, postmenopausal women 44-50.   
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 The inverse relationship between physical activity and CVD may be explained by the 
reduction of cardiovascular risk factors (ie. hypertension, diabetes) in women who are physically 
active.  However, the relationship between physical activity and lipids in postmenopausal women 
has been inconclusive51.  Some studies have demonstrated a beneficial relationship between 
physical activity and lipids, while others suggest no association.  To complicate matters, the 
association with physical activity may differ depending upon the specific lipoprotein in question.  
For example, some studies may suggest a positive association between physical activity and 
HDL levels; however, in the same investigation find no relationship between physical activity 
and other lipids.   
The inconsistent findings on the relationship between physical activity and lipids in 
postmenopausal women may be due to a number of factors.  For one, there were differences in 
the assessment of physical activity.  For example, some studies on physical activity and lipids 
assessed fitness levels using maximum VO2  testing 7, 8, 19, 52-55, rather than physical activity 
levels.  Secondly, the study population differed in their hormone therapy use.  Some studies 
included women taking hormone therapy52, 54, 55, while others specifically excluded hormone 
therapy users 56-58.  In addition, when controlling for hormone therapy during statistical analyses, 
some studies adjusted for current use of hormones52, 54, 55, while others adjusted for past hormone 
therapy use7.   
The relationship between physical activity and lipids in postmenopausal women may be 
better clarified using specific lipoprotein subclasses and not traditional cholesterol measures.  
Specific lipoprotein subclasses, such as LDL size, total and small LDL particle number may 
relate better to cardiovascular disease development than traditional measures 59.  Nuclear 
magnetic spectroscopy (NMR) is a relatively new technique that directly measures lipoprotein 
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 subclasses.  Little is known about the relationship between physical activity levels and 
lipoprotein subclasses and this relationship has yet to be explored in postmenopausal women on 
and off HT.    
Despite the inconclusive relationship between physical activity and lipid levels, physical 
activity has been suggested to be beneficially related to other CVD risk factors.  Regular activity 
improves the sensitivity of liver, skeletal muscle, and adipose tissue to insulin37-39.  Furthermore, 
physical activity decreases both overall body weight and visceral fat accumulation21, 60-63.  It is 
also well established that physical activity decreases blood pressure 21, 60, 64 and favorably alters 
markers of the inflammatory process65-69.   
In addition to examining the independent associations between physical activity and 
CVD risk factors, more recent randomized clinical trials have explored the combined effect of 
physical activity, diet, and weight loss (lifestyle based approach) on CVD risk factor reduction 
and/or chronic disease prevention.  Results from randomized clinical trials have demonstrated 
success in populations at risk for diabetes25-28 and heart disease70; however, few studies 
incorporating lifestyle changes have targeted women at or after menopause.  The Women’s 
Healthy Lifestyle Project (WHLP), a randomized clinical trial, examined the effects of a lifestyle 
intervention on CVD risk factor change from pre- to post-menopause71, 72.  Results from WHLP 
demonstrated that a lifestyle based approach was successful at preventing weight gain73 and rise 
in LDL-C levels74 among women in peri- to post-menopause.  However, these previous reports 
did not account for concurrent changes in HT status, an issue which has become particularly 
relevant in the post-WHI era.   
 
  6
 The identification of women who are at an increased risk of incident CVD is as important 
to primary CVD prevention efforts.  As stated above, a large proportion of CVD related deaths 
occur in women with no previous symptoms1, 2.  The identification of asymptomatic women who 
are at increased risk for CVD also has important public health implications.  Past 
epidemiological studies have suggested that exercise capacity and/or cardiovascular fitness is an 
independent predictor of cardiovascular events and death among asymptomatic women2, 75.  
However, the gold standard technique used to evaluate cardiovascular fitness levels [maximal 
oxygen uptake (VO2 max)] may not be financially practical in large epidemiological studies due 
to time constraints, staff burden, high equipment costs, and safety concerns76.  Tests of walking 
endurance, such as the long distance corridor walk (LDCW) have been substituted for this gold 
standard measure in older populations with promising results.  However, few data are available 
regarding the applicability of this test in middle-aged, postmenopausal women.   
1.4 STUDY GOAL 
The identification of safe and effective primary CVD prevention strategies and screening tools 
that will aid in the early detection of asymptomatic women who are at increased risk for incident 
CVD has major public health implications.  Therefore, the specific aims of the current 
investigation are to: 1). examine the cross-sectional relationship between physical activity, lipids, 
and lipoprotein subclass levels by current HT use, 2). determine the effect of lifestyle 
intervention on adverse CVD risk factor changes that may result from HT discontinuation, and 
3). investigate the utility of a walking performance protocol among a cohort of overweight, 
middle-aged postmenopausal women.  To accomplish these goals, we utilized a cohort of 508 
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 postmenopausal women, aged 52 to 62, enrolled in the Women On the Move through Activity 
and Nutrition (WOMAN) Study.  The WOMAN study is a randomized clinical trial of primary 
cardiovascular disease prevention in Pittsburgh, Pennsylvania (PA).  Eligibility criteria for 
enrollment into the study included waist circumference ≥ 80 centimeters (cm), body mass index 
between 25-39.9 kilograms per meters squared (kg/m2), not currently taking lipid lowering 
drugs, having a low density lipoprotein (LDL-c) level between 100-160 milligrams per deciliter 
(mg/dL), no physical limitation that would preclude walking, no known diabetes, and no 
diagnosed psychotic disorder and depression.   
The recruitment of eligible WOMAN study participants was directly impacted by 
publication of the results from the combined estrogen progestin arm of the WHI and resulted in a 
natural experiment.  Initial entry criteria for the WOMAN study required potential participants to 
be current HT users with at least two years of prior use.  Approximately midway through the 
recruitment process, results were publicized from the estrogen/progestin (E+P) arm of the WHI 
trial indicating adverse effects among HT users13.  In response to the WHI findings, the 
eligibility criteria in the WOMAN study were modified to include women with a recent history 
of HT use as it was deemed unethical to require potential participants to use HT.  As a result, 204 
(40.2%) of the WOMAN study participants were not current HT users at baseline.  The changes 
in these eligibility criteria have provided the unique and timely opportunity to investigate the 
separate and combined role of physical activity as part of a lifestyle intervention for CVD risk 
factor reduction by current HT use and during HT discontinuation.   
Using the WOMAN study cohort, we have the opportunity to clarify the cross-sectional 
associations between leisure physical activity and lipids using specific lipoprotein subclass 
measures and investigate how these relationships may be influenced by current HT use.  In 
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 addition to examining the independent contribution of physical activity for primary CVD 
prevention, we will also be able to investigate the effectiveness of a lifestyle intervention that 
includes physical activity in attenuating adverse changes to CVD risk factors that may develop as 
a result of discontinuing HT.  Finally, tests of walking endurance have been used with promising 
results for estimating fitness levels, functional ability, and general health status in older adults.  
However, little is known regarding the applicability of these tests in younger populations.  Data 
from the WOMAN study will allow us the opportunity to investigate the usefulness of the long 
distance corridor walk (LDCW) in middle-aged, postmenopausal women.   
Specifically, the study meets the following objectives: 
Paper 1: Examine the cross-sectional relationship between physical activity levels and 
lipoprotein subclasses by hormone therapy status at baseline.   
a. It is hypothesized that leisure physical activity will be beneficially related to some 
of the lipoprotein sub-classes in postmenopausal women; however, there will be a 
few lipoprotein subclasses in which physical activity is only significantly related in 
women not taking hormone therapy.  
Paper 2: To determine if a lifestyle intervention promoting weight and waist circumference 
reduction through beneficial physical activity and dietary practices can attenuate unfavorable 
CVD risk factor changes that are likely to occur as postmenopausal women discontinue hormone 
therapy (HT) use.   
a. It is hypothesized that discontinuation of hormone therapy has negative 
consequences on many CVD risk factors. 
b. A lifestyle intervention will attenuate these negative consequences of discontinuing 
hormone therapy with regards to many CVD risk factors. 
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 Paper 3: To determine the utility of the LDCW as a measure of health status in middle-aged, 
postmenopausal women. 
a. Walking performance, more specifically walk time, will be significantly related to 
demographic factors, anthropometric measures, subjective and objective measures of 
physical activity, and CVD risk factors in postmenopausal women.   
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 2 REVIEW OF LITERATURE 
In this literature review, the results of studies that have examined the relationship between 
physical activity (separately and as part of a lifestyle intervention), cardiovascular disease risk 
factors, and hormone therapy in postmenopausal women are presented.  In addition, the results of 
investigations that have utilized tests of walking endurance to determine associations with 
mortality and incident CVD are briefly outlined.  The strengths and weaknesses of the existing 
literature that lead to the development of the current project will also be discussed.   
 
2.1 MENOPAUSE AND CARDIOVASCULAR DISEASE RISK 
Currently, cardiovascular disease (CVD) is the leading cause of morbidity and mortality among 
older women and mortality rates continue to rise.  Coronary heart disease (CHD) accounts for the 
majority of CVD deaths in women and disproportionately affects racial and ethnic minorities4.  
In the past, the number of CVD related deaths was strikingly higher in men when compared to 
women.  Since 1984, the gap between male and females deaths attributed to CVD has narrowed 
dramatically4.  The reasons for this gender discrepancy are not well understood; however, studies 
have suggested that the clinical presentation of CVD in women differs from that of men.  A large 
proportion of deaths attributable to CVD occur in women with no previous symptoms1, 2, making 
  11
 early detection in women particularly challenging.  Risk factors suggested to be specific to 
development of CVD in women include dyslipidemia, inflammation, and insulin resistance77.   
Menopause is defined as the permanent cessation of menses.  The menopausal transition 
defines the period of time in a woman’s life between her pre- and post-menopausal years.  
During this time, levels of endogenous sex hormones such as estrogen decrease.  The lack of 
estrogen is thought to be related to unfavorable changes in cardiovascular risk factors.  In many 
women, CVD risk factors, including dyslipidemia, hypertension, abdominal adiposity, and 
insulin resistance begin to develop during the menopausal transition5, 6.  These changes have 
been suggested to explain the increase in development of CVD in older, postmenopausal women.   
One consequence of estrogen loss at menopause is an increase in centralized, or intra-
abdominal fat78.  Higher intra-abdominal fat has been identified as an important CVD risk factor, 
independent of overall obesity79, due in part to its role in the development of dyslipidemia, 
inflammation, and insulin resistance6.  Furthermore, centralized adiposity is associated with a 
greater risk for type 2 diabetes, higher triglyceride levels, and greater number of atherogenic, 
small, dense LDL particles 80.   
Alterations in lipid metabolism caused by the excess in intra-abdominal fat are thought to 
contribute to the increase in CVD development in postmenopausal women.  The proposed 
mechanism by which centralized fat stores increase risk of dyslipidemia is outlined briefly.  It 
has been suggested that excess intra-abdominal fat is associated with an increase in insulin 
resistance, free fatty acid (FFA) levels, and decreased adiponectin (an adipocyte-derived 
peptide).  These factors contribute to the increased secretion of apolipoprotein B (apo B) 
containing particles, which subsequently lead to high triglyceride levels, as well as an increase in 
hepatic lipase activity (liver enzyme).  The increase in hepatic lipase activity results in a 
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 preponderance of small, dense LDL particles, which are thought to be atherogenic, and a 
reduction in larger, anti-atherogenic HDL particles 6.   
The increase in intra-abdominal fat is also associated with increased levels of 
inflammatory markers, including C-reactive protein (CRP).  Increased CRP levels have been 
shown to be a strong predictor of future cardiovascular events 81.  Centralized adiposity is also 
directly related to insulin resistance and compensatory hyperinsulinemia, independent of total 
body fat82.   
The adverse changes to cardiovascular risk factors among postmenopausal women, such 
as the development of dyslipidemia, are demonstrated in results published from the Healthy 
Women Study (HWS).  HWS was designed to investigate the changes in biological 
characteristics of a woman as she transitions through menopause.  At study entry, all participants 
were between the ages of 42 and 50 years and pre-menopausal.  Following the baseline 
assessment, women were asked to report their menstrual status on a monthly basis.  A woman 
was considered postmenopausal when she stopped menstruating and/or had taken hormone 
therapy for 12 consecutive months.  Study participants were re-evaluated at that time and 2, 5, 
and 8 years after menopause.  Changes in cardiovascular risk factors were then compared during 
the perimenopause (defined as premenopause to 1 year after cessation of menses) and early 
postmenopause (defined as 1 to 5 years after the menopause).  Results suggested that 
perimenopause was associated with increases in LDL cholesterol, triglycerides, and body mass 
index, while postmenopause was associated with increases in systolic blood pressure, pulse 
pressure, and fasting glucose 83.   
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 2.2 HORMONE THERAPY AND CARDIOVASCULAR DISEASE  
As mentioned previously, the lack of estrogen that accompanies menopause is related to a 
number of CVD risk factors, including dyslipidemia, inflammation, and insulin resistance.  As a 
result, the use of exogenous hormone therapy was thought to be a cardio-protective strategy in 
postmenopausal women. Earlier observational studies supported the beneficial relationship 
between hormone therapy use and prevention of CVD84-89.  A meta-analysis of epidemiological 
studies suggested that overall hormone therapy users had a 40-50% reduction of CVD risk when 
compared to non-hormone therapy users 11.  However, recent evidence from randomized clinical 
trials has failed to validate the proposed cardio-protective benefits of hormone therapy.   
The evidence for the relationship between hormone therapy and cardiovascular disease in 
postmenopausal women is presented in table 2.1 by type of study design.  Of the five hospital 
based case/control studies, one demonstrated a positive association 90, two a negative 
association91, 92, and two investigations suggested no association between hormone therapy and 
cardiovascular disease development 93, 94.  Population-based case/control studies found more 
promising results.  Of the eleven studies presented, nine found a negative association 95-103 and 
only two found no association between hormone therapy and cardiovascular disease 
development 104, 105.   
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 Table 2-1: Evidence for the relationship between hormone therapy and cardiovascular disease prevention 
 
Study Design  Association Studies 
Case-Control 
(Hospital 
Based) 
 0/+/-/0/- Rosenberg93;Jick90; Jick91; Rosenberg94; Szklo92 
Case-Control 
(Population 
Based) 
 -/-/-/-/-/-/0/-/-/-/0 Talbott95; Pfeffer96; Ross97; Bain98; Adam99; Beard100; 
Thompson104; Psaty101; Newton102; O’Keefe103; Sidney105 
Cross-Sectional  -/-/- Sullivan106; Gruchow107; McFarland108 
Prospective Includes 
Non-HT 
Users  
-/-/-/+/-/-/-/-/-/-/-
/-/-/-/-/-/ 
+ new use; 0 
prior-current use/ 
+ new use; - 
prior-current use/ 
+ new use; - 
prior-current use 
Hammond109; Lafferty110; Stampfer111; Wilson89; Bush112; 
Petitti113; Criqui114; Henderson115; Croft116; Hernandaz117; 
Sullivan118; Henderson119; Stampfer120; Wolf121; Sullivan122; 
Grodstein123; Alexander124; Heckbert125; Grodstein84 
 No Non-
HT Users 
-/- Burch126; Hunt127 
Randomized 
Clinical Trial 
 -/0/0/+/+/+/0 Nachtigall128; Hulley12; Herrington129; Waters130; Clarke131; 
Rossouw13; Anderson14 
+ indicates positive association (hormone therapy users had an increased CVD risk); - indicates negative association 
(hormone therapy users had a decreased CVD risk); 0 indicates no association 
 
The limitations of the case-control study design itself may partially explain the 
inconsistent findings that that are presented in table 2.1.   Case-control studies have a number of 
limitations, including the possibility of recall bias.  For example, it may be difficult for a woman 
to accurately recall the correct type, dosage and/or number of years that she had taken hormone 
therapy.  In addition, case-control studies often rely on existing medical records and proper 
selection and enrollment of an appropriate control group.  This is especially true in hospital 
based case-control studies where the distribution of a particular exposure, in this case hormone 
therapy, may not reflect the distribution of the hormone therapy in the general population132. 
As presented in table 2.1, all three of the cross-sectional studies demonstrated a negative 
relationship between hormone therapy and CVD.  The results from these studies suggest that 
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 current hormone therapy users had a decreased risk of cardiovascular disease when compared to 
non-hormone therapy users 106-108.   
The cross-sectional study design eliminates some of the restrictions of other study 
designs including case-control and prospective studies.  As compared to case-control studies, 
cross-sectional study participants no longer have to recall hormone use and are typically defined 
as current hormone therapy users or non-users.  Also, cross-sectional studies do not require the 
use of an appropriate control group.  These factors may partially explain the consistent findings 
from the cross-sectional studies.  Similarly, cross-sectional studies are not subject to limitations 
that are encountered when using prospective study designs.  In cross-sectional studies, there are 
no issues on misclassification of hormone therapy status, which may affect the results of 
prospective studies.   
Although, all three cross-sectional studies presented in table 2.1 suggested a negative 
association between hormone therapy and CVD, they are subject to a number of limitations.  
Cross-sectional studies cannot establish a temporal relationship between hormone therapy use 
and CVD.  Also, prevalent, rather than incident, cases of CVD are identified; therefore, a 
relationship between hormone therapy use and CVD may be associated with survival rather than 
risk of development of the disease132.   
Table 2.1 also presents the prospective studies that examined the relationship between 
hormone therapy and cardiovascular disease in postmenopausal women.  The results of these 
studies are broken down into prospective studies that included a group of non-hormone therapy 
users and those that included hormone therapy users only.  Of the nineteen prospective studies 
that included a group of non-hormone therapy users, fifteen demonstrated a negative relationship 
109-114, 119-123 and one a positive relationship 89 between hormone therapy use and cardiovascular 
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 disease risk.  The three remaining prospective studies included a group of postmenopausal 
women that were non-hormone therapy users.  These three studies found mixed results 
depending upon whether the woman was a new, current, or prior hormone therapy user. All three 
of these studies, suggested that new users had an increased risk of developing CVD, while prior 
or current hormone therapy users showed no additional benefit beyond non-hormone therapy 
users84, 124, 125.  Two studies presented in table 2.1 excluded non-hormone therapy users and 
demonstrated a negative association between hormone therapy and CVD 126, 127.  
Prospective study designs avoid the issues that affect other study designs.  One important 
benefit of prospective study designs is that a temporal relationship between hormone therapy use 
and CVD risk can be established when investigating this relationship.  However, as mentioned 
previously, prospective studies in which the exposure is only measured at one time point, may 
have problems with misclassification of hormone therapy status and may negatively impact the 
study results 132.  This may be one possible explanation for those prospective studies that did not 
suggest a negative association between hormone therapy and CVD. 
The evidence from randomized clinical trials is far more conclusive than observational 
studies.  The randomization process done in many clinical trials ensures that the study groups 
will be comparable in all respects except for hormone therapy status.  Therefore, hormone 
therapy use and risk of CVD can be more clearly studied, without the known and unknown 
influence of potential confounding factors 132.  An early randomized clinical trial found a 
negative association between hormone therapy and CVD risk 128. However, after ten years of 
follow-up, only 4 of the 168 total women randomized developed CVD.  The negative association 
that was suggested by this early study may have been due to the limited sample size as well as 
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 the low number of cardiovascular events that were observed.  Therefore, results from this 
randomized clinical trial may be difficult to interpret.  
Evidence from recent randomized clinical trials has failed to validate the results 
suggested by past observational studies.  The Heart and Estrogen/progestin Replacement Study 
(HERS), a secondary CVD prevention trial, found that among postmenopausal women with 
documented CVD there was an increased risk of CVD within the first year of study 
randomization for women randomized to hormone therapy 12.  Two additional secondary 
prevention studies found no association between hormone therapy and progression of coronary 
atherosclerosis 129, 130, while another found an increased risk of CVD among users of a 
transdermal estrogen patch 131.   
Primary CVD prevention randomized clinical trials were conducted in addition to 
secondary prevention trials.  The Women’s Health Initiative (WHI) was the foremost primary 
CVD prevention trial conducted in postmenopausal women.  The WHI focused on defining 
strategies that could potentially decrease CVD, breast and colorectal cancer, and fractures risk in 
postmenopausal women.  The WHI enrolled 161,809 postmenopausal women, aged 50 to 79 
years, between 1993 and 1998 across 40 clinical centers in the United States.  Eligible study 
participants were randomized into one of three separate study arms: 1) low-fat dietary pattern, 
calcium and vitamin D supplementation, 2) combined estrogen and progestin hormone therapy, 
and 3) hormone therapy consisting of estrogen only 13.   
The primary outcome for the estrogen plus progestin arm of the WHI was CHD.  CHD 
was defined as acute myocardial infarct (MI) requiring overnight hospitalization, silent MI 
determined from serial electrocardiograms, or CHD death.  The study population for this arm of 
the clinical trial included 16,608 women of which 8,506 received conjugated equine estrogens 
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 (0.625 mg/d, plus 2.5 mg/d medroxyprogesterone acetate) and the remaining 8,102 were given a 
placebo.  Formal monitoring began in 1997.  In 1999 the data safety monitoring board (DSMB) 
observed small, early adverse effects in cardiovascular outcomes, but none of the disease specific 
boundaries had been crossed.  Approximately three years later (2002), the DSMB observed that 
the adverse effects in cardiovascular diseases persisted, although these results were still within 
monitoring boundaries.  However, at this point, the boundary for breast cancer incidence had 
been crossed.  Based on these data, the DSMB concluded that the evidence for breast cancer 
harm, along with the increase in CHD and other cardiovascular disease outcomes, outweighed 
the benefit of reduced fractures and colorectal cancer.  As a result of these findings, the 
combined estrogen and progestin arm was terminated early after a mean follow-up of 5.2 years 
(planned duration was 8.5 years) 13.   
In 2004, the final results from the estrogen plus progestin arm of the WHI were published 
and provided an updated analysis of coronary endpoints (acute MI, silent MI, CHD death, 
angina, acute coronary syndromes, and congestive heart failure).  Women randomly assigned to 
receive estrogen plus progestin had a 24% higher risk of CHD when compared to women in the 
placebo group. Furthermore, the cumulative hazard rates of CHD showed an elevated risk among 
women taking estrogen and progestin soon after randomization and rates did not begin to 
converge between groups until 6 years post randomization.  Additional analysis was performed 
to determine whether certain subgroups of women were at a higher or lower risk for CHD with 
estrogen and progestin based on baseline levels of lipid, inflammatory and thrombotic 
biomarkers.  Only women randomized to hormone therapy, with higher levels of LDL 
cholesterol at baseline, had evidence of a pattern of hazard ratios for CHD that were different 
from patterns found among other women (Manson, 2003).   
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 Similarly, the primary outcome for the estrogen only arm of WHI was CHD 
development.  Again, CHD was defined as acute myocardial infarct (MI) requiring overnight 
hospitalization, silent MI determined from serial electrocardiograms, or CHD death.  The study 
population for this arm of the clinical trial included 10,739 postmenopausal women with prior 
hysterectomy.   Women were randomly assigned to receive either conjugated equine estrogens 
[n=5310 (0.625 mg/d)] or placebo (n=5429).  As with the combined hormone therapy arm, 
formal monitoring of disease rate comparisons began in 1997 by the DSMB.  In early 2000 and 
again in 2001, the DSMB recommended that participants in both arms of the study be informed 
of the early increases in CHD, stroke, and blood clot development that was found in women 
taking either form of hormone therapy.  After the early termination of the estrogen and progestin 
arm, participants in the estrogen alone arm were notified about the increase in breast cancer that 
was observed in the E+P arm.  In 2004, after additional review, the National Institutes of Health 
(NIH) decided to stop the intervention phase of the trial on the basis that estrogen increased the 
risk of stroke and did not appear to affect CHD development 14.   
Despite the benefits suggested in observational studies, the negative results generated 
from both the primary and secondary prevention randomized clinical trials are far more 
conclusive.  Only randomized clinical trials can establish the efficacy and safety of hormone 
therapy use for prevention CVD in postmenopausal women.  As a result of the negative findings, 
current guidelines recommend against routine hormone therapy use for chronic conditions, 
including CVD.  Furthermore, current hormone therapy users are currently advised to taper doses 
and ultimately discontinue use 15.   
Hormone therapy has been shown to impact a number of cardiovascular risk factors.  In 
the estrogen and progestin arm of the WHI, women randomly assigned to hormone therapy had 
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 greater reductions in glucose and insulin levels.  Also, body weight and waist circumference 
were lower among women taking hormone therapy; however, waist to hip ratio did not differ 
between groups.  Among women receiving hormones, systolic blood pressure was 1 mmHg 
higher at the first year follow-up visit and remained 1 to 2 mmHg higher at subsequent follow-up 
visits.  Diastolic blood pressure did not differ between groups 20.   
Hormone therapy use has also been suggested to improve the overall lipid profile of 
older, postmenopausal women.  Past studies have shown that, estrogen users had lower levels of 
LDL cholesterol levels and higher HDL cholesterol and triglyceride levels than non-users 3, 7, 9, 18, 
19. All can be considered beneficial changes with the exception of the rise in triglyceride levels.  
Triglycerides have been identified as an independent risk factor for CVD among women 18, 133.   
Lipoproteins comprise several distinct subclasses that differ in size, density, and 
composition 18, 133, 134.  Disease risk is typically based on the indirect measurement of cholesterol 
that is carried by these lipoproteins.  However, the amount of cholesterol that the particles 
actually contain varies from person to person due to differences in particle core composition and 
diameter.  It has been suggested that CVD risk may be better quantified using specific 
lipoprotein subclasses measurement as opposed to traditional methods 134, 135.  Traditional 
methods simply quantify the cholesterol carried within the particle as a surrogate marker for the 
actual lipoprotein concentration 134.  Nuclear Magnetic Resonance (NMR) spectroscopy allows 
lipoproteins and their subclasses to be rapidly and directly quantified in order to provide a more 
accurate assessment of risk factors relating to CVD development among postmenopausal 
women.  Past studies have suggested that LDL particle size, total and small LDL particle number 
is associated with incident CVD among older women 59.   
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 Although hormone therapy users tend to have lower LDL cholesterol levels than non-
users, estrogen has been found to also decrease LDL particle size 136, 137.  Small LDL particles 
have been shown to be more atherogenic than larger LDL particles and are negatively correlated 
with large HDL levels 133, 138.  Moreover, small LDL particles have a low affinity to LDL 
receptors and are more susceptible to oxidative metabolism and binding to arterial wall 
protoglycans, setting the stage for atherosclerosis 139.   
2.3 PHYSICAL ACTIVITY ASSESSMENT IN EPIDEMIOLOGICAL STUDIES 
Physical activity is a complex behavior and selecting the proper assessment tool(s) is 
challenging, particularly among free-living populations.  The lack of a reasonable gold standard 
measure and inconsistent use of physical activity terminology has contributed to confusion in 
this field.  Measurement is further complicated by the fact that there are several health-related 
dimensions of physical activity140, which may require the use of different assessment tools.  The 
qualitative difference among the various dimensions of physical activity contributes to the 
diversity in the mechanisms behind the relationship of physical activity and specific diseases 
and; therefore, alter how physical activity should be assessed.  When examining the relationship 
between physical activity and a disease or condition, it is important to focus on the dimension(s) 
of physical activity that is most likely to be associated with the specific outcome of interest.  
Energy expenditure is defined as the exchange of energy required to perform biological 
work.  Components of total energy expenditure include basal metabolic rate, which typically 
encompasses 50-70% of total energy, the thermic effect of food, which accounts for another 7-
10% and physical activity 141.  Physical activity is the most variable component of total energy 
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 expenditure and includes structured (sports, leisure, and occupational activity) and non-
structured activities (housework, childcare, and activities of daily living).   
Although similar, the terms physical activity and exercise have different meanings.  
Physical activity is defined as any bodily movement produced by skeletal muscles that result in 
increased energy expenditure142.  Therefore, things such as housework, gardening, occupational, 
and leisure activity may all be considered types of physical activity.  On the other hand, exercise 
is defined as planned, structured, and repetitive bodily movements done to improve or maintain 
one or more components of physical fitness and is usually associated with sport or conditioning 
activities142.  When differentiating between the two, exercise is a type of physical activity, but 
not all physical activity is considered exercise.  The term physical fitness is also confused with 
physical activity and/or exercise and can been defined as a set of attributes, such as 
cardiorespiratory fitness or muscle strength, that individuals have or can achieve that relate to the 
ability to participate in exercise and/or physical activity142.   
Physical activity may be comprised of several different domains, including 
transportation, sports/leisure, school/occupation, and housework/child or elderly care and may 
span across an entire continuum of intensity levels.  In order to accurately assess physical 
activity levels, it is essential that the entire spectrum of activity be captured (Figure 2.1)143.  It 
also becomes imperative that the assessment tool elicits information on the types of physical 
activities that encompass the greatest proportion of energy expenditure in the study population of 
interest.  As illustrated in figure 2.1, the lower end of the physical activity intensity spectrum is 
comprised of general activities of daily living such as bathing, feeding, and grooming.  The 
remainder of the intensity spectrum is comprised of activities that range in intensity from low to 
moderate and moderate to high levels.  The relative contribution of each of these types of activity 
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 to total energy expenditure in a specific population will vary depending upon the population of 
interest.   
 
 
Figure 2-1:  Physical Activity Spectrum (Adapted from Kriska, 2000) 143 
 
2.3.1 Subjective Measures: Physical Activity Questionnaires 
Self-report questionnaires are the most frequently used method of assessing physical activity 
levels among community-based individuals.  Questionnaires vary in their complexity, time 
frame, and type of activity that is assessed.  Each of these considerations will be outlined in more 
detail in the following section. 
2.3.1.1 Complexity  
Physical activity questionnaires vary in their complexity, from single item questionnaires to 
more complex quantitative history questionnaires estimating physical activity over a lifetime.  
More complex questionnaires, such as recall questionnaires, attempt to survey a wide range of 
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 popular activities over a defined time frame.  Recall questionnaires detail the frequency, 
duration, and types of activities performed during a defined recall period (e.g., past day, week, 
month, or year)144.  
2.3.1.2 Time Frame  
Subjective questionnaires can either ask about usual activity or inquire about activity performed 
within the past day, week, month, year, or even over a lifetime.  Participants may be asked to use 
diaries and logs to record activities over 1 day, 3 days, or the past week.  Questionnaires focusing 
on a long time frame, such as 1 year, are more likely to reflect usual activity patterns and have 
been used extensively in epidemiologic studies.  Questionnaires with short time frames have two 
advantages over those with longer time frames: the estimates are less vulnerable to recall bias 
and more practical to validate with objective tools.  However, assessment over a short time 
period is less likely to reflect “usual” behavior, as activity levels may vary with seasons or as a 
result of illness or time constraints 144.  To obtain the best estimate of physical activity levels, 
some questionnaires include assessment over both a short and long time period. 
2.3.1.3 Activity Type 
As mentioned previously, physical activity may be comprised of several different domains.  
Early studies in physical activity epidemiology estimated physical activity performed at work 145, 
146.  However, since physical activity levels at work have continued to decline in most 
industrialized countries 36, assessment of leisure-time physical activity is often assumed to be the 
best representation of physical activity in a population.  For this reason, most contemporary 
physical activity surveys only assess leisure-time activities that require energy expenditure above 
that of daily living.  Some questionnaires include both leisure and occupational activity 
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 components to be used in situations where the contribution of these components are either 
unknown or cannot be assumed 147, 148.  
2.3.2 Objective Measures: Pedometer 
Pedometers have gained widespread popularity in research and practice settings to quantify 
ambulation in terms of accumulated steps in free-living settings.  Pedometers are small, 
inexpensive, battery operated devices worn at the waist that have the ability to measure 
ambulatory activity in terms of steps taken (and distance walked if stride length is available) 149.  
The vertical forces of foot-strike cause movement of a spring-suspended lever arm to open and 
close an electrical circuit, which registers a “step”.  In theory, step registration should reflect 
only the vertical forces of foot-strike and hence ambulatory activity. However, any vertical force 
through the hip area (e.g., sitting down hard onto a chair, riding on a bike or in a car over rough 
terrain) can also trigger the device.   
Pedometers have demonstrated reasonable precision for use in research and clinical 
settings where walking is the primary type of activity. Moreover, their ease of administration 
makes them a practical assessment tool for individuals encompassing nearly all age groups 150. 
However, pedometers do not provide information relating to activity type, duration, or intensity. 
Therefore, accurate quantification of activity-related energy expenditure, time spent in type- or 
intensity-specific activities, and patterns of activity (e.g., short versus continuous bouts) cannot 
be assessed using the pedometer. Similar to other movement monitors, pedometers are unable to 
quantify upper body movements or to assess activity levels in individuals at slower gait speeds 
149. 
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 2.3.3 Physical Activity Assessment Issues in Women 
It is well established that certain subgroups of the population (older adults and women) acquire 
most of their physical activity in lower intensity activities of which subjective measures tend to 
do a poor job assessing 144, 151.  Therefore, the supplemental use of objective measures may be 
required for a more accurate assessment of physical activity in these populations.  This is 
particularly important when lower intensity activities comprise the bulk of energy expenditure 
143. 
2.4 POSTMENOPAUSAL WOMEN AND PHYSICAL ACTIVITY LEVELS 
2.4.1 Relationship between Physical Activity Levels and CVD 
With the mounting evidence against any cardio-protective benefits of hormone therapy, it is 
essential that other strategies be developed in order to prevent CVD among postmenopausal 
women.  As mentioned previously, non-pharmacological strategies such as maintaining regular 
physical activity levels are particularly appealing.  Unfortunately, older, postmenopausal women 
are among the least active subgroups in the U.S., with more than 41% of women in this age 
group reporting being physically inactive during their leisure time 35.   
Over the past few decades, evidence has accumulated on the role of physical activity in 
the prevention and treatment of CVD.  The evidence clearly suggests that individuals who 
participate in regular physical activity have a reduced risk of developing CVD21, 22.  As a result, 
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 physical inactivity has been identified as one of the major modifiable risk factors for CVD 
development due in part to the numerous physiological benefits.   
In terms of cardiovascular benefits, physical activity improves myocardial contraction, 
decreases resting heart rate, and increases stroke volume both at rest and during exercise 38, 40, 42.  
Regular physical activity has been shown to improve endothelial function and flow-mediated 
dilation and increase coronary collateral artery formation38, 40, 42.  Physical activity also reduces 
platelet aggregation, which decreases the risk for clotting38, 40, 42.  Other adaptations that occur as 
a result of physical activity include the stimulation of lipid oxidation during activity and recovery 
and increases in lipoprotein lipase activity increases which in turn increases triglyceride 
clearance at rest and during activity38, 39.  Regular physical activity levels also improves the 
sensitivity of liver, skeletal muscle, and adipose tissue to insulin38, 39. Physical activity is also 
indirectly protective against CVD development because it decreases blood pressure and obesity 
38.     
Prior studies demonstrating an inverse relationship between physical activity and CVD 
risk were mainly performed in men.  The relationship between physical activity and CVD risk in 
women was inconclusive, with an assumed benefit extrapolated from what was found in men 43.  
The recent evidence for the relationship between physical activity levels and cardiovascular 
disease in postmenopausal women is presented in table 2.2 by study design.   
Table 2-2: Recent evidence for the relationship between physical activity levels and cardiovascular disease 
development in postmenopausal women. 
 
Study Design Association Studies 
Case-Control -/0 Lemaitre152; O’Conner153 
Prospective -/0/-/-/0/-/-/-/- LaCroix44; Lissner154; Folsom45; 
Kushi46; Sesso43; Manson48; 
Lee49; Manson47; Owens50 
+ indicates positive association; - indicates negative association; 0 indicates no association 
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 Of the two case/control studies presented in table 2.2, one found a beneficial relationship 
between physical activity and cardiovascular outcome152 while another showed no relationship 
153.  Seven of the nine prospective studies presented in Table 2.2 found a beneficial relationship 
between physical activity and cardiovascular disease 44-50.  The large number of studies 
suggesting an inverse relationship between physical activity levels and cardiovascular disease in 
postmenopausal women may be due to a number of factors, including the physical activity 
assessment tool that was used.  The accuracy of the physical activity measure as other 
methodological factors will be described in detail in the following sections. 
2.4.1.1 Accuracy of Physical Activity Assessment 
All nine of the prospective studies presented in table 2.2 assessed leisure physical activity levels 
by subjective questionnaires 43-50, 131, 153, 154 and did not rely on fitness measures that often reflect 
more vigorous types of activities.  Three of the nine longitudinal studies examined if the 
protective effect of physical activity on CVD risk applies for moderate intensity activities that 
are common in women, such as walking.  Data from these investigations indicate that moderate 
intensity activities are, in fact, associated with lower CVD rates in women 48, 49, 155, and that the 
benefits are similar for both moderate and vigorous activities 48, 155.  There are no studies to date 
examining the relationship between CVD and lower intensity activities using objective 
monitoring.   
2.4.1.2 Methodological Concerns 
Although many studies presented in table 2.2 suggest an inverse relationship between physical 
activity and CVD, it should be noted that research in this area may have been affected by the 
possible misclassification of physical activity.  Non-differential misclassification, a problem 
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 intrinsic to the data collection methods, results from the degree of inaccuracy that characterizes 
how information was obtained in a particular study 132.  For example, misclassification could 
occur in prospective studies if physical activity is measured only during study entry while 
current, not prior, activity levels would have been more protective against incident CVD that was 
assessed at the end of the study.  Six of the nine prospective studies presented in table 2.2 
assessed physical activity only at baseline 43-46, 49, 155 and all had follow-up periods of 4 years or 
longer.  Therefore, a major limitation to the findings of these six prospective studies is the 
possible misclassification of physical activity.  Despite this potential limitation, only one of these 
six studies did not find an inverse association between physical activity and CVD 43. 
Another consideration in prospective study designs is the possibility that the study cohort 
will not have enough incident cases of CVD during the study duration.  A low CVD incidence 
affects the power to detect a statistically significant association.  Five studies presented in table 
2.2 had less than a 2% incident rate for CVD [Folsom (1.2%); Kushi (1.8%); Manson (0.8%); 
Lee (0.6%); Manson (0.4%)]45, 46, 48, 49, 155.  However, despite this low incidence rate, all five 
studies suggested an inverse relationship between physical activity levels and CVD development 
in women.  This suggests that the beneficial effects of physical activity on CVD development 
may be mediated through positive changes to cardiovascular risk factors.                                                                
Another potentially important limitation of past studies on the role of physical activity in 
cardiovascular disease prevention in post-menopausal women is the treatment of hormone 
therapy.  As mentioned in an earlier section, use of hormone therapy has been shown to affect 
the development of cardiovascular disease in postmenopausal women.  However, five of the 
eleven studies presented in table 2.2 did not assess hormone therapy status and; therefore, did not 
adjust for this potentially confounding factor in their analyses 44, 46, 152-154.   
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 Loss to follow-up presents another methodological limitation.  One investigation reported 
a high percentage loss to follow-up.  In the College Alumni Health Study, only 66% of the study 
cohort was followed successfully 43.  This high loss to follow-up rate may explain why this study 
failed to find an association between physical activity and CVD.   
A final methodological concern is that individuals who avoid physical activity may do so 
because of poor health or a functional limitation that is a result rather than a cause of his/her 
disease status.  Individuals with sub-clinical disease may have limited function, which may limit 
physical activity.  Sub-clinical disease has no recognizable clinical diagnosis and is distinct from 
a clinical disease with specific signs and symptoms.  Therefore, low reported physical activity 
levels may serve as a marker of the disease process and not usual behavior.  Likewise, 
individuals who participate in physical activity may also have other health-promoting lifestyle 
behaviors which may also affect CVD development.   
2.4.2 Relationship between Physical Activity Levels and Lipids 
Research investigating the relationship between physical activity and lipid levels in women has 
been inconclusive 156.  The evidence for the relationship between lipids in postmenopausal 
women and physical activity is presented in table 2.3.  Some prior cross-sectional studies have 
suggested that total cholesterol does not change with physical activity 52, 57, while others have 
shown a decrease in total cholesterol levels 54, 55.  Prospective studies show the same 
inconsistencies with regards to total cholesterol levels, some have suggested no association 8, 53, 
while others demonstrated an inverse relationship with physical activity 7, 19.  There has also been 
suggestion that physical activity is beneficially related to LDL levels, while others have shown 
no change.  One cross-sectional study suggested a negative association55, while another found no 
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 association between physical activity levels and LDL cholesterol52.  Similar inconsistencies are 
obtained in longitudinal studies.  An investigation by Binder et al.7, suggested an inverse 
relationship, while others showed no association 8, 53 between physical activity and LDL levels.  
With regards to triglycerides, some cross-sectional studies have suggested a decrease in 
triglyceride levels among postmenopausal women who participate in physical activity52, 54, 55, 
while an investigation by Cauley et al.57 reported no change.  Longitudinal studies investigating 
the relationship between physical activity and triglyceride levels among postmenopausal women 
have also be subject to the same discrepancies.  Some investigations reported no association7, 8, 53, 
58, while one study reported an inverse relationship between physical activity and triglyceride 
levels19.   Many cross-sectional studies have suggested a beneficial effect of physical activity on 
HDL levels 54-57; however, prospective studies investigating this relationship have failed to 
validate this response 7, 8, 19, 53, 58.   
Because of these uncertain findings, some have suggested that participation in physical 
activity may not be effective in postmenopausal women 8.  However, as discussed in the 
following sections, the conflicting findings of prior studies may be related to the assessment tool 
used to measure physical activity as well as other methodological concerns, such as the selection 
of an appropriate study population and the possible interaction of hormone therapy in the 
relationship between physical activity and lipid levels.   
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 Table 2-3: Evidence for the relationship between physical activity levels and lipids in postmenopausal women. 
Lipid  Association Studies 
Total Cholesterol Cross-sectional 0/0/-/- Cauley58; Stevenson52;; 
Haddock54; Hagberg55 
 Prospective -/0/-/0 Lindheim19; Ready53; Binder7; 
Klebanoff8 
Low Density Lipoprotein Cross-sectional 0/- Stevenson52; Hagberg55 
 Prospective 0/-/0 Ready53; Binder7; Klebanoff8 
High Density Lipoprotein Cross-sectional +/+/0/+/+ Cauley56; Cauley57; 
Stevenson52; Haddock54; 
Hagberg55 
 Prospective 0/0/0/+/0 Cauley58; Lindheim19; Ready53; 
Binder7; Klebanoff8 
Triglyceride Cross-sectional 0/-/-/- Cauley57; Stevenson52; 
Haddock54; Hagberg55 
 Prospective 0/-/0/0/0 Cauley58; Lindheim19; Ready53; 
Binder7; Klebanoff8 
+ indicates positive association; - indicates negative association; 0 indicates no association 
2.4.2.1 Accuracy of Physical Activity Assessment 
A number of investigations in the area of physical activity and lipids in postmenopausal women 
utilized measures of physical fitness as surrogates for population appropriate measurements of 
physical activity7, 8, 53-55.  As mentioned previously, women tend to participate primarily in low to 
moderate intensity activities157.  Therefore, fitness measures that reflect more vigorous activities 
may not be appropriate assessment tools to use in this population.      
Surprisingly, the earliest three investigations included both subjective and objective 
measures of physical activity when examining this relationship in 229 postmenopausal women 56-
58.  The combination of physical activity assessment measures provides information across the 
physical activity spectrum (Figure 2.1).  In these studies, physical activity was measured 
subjectively using the Paffenbarger Harvard Alumni Survey and objectively using a Large-Scale 
Integrated (LSI) monitor.  Both the cross-sectional 56, 57 and longitudinal investigations58 
suggested that physical activity as measured by objective measures of physical activity were not 
related to lipid levels.  However, both  cross-sectional studies 56, 57 suggested a beneficial 
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 relationship with HDL when physical  activity was assessed subjectively.  Despite the utilization 
of objective monitoring in these investigations, more work is needed using more recent and 
technologically advanced objective devices in a larger cohort of postmenopausal women.    
2.4.2.2 Methodological Concerns 
One methodological concern in the area of physical activity and lipids is the suggestion that 
individuals with elevated pre-exercise cholesterol levels respond more favorably to physical 
activity158.  Therefore, it may be unlikely that physical activity will make an impact on lipid 
levels that appear to be within normal limits.  To date studies investigating the relationship 
between physical activity and lipids in postmenopausal women included only those with normal 
lipid profiles 7, 8, 19, 52-58.   
Also, as mentioned previously, exogenous hormone therapy use alters the lipid profile of 
postmenopausal women.  Past studies examining the relationship between physical activity and 
lipids have differed in their inclusion or exclusion of postmenopausal women on hormone 
therapy.  Four of the ten studies presented in table 2.3 excluded hormone therapy users 53, 56-58, 
while another four investigations included both hormone therapy users and non-users 8, 52, 54, 55.  
Therefore, the inconclusive results demonstrated between physical activity and lipids in 
postmenopausal women may be partially explained by the differing inclusion/exclusion criteria 
used to define the study population. 
NMR spectroscopy is a diagnostic test for the rapid and direct measurement of 
lipoprotein particle subclasses.  Due to the novelty of this technology, there is currently limited 
information available on the relationship between physical activity and lipoprotein subclasses.  
The role of physical activity on specific lipoprotein subclasses, as well as those lipoprotein 
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 subclasses that are thought to be related to CVD among postmenopausal women, has yet to be 
explored. 
2.4.3 Relationship between Lifestyle Intervention and CVD Risk Factor Reduction  
The combined benefit of physical activity, diet, and weight loss has been examined in 
randomized clinical trials testing the overall effect of a lifestyle based approach on CVD risk 
factor reduction and/or chronic disease prevention.  Results from randomized clinical trials have 
demonstrated success in populations at risk for both type 2 diabetes25-28 and heart disease70; 
however, few studies incorporating lifestyle have been done specifically in women at or after 
menopause.   
The Women’s Healthy Lifestyle Project (WHLP) was developed in response to the 
previously mentioned prospective investigation known as the Healthy Women Study (HWS) 
(refer to section 2.1: Menopause and Cardiovascular Disease Risk).  Again, the HWS was 
developed to examine the physiologic changes that take place during the menopausal transition.  
Findings from the HWS suggested that menopause is associated with weight gain and adverse 
CVD risk factor changes83.  Consequently, the WHLP was a 5-year randomized clinical trial 
designed to examine the effect of a behavioral based lifestyle intervention on weight gain and 
adverse changes to LDL-C that likely result during the menopausal transition71, 72.  At study 
entry, the WHLP population consisted of 535 healthy, pre-menopausal women who were 
randomly assigned to either a lifestyle intervention consisting of dietary and behavioral 
modification or to an assessment-only control group.  Participants in the lifestyle intervention 
group were also given modest weight loss goals (5-15 lbs) to prevent weight gain above baseline 
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 levels.  Both groups attended follow-up clinic visits at 6, 18, 30, 42, and 54 months after 
randomization.    
At the 54 month follow up visit, 56% of the entire study cohort were still menstruating 
regularly and considered pre-menopausal; 10% were peri-menopausal (having missed 3-11 
consecutive periods), and 35% were post-menopausal (having missed 12 consecutive periods or 
having had a hysterectomy).  Of those women who had become postmenopausal by 54 months, 
56% of control and 61% of intervention participants reported HT use.  Results from the WHLP 
demonstrated significant differences between randomized groups with regards to systolic and 
diastolic blood pressure, triglyceride, glucose, and insulin levels.  In addition, the lifestyle 
intervention resulted in a significantly smaller increase in LDL-C levels over 54 months; this 
difference between randomized groups was similar among hormone users and non-users.  Based 
on these promising findings, the investigators concluded that a lifestyle based approach can 
successfully attenuate the rise in LDL-C levels that results due to menopause74.   
The investigators from WHLP also explored the effectiveness of the lifestyle intervention 
to prevent weight gain.  Again, the main weight goal of the intervention was to prevent weigh 
gain above baseline levels.  At 54 months, 55% of the participants randomized to receive the 
intervention were at or below baseline weight compared with only 26% of controls.  More 
specifically, the mean weight change in the intervention group was 0.1 (5.2) kg below baseline 
levels compared with an average gain of 2.4 (4.9) kg that was observed in the assessment group.  
Not surprisingly, change in WC followed the same trend as weight change.  With regards to 
behavioral modification, participants randomized to the intervention reported higher physical 
activity levels and consumed fewer calories and less fat than women in the assessment group.  
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 Therefore, in addition to CVD risk factor reduction, the lifestyle intervention was also successful 
at preventing weight gain among women from peri- to post-menopause73.   
Unfortunately, little is known regarding the overall effectiveness of lifestyle modification 
for primary CVD prevention among postmenopausal women.  In addition, findings from WHLP 
did not account for concurrent changes in HT status, an issue which has become particularly 
relevant in the post-WHI era.  Therefore, the role of lifestyle on CVD risk factor reduction 
among postmenopausal women in various states of HT use has yet to be explored. 
2.4.4 Relationship between Physical Activity, Walking Performance and Subclinical CVD 
Measures 
As mentioned previously a large proportion of CVD related deaths occur in asymptomatic 
women.  Specifically, approximately 2/3 of all sudden deaths attributable to CVD occur in 
women with no previous symptoms1, 2.  Women differ from men with regards to both the clinical 
presentation of CVD and performance on standard diagnostic tests75, making early detection 
among women a challenge.  Therefore, in addition to prevention strategies, the development of 
tools that aid in the early detection of asymptomatic women who are at an increased risk of CVD 
has major public health implications.     
Past epidemiological studies have shown that cardiovascular fitness, as measured by 
exercise capacity, is an independent predictor of cardiovascular events and death among 
asymptomatic women2, 75, 159, 160.  Results from the St. James Women Take Heart Project study 
suggested that for each 1 MET increase in exercise capacity, there was a 17% reduction in all 
cause mortality among asymptomatic women75.  The prognostic value of measuring exercise 
capacity in women asymptomatic for CVD was confirmed in the Lipids Research Clinics 
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 Prevalence Study161.  Based on these findings, the investigators concluded that the addition of a 
cardiorespiratory fitness measure to traditional risk factor assessment may be valuable for early 
detection, particularly among women with no apparent symptoms.   
Maximal oxygen uptake (VO2 max), the most accurate assessment of cardiovascular 
fitness, is typically estimated from a symptom limited treadmill or cycle ergometry based 
exercise stress test.  However, VO2 max protocols may not be practical in large epidemiological 
studies due to time constraints, staff burden and required medical oversight, high equipment 
costs, and safety concerns76, 162.  In instances where VO2 max testing is not realistic, tests of 
walking endurance have been substituted for this gold standard measure to estimate fitness 
levels.   
Walking endurance protocols were primarily developed to estimate exercise capacity in 
diseased and/or older populations163.  The walking endurance test, a 12 minute walking test, was 
introduced in 1968 as a submaximal, field test to estimate VO2 max (based on achieved HR)164.  
In 1982, Butland et al. found that decreasing the total duration of the test from 12 to 6 minutes, to 
make it more feasible in populations with chronic diseases, did not significantly reduce the utility 
of the test165.  As a result, the 6 minute walk test (6MWT) was used primarily in diseased 
populations who were not able to tolerate traditional VO2 max protocols and/or long periods of 
exertion.  Originally, the 6MWT was used to estimate fitness levels in individuals with chronic 
respiratory disorders165-167.  However, in the mid-1980’s, researchers reported the utility of this 
test to assess fitness levels in individuals with chronic heart failure168, 169.  Over time, the 6MWT 
protocol was applied to the elderly as a measure of functional status 170.  Although the 
information obtained from the 6MWT provided information beyond that of traditional indicators, 
when validating this measure against the gold standard (treadmill or cycle ergometry based 
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 exercise stress tests), it was determined that the relationship between peak O2 consumption and 
distance walked during the 6MWT was not linear169; therefore, the convergent validity of this 
instrument could not be assumed.    
The long distance corridor walk (LDCW) is a slight modification of the 6MWT protocol, 
and was developed to extend the range of self paced walking tests in older adults163.  As opposed 
to measuring the distance covered over a predetermined duration (6 minutes), the LDCW 
protocol assesses the total time necessary to walk a 400 meter course.  The LDCW was 
developed based on the thought that an individual may be more intrinsically motivated to 
complete a predetermined distance that can be visualized, in as little time as possible, thus 
providing a more maximal effort162.  A 2001 investigation directly compared the overall work 
effort, as indicated by walking speed, and ending heart rate (HR) and systolic blood pressure 
(SBP), from the 6MWT and LDCW, and results confirmed that a target distance encouraged 
individuals to walk closer to their maximal effort when compared to a time dependent 
protocol162.  
The LDCW has been utilized in well-functioning healthy older individuals with 
promising results. Results from a cross-sectional investigation using the Health, Aging, and 
Body Composition study (Health ABC) suggested that walking performance was influenced by 
both clinical and subclinical diseases and was strongly related to anthropometric measures and 
self reported physical activity levels.  Results from the follow-up Health ABC investigation 
suggested that exclusion or inability to complete the LDCW protocol was associated with an 
increased risk of mortality, incident CVD, and mobility limitation171.  For those that completed 
the protocol, each additional minute of walk time was associated with a 29% higher rate of 
mortality, a 20% higher rate of incident CVD, and 52% higher rates of mobility limitation and 
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 disability171.  These findings suggest that measured parameters from the LDCW, particularly 
walk time, are useful for estimating risk of mortality and/or disease among older adults.   
In addition to risk assessment, the use of the LDCW to estimate physical fitness levels 
was investigated172.  The relationship between walk time from the LDCW and peak VO2 
measures obtained during a treadmill based protocol (modified Balke173) were examined in 102 
participants, aged 60 to 91, from the Baltimore Longitudinal Study of Aging (BLSA).  The 
correlation between walk time and peak VO2 was -0.79, indicating a strong relationship between 
the measured parameters.  Therefore, in contrast to the 6MWT, the convergent validity of the 
LDCW to estimate fitness levels among older individuals can be assumed172.   
It is fairly well established in the literature that the LDCW is a low cost alternative for 
estimating cardiovascular fitness levels and is useful for assessing mortality and incident disease 
risk in older individuals; however, little is known regarding the applicability of this test in 
middle-aged, postmenopausal women.  
2.5 CONCLUSION 
The literature provides strong evidence for the 1) association between physical activity and lipid 
levels, 2) positive role of lifestyle based interventions for CVD risk factor reduction and primary 
CVD prevention, and 3) usefulness of the LDCW to ascertain CVD risk.  However, an 
examination of this literature also exposes the fact that several studies in this field have 
limitations in their design that can be addressed in future research.  This project will address 
these shortcomings by using 1) both subjective and objective physical activity assessment tools, 
2) direct measure of lipoprotein particle subclasses, 3) subclinical CVD measures, and 4) 
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 measured parameters from the LDCW.  The project will also examine the added influence of 
current and/or change in HT use on these relationships.  With these improvements, we expect 
that this project will make a significant contribution to the existing literature. 
2.5.1 Objectives of the Project 
The proposed investigation will examine the 1) relationship between leisure physical activity, 
lipids, and lipoprotein subclass levels and investigate how current HT use may influence these 
associations, 2) effectiveness of a lifestyle intervention to attenuate unfavorable changes to CVD 
risk factors that result from HT discontinuation, and 3) associations between walking 
performance, physical activity levels, and subclinical CVD measures in 508 postmenopausal 
women, aged 52-62 years.  Specifically, the study meets the following objectives: 
Paper 1: Examine the cross-sectional relationship between physical activity levels and 
lipoprotein subclasses by hormone therapy status at baseline.   
a. It is hypothesized that leisure physical activity will be beneficially related to some of 
the lipoprotein sub-classes in postmenopausal women; however, there will be a few 
lipoprotein subclasses in which physical activity is only significantly related in women 
not taking hormone therapy.  
Paper 2: To determine if a lifestyle intervention promoting weight and waist circumference 
reduction through beneficial physical activity and dietary practices can attenuate unfavorable 
CVD risk factor changes that are likely to occur as postmenopausal women discontinue hormone 
therapy (HT) use.   
a. It is hypothesized that discontinuation of hormone therapy has negative consequences 
on many CVD risk factors. 
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 b. It is further hypothesized that a lifestyle intervention will attenuate negative 
consequences of discontinuing hormone therapy with regards to many CVD risk 
factors. 
Paper 3: To determine the utility of the LDCW as a measure of health status in middle-aged, 
postmenopausal women. 
a. Walking performance, more specifically walk time, will be significantly related to 
demographic factors, anthropometric measures, subjective and objective measures of 
physical activity, and CVD risk factors in postmenopausal women.   
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 3 METHODS 
3.1 BRIEF OVERVIEW OF THE WOMAN CLINICAL TRIAL 
The WOMAN Study is a five-year randomized clinical trial designed to test whether an 
aggressive non-pharmacological intervention among postmenopausal women currently or 
previously on HT would modify or reduce measures of subclinical cardiovascular disease.  
Eligibility criteria for enrollment into the study included: age 52-62 years, waist circumference ≥ 
80 centimeters (cm), body mass index between 25-39.9 kilograms per meters squared (kg/m2), 
not currently taking lipid lowering drugs, having a low density lipoprotein (LDL-C) level 
between 100-160 milligrams per deciliter (mg/dL), no physical limitation that would preclude 
walking, no known diabetes, and no diagnosed psychotic disorder and depression.  Eligible 
WOMAN study participants (n=508) were randomized into one of two groups: lifestyle change 
(intervention) (n=253) and health education control (n=255). 
Table 3.1 illustrates the measures central to this proposed plan and the number of 
WOMAN study participants that completed each measure.  Those that completed the clinic visit 
also completed all measurements that were obtained during that visit including demographics, 
medication inventory (hormone therapy (HT) and other medication use), anthropometric 
measures (BMI and waist circumference), blood pressure, and fasting blood draw (plasma 
cholesterol, insulin, and glucose).  It should be noted that the WOMAN study cohort represents a 
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 higher than normal risk for CVD based on higher waist circumference and BMI criteria at entry.  
Changes in HT recommendations13 that were made during mid-recruitment resulted in a cohort 
of postmenopausal women with varied HT status.  Therefore, the HT component of the 
WOMAN study was not randomized.  Additionally, these changes in recommendations resulted 
in a number of women changing HT status as they progressed through the first 18 months of the 
5-year long study.   
Table 3-1: Time Line for WOMAN Study Measurements through the 18 Month Follow-Up 
 Baseline/Screening 
Visit 
6-Month 
Follow-up 
Visit 
18-Month 
Follow-up 
Visit 
Completed Clinic Visit (including demographic 
survey, medication inventory, anthropometric 
measures, blood pressure, and fasting blood draw) 
x 
(n=508) 
x 
(n=485) 
x 
(n=455) 
Physical Activity Measures 
Past Year MAQ x 
(n=504) 
x 
(n=484) 
x 
(n=455) 
Past Week MAQ x 
(n=506) 
x 
(n=467) 
x 
(n=440) 
Pedometer x 
(n=173) 
 x 
(n=323) 
Long Distance Corridor Walk  
 X 
(n=505) 
  
Cardiovascular Disease Risk Factors 
Lipoprotein Subclasses 
 
x 
(n=493) 
x 
(n=479) 
x 
(n=454) 
C-Reactive Protein x 
(n=201) 
 x 
(n=201) 
Subclinical Measures of Cardiovascular Disease 
Coronary Artery Calcification (EBCT) 
 
x 
(n=507) 
  
Carotid Ultrasound  x 
(n=503) 
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 3.2. MEASURES 
3.2.1. Physical Activity Measures 
3.1.1.1 Past Year Modifiable Activity Questionnaire (MAQ) 
Physical activity was measured using the MAQ, an interviewer administered, past-year 
questionnaire 144.  The MAQ has been shown to be both reliable144, 174 and valid144, 174, 175 and has 
been used to assess physical activity levels in over 200 studies consisting of populations from all 
over the world.  This questionnaire assesses current leisure and occupational activities, as well as 
extreme levels of inactivity due to disability.  Study participants were asked to report if they 
participated in specific activities, such as walking for exercise, at least 10 times over the past 
year (12 months).  For those that participated in a specific activity, they were asked which 
months they had participated in that specific activity over the past year and then estimated the 
number of times each month and length of time that they spent doing the specific activity.  
Physical activity levels were calculated as the product of the duration and frequency of each 
activity (in hours per week), weighted by an estimate of the metabolic equivalent (MET) of that 
activity and summed for all activities performed.  One MET represents the energy expenditure 
for an individual at rest, whereas a 10-MET activity requires 10 times the resting energy 
expenditure 176.  Physical activity data were expressed as metabolic equivalent hours per week 
(MET hr-wk).   
For occupational activity, individuals were asked to list all jobs held during the past 12 
months. For each job entry, data were collected for minutes per day walking or cycling to work, 
as well as the number of months per year, days per week, and hours per day spent working in 
that job.  Job activity was determined by the number of hours spent sitting at work and the most 
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 frequent activities performed when not sitting. Housewives, unemployed, physically challenged, 
and retired individuals were questioned about activities during a normal “40 hour work week” 
144. 
Estimates of leisure and occupational activity were calculated separately as hours per 
week (h-wk) averaged over the past year.  Total physical activity was the combination of leisure 
and occupational activity averaged over the past year.   
 
3.1.1.2 Past Week Modifiable Activity Questionnaire (MAQ) 
Physical activity was also assessed using a past week version of the MAQ.  This questionnaire 
measures participation in leisure activities performed over the past 7 days.  Study participants 
were given the past week MAQ during the eligibility visit and were asked to record leisure 
activities for the 7 days prior to their clinic assessment.  Past week leisure physical activity levels 
were calculated similar to that used for the leisure section of the past year MAQ.   
3.1.1.3 Pedometer 
Physical activity was measured using the Accusplit Eagle (AE120) pedometer. At baseline, 
pedometer data was collected on a subgroup of women entering the study; however, was 
available to all participants at the 18 month clinic visit.  The participant was instructed to wear 
the pedometer clipped to her waistband over the dominant hip for one week, and at the end of 
each day to record the number of steps taken in a diary.  At the end of the week the participant 
returned the activity diary to the investigator.  The number of steps recorded in the diary from the 
pedometer was averaged for the week to obtain a seven-day average of the number of steps taken 
per day.   
  46
  
3.1.2 Completed Clinic Visit  
The proposed investigation examines the relationship between physical activity and 
cardiovascular risk factors in postmenopausal women during the first 18 months of the 5 year 
long study.  The completed baseline and 18 month clinic visits will be critical for proposed 
examination.  All relevant demographic and clinical measures (ie. anthropometrics, fasting blood 
draw) were collected during these time points.   
3.1.3 Lipoprotein Subclasses 
Participant blood samples were drawn after a 12 hour fast.  Lipoprotein subclasses were 
measured by nuclear magnetic resonance (NMR) spectroscopy (Liposcience Inc., Raleigh, NC), 
as previously described 177.  In brief, the lipoprotein subclasses were quantified using 
characteristic signals, which differ in frequency and shape depending on the diameter of the 
lipoprotein particle, as a basis for quantification.  Each signal was derived from the total number 
of terminal methyl groups on the lipids contained within the particle core and in the surface shell.  
The intensity of each signal was proportional to the quantity of the subclass and was multiplied 
by a standard lipid amount to provide results in mg/dL of cholesterol for low density lipoprotein 
(LDL) and high density lipoprotein (HDL) and mg/dL of triglyceride for very low density 
lipoprotein (VLDL).  The lipoprotein subclasses were categorized as large (60- to 200-nm), 
medium (35- to 60-nm), and small (27- to 35-nm) VLDL; IDL (23- to 27-nm), large (21.3- to 
23.0-nm), medium (19.8- to 21.2-nm), small (18.3- to19.7-nm), and very small (≤ 18.2-nm) 
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 LDL; and large (8.8- to 13-nm), medium (8.2- to 8.8-nm), and small (7.3- to 8.2-nm) HDL. 
Particle concentrations (nmol/L for VLDL and LDL; μmol/L for HDL) were calculated for each 
subclass standard by measuring the total concentration of core lipid and dividing the volume 
occupied by these lipids by the core volume per particle calculated from the diameter of that 
particle 178, 179. 
3.1.4 Long Distance Corridor Walk 
The LDCW consisted of 400 meter walk along a course consisting of 10 laps along a hallway 
with cones set 20 meters apart (40 meters per lap).  Participants were instructed to walk “at a 
pace that you can maintain for the full 10 laps.”  Standard encouragement by a trained clinician 
was given at each lap.  Heart rate was monitored with a Polar Pacer hear monitor (Model 60905; 
Woodbury, NY).  Persons with elevated blood pressure (BP ≥200/110), resting heart rate (>110 
or <40), recent exacerbation of chest pain, shortness of breath, or reporting a recent cardiac event 
or procedure were excluded for safety reasons.  The LDCW was stopped if the participant’s heart 
rate exceeded 135 beats per minute (bpm) of if a participant reported chest pain or dyspnea 
during the test.  Heart rate (HR) was recorded at rest before starting the walk, at completion, and 
at recovery 2 minutes later.  Systolic blood pressure (SBP) was measured while seated prior to 
the walk and while standing at test completion.  Based on these measures, cardiovascular 
response variables were generated.  HR and SBP response were calculated by subtracting the 
resting values from those obtained immediately following completion.  HR recovery was 
calculated by subtracting the HR obtained 2 minutes after LDCW completion from the value 
measured at completion.   
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 3.1.5  Measures of Subclinical Disease 
3.1.5.1 Electron Beam Computed Tomography (EBCT) 
The participant was positioned supine on the table with the head toward the gantry; a bolster 
pillow was placed under the knees for comfort.  After careful skin preparation, electrodes were 
placed and an optimum EKG tracing was obtained.  The participant’s body was next positioned 
within the gantry with arms over head and resting on the arm rests.  The laser-guided light was 
positioned over the participant’s xiphoid process.  A second laser-guided light was used to adjust 
the table height so the participant was centered within the gantry.  The participants had to hold 
their breath during the scanning.  Each time the scanner was operated, they were instructed to 
take a breath in, let it out, take a second breath, let it out, and take a third breath, and hold it.  The 
first scan was a preview scan, which served the purpose of calibrating to chest size of the given 
participant.  The second scan imaged the entire heart, with cross-sectional images at every 3 mm.  
The pictures were taken during the diastolic phase of the cardiac cycle, one image during each 
heart beat.  We obtained 30-40 contiguous 3mm thick transverse images from the level of the 
aortic root to the apex of the heart.  Images were obtained during maximal breath holding using 
EKG triggering so that each 100m second exposure was obtained during the same phase of the 
cardiac cycle, 60% of the RR interval.  
All EBCT studies were read at the University of Pittsburgh.  Readings of coronary 
calcification were done using a DICOM workstation and software by Accuimage (San Francisco, 
CA).  This software program implements the widely accepted Agaston scoring method 180.  
Coronary artery calcium was considered to be present when 3 contiguous pixels greater than 130 
Hounsfield units were detected overlying the vessels of interest.  Scoring results in a total 
calcium score as well as a total number of calcifications.   
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 3.1.5.2 Carotid Ultrasound 
The scanning procedure results in three primary carotid disease measures: average wall (intima-
media) thickness, a measure of degree of focal plaque called the plaque index, and the ICA/CCA 
velocity ratio, a determination of whether or not plaque is interfering with blood flow in the 
internal carotid artery.  Carotid ultrasound measurements were obtained using a Toshiba SSA-
270A scanner in Pittsburgh, PA.  Briefly, detailed B-mode images of the right and left common 
carotid artery, carotid bifurcation and the first centimeter of the internal carotid were obtained.  
Selected images were digitalized for later measurement of the intima-media thickness by central 
readers in Pittsburgh.  After imaging, the sonographer obtained Doppler measures of blood flow 
velocity at mid common (2 cm proximal to the carotid bulb) and in the internal carotid at the 
point of the highest velocity distal to the flow divider.  These were used to calculate the degree to 
which plaque may be interfering with blood flow.  Plaque was defined as a distant focal area 
protruding into the vessel lumen.  Plaque was assessed in 4 areas: proximal common, distal 
common, carotid bulb, and internal carotid.  For each segment, the degree of plaque was graded 
using the following criteria: Grade 0 = no observable plaque; grade 1 = one small plaque (less 
than 30% of the vessel diameter); grade 2 = one medium plaque (between 30 and 50% of the 
vessel diameter) or multiple small plaques; grade 3 = one large plaque (greater than 50% of the 
vessel diameter) or multiple plaques with at least one medium plaque.  The grades were then 
summed to create a plaque index, a measure of the extent of eccentric plaque.  
Stiffness of the aorta was measured using the gold standard, carotid-femoral (or aortic) 
pulse wave velocity (aPWV), as previously described in detail181, 182. Briefly, for each 
participant, 20 seconds of carotid and femoral pulse waveforms were collected simultaneously 
with non-directional Doppler probes and recorded to data files. Files were “scored’ using 
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 software developed by the Laboratory of Cardiovascular Science, Gerontology Research Center, 
National Institute on Aging.    For each file, the trained reader selected all clear waveforms for 
averaging into composite carotid and femoral waveforms, to determine the “foot” (or upstroke) 
of each.   The transit time of the pulse wave was calculated as the foot-to-foot delay between the 
averaged carotid and femoral waveforms.  The distance traveled by the pulse waveform between 
the carotid and femoral measurement sites was measured manually with a metal tape measure, 
above the surface of the participant’s torso.  Aortic pulse wave velocity was calculated by 
dividing the distance traveled by the time differential between the two waveforms and expressed 
as distance/transit time (cm/sec).  Results from all usable data collection runs (n = 3) for each 
participant are averaged. In our lab this measure has been demonstrated to have good 
reproducibility with an intraclass correlation of 0.72-0.83181.  
3.3. STATISTICAL ANALYSIS 
Briefly described below are the analytical procedures for papers 1-3.  The specific methodologies 
are described in greater detail within the context of each respective paper.   
Paper #1: The primary hypothesis of paper #1 was to determine if leisure physical 
activity is beneficially related to many of the lipoprotein sub-classes in postmenopausal women.  
A secondary hypothesis was that there are some lipoprotein subclasses in which physical activity 
is only significantly related in women not taking hormone therapy.  To test the primary and 
secondary hypotheses, the following statistical procedures were performed. 
Descriptive statistics were used to describe demographic, anthropometric measures, 
physical activity, and lipoprotein subclass levels in the entire cohort and stratified by HT use.  
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 All variables were assessed for normality.  Normally distributed variables were reported as mean 
± standard deviation; not normally distributed variables were reported as median with 25th and 
75th percentiles.  Depending upon the characteristics of the variable, t-tests, Wilcoxon Rank Sum, 
or Chi Square (χ2) tests were used to compare HT users and non-users.   
For each lipoprotein subclass, we evaluated four multivariate linear regression models.  
The first model examined the association between physical activity and lipoprotein subclasses 
after controlling for age and saturated fat/cholesterol intake.  The second model added BMI and 
the third model added HT status as covariates.  The fourth model evaluated the addition of a 
physical activity*HT interaction term to these models.  For graphic representation, we evaluated 
the lipoprotein subclass levels across physical activity quartiles.  Jonckheere-Terpstra tests were 
also used to estimate linear trends in mean lipoprotein subclass levels across physical activity 
quartiles stratified by HT status.   
Paper #2: The primary hypothesis of paper #2 was that discontinuing hormone therapy 
may increase certain CVD risk factors and that a lifestyle intervention can attenuate the effect of 
discontinuing HT on CVD risk factors.  To test the primary hypothesis, the following statistical 
procedures were performed. 
The study population for this analysis consisted of a subgroup of the WOMAN study 
participants who were on HT at study entry.  Descriptive statistics were used to describe baseline 
anthropometric measures, leisure physical activity levels, and CVD risk factor levels by HT 
group (those that continued verses discontinued use at the 18 month follow-up visit).   Normally 
distributed variables were reported as mean ± standard deviation; non-normally distributed 
variables were reported as median with 25th and 75th percentiles.  Depending upon the 
  52
 characteristics of the variable, t-tests or Wilcoxon Rank Sum tests were used to compare baseline 
CVD risk factor values between HT continuers and HT discontinuers.     
The 18 month change in anthropometric, physical activity, and CVD risk factor variables 
over time were calculated as the difference in values between the 18 month follow-up and 
baseline.  Change variables were reported and compared between HT continuers and HT 
discontinuers, stratified by randomized group assignment using t-tests or Wilcoxon Rank Sum 
tests.  CVD risk factor change was also reported and compared between randomized groups, 
stratified by HT status at the 18 month clinic visit.   
Further post-hoc analyses were conducted to determine the independent effect of healthy 
lifestyle behaviors that were promoted in the lifestyle intervention on CVD risk factor reduction 
using multivariate linear regression models.  The multivariate model examined the longitudinal 
relationship between CVD risk factor and change in leisure physical activity, and saturated 
fat/cholesterol intake, after adjusting for HT status at 18 months and baseline levels of leisure 
physical activity, saturated fat/cholesterol intake, and relevant CVD risk factor.   
Paper #3: The primary hypothesis of paper #3 was that walking performance obtained 
from the LDCW was related to physical activity levels and measures of subclinical CVD among 
postmenopausal women.  A secondary hypothesis was that the cardiovascular response measures 
obtained from the LDCW was related to physical activity levels and measures of subclinical 
CVD.  To test the primary and secondary hypotheses, the following statistical procedures were 
performed. 
Univariate analyses were conducted on measured parameters from the LDCW, 
demographics, physical activity levels, and measures of subclinical CVD.  Normally distributed 
variables were reported as mean ± standard deviation, non-normally distributed variables were 
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 reported as median with 25th and 75th percentile, and proportions were noted for categorical 
variables.  Spearman rank order correlation coefficients were used to assess the bivariate 
associations between walk time and CV response measures from the LDCW, demographics, 
physical activity levels, and CVD risk factors and partial Spearman rank order correlations were 
used to examine these relationships adjusted for age and BMI.    Descriptive statistics were used 
to illustrate demographics, physical activity levels, and CVD risk factors across quartiles of 
LDCW time.  Depending upon the characteristics of the variable, ANOVA, Kruskal-Wallis, or 
Chi Square Test of Proportions was used to compare demographic factors, physical activity 
levels, clinical and subclinical CVD measures across quartiles of LDCW time in those who 
completed the 400-meter walk.  Jonckheere-Terpstra tests were used estimate the linear trend in 
continuous variables and Cochran-Armitage Trend test were used to determine linear trend for 
categorical variables.  To adjust for the high number of planned comparisons, a p value of 
<0.002 was used to denote statistical significance using the Bonferonni correction method.  
3.4. CONCLUSION 
Results from the proposed three papers will add to the growing body of evidence 
regarding strategies for primary prevention of CVD in postmenopausal women.  The proposed 
investigation will add to the literature through the use of 1) both subjective and objective 
physical activity assessment measures, 2) direct measure of lipoprotein particle subclasses, 3) 
subclinical measures of CVD, and 4) measured parameters from the LDCW.  Finally, the 
WOMAN study participants represent a unique cohort who were directly affected by the results 
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 from the WHI13.  The change in HT recommendations provides the opportunity to examine the 
health impact of the widespread discontinuation of HT. 
With this information we will be able to: 1) examine the cross-sectional relationship 
between physical activity levels and lipoprotein subclasses by HT status at baseline, 2) determine 
if a lifestyle intervention can attenuate unfavorable CVD risk factor changes that are likely to 
result from HT discontinuation, and 3) determine the construct validity of the LDCW in 
postmenopausal women.   
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 4.1 ABSTRACT 
OBJECTIVE: To determine if the association between physical activity and lipids and 
lipoprotein subclasses in postmenopausal women varies by hormone therapy (HT) use.    
DESIGN: The cross-sectional relationship between physical activity and lipid and lipoprotein 
subclass relationship was examined prior to group randomization in 485 postmenopausal [mean 
age 56.9 (2.9 years)] Caucasian and African-American women from the Woman On the Move 
through Activity and Nutrition (WOMAN) Study.  The WOMAN study is a randomized clinical 
trial designed to test whether a lifestyle intervention will reduce subclinical cardiovascular 
disease measures.  RESULTS: HT users (n=286) were significantly (p<0.05) younger, less 
likely to be African American, reported higher levels of physical activity, large VLDL particles 
(VLDL-P), and medium HDL particles (HDL-P), had a larger mean HDL particle size, and lower 
levels of total cholesterol, LDL cholesterol (LDL-C), small HDL-P, and small VLDL-P than non 
users (n=196). Physical activity was significantly associated with favorable lipoprotein and lipid 
levels, regardless of HT use.  Some relationships were found to vary significantly by HT use.  In 
non-users, mean HDL and LDL particle size was significantly smaller and total and small LDL 
particles (LDL-P) were significantly lower as activity increased.  These relationships were not 
found in HT users. CONCLUSIONS: Physical activity was significantly related to some 
lipoprotein subclasses regardless of HT. However, several key lipoprotein subclasses were 
associated with higher levels of activity only among non-HT users.   
Key Words: physical activity, lipids, lipoprotein subclasses, hormone therapy, postmenopause 
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 4.2 INTRODUCTION 
Currently in the United States, cardiovascular disease (CVD) is the leading cause of death among 
older women (1).  The cessation of ovarian function and the subsequent decrease in endogenous 
sex steroid hormone levels that occur as a result of the menopausal transition are associated with 
adverse lipid changes, which are thought to be largely responsible for the rising prevalence of 
CVD in postmenopausal women (2, 3).  The menopausal transition is associated with increases 
in both total cholesterol and LDL cholesterol (LDL-C) and a decrease in HDL cholesterol (HDL-
C) (4, 5). 
Among postmenopausal women, hormone therapy (HT) has been shown to lower total 
and LDL-C and increase HDL-C (2).  As a result, HT was widely prescribed lipid lowering and 
general CVD prevention in addition to menopausal symptom relief (6, 7).  However, recent 
evidence from randomized clinical trials (8-11) has failed to confirm the cardio-protective 
benefits of HT that were suggested from earlier, observational studies.  Since these results have 
been published, there have been significant changes in clinical practice regarding the prescription 
of HT.  HT is no longer prescribed for lipid lowering and/or general CVD prevention.  This 
clinical trend, combined with other documented risks of HT has caused prescription rates of HT 
use to plummet (12).  This creates the need for other strategies to be employed to favorably alter 
the lipid profile and decrease CVD risk in postmenopausal women. 
CVD risk attributable to dyslipidemia may be better quantified using specific lipoprotein 
subclass measurement as opposed to conventional methods (13).  There is increasing evidence 
that subclasses of LDL, HDL, and VLDL (differentiated by particle size or density) may 
differentially predict CVD.  Among postmenopausal women, the measurement of LDL 
subclasses may be particularly important.  Past studies have suggested that smaller mean LDL 
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 particle size, higher levels of total LDL particles (LDL-P) (14), and higher levels of small LDL-P 
are associated with incident CVD (15) and subclinical atherosclerosis (16) among 
postmenopausal women.  Evidence also suggests that the associations between these key LDL 
lipoprotein subclasses and measures of subclinical CVD remain regardless of hormone therapy 
status (17).  HDL subclass measures [e.g. larger mean HDL particle size or higher large HDL 
particles (HDL-P)] have also been shown to have incremental predictive value for coronary 
artery disease (CAD) and incident coronary heart disease (CHD) (18-20).   
Past research does not clearly define the relationship between physical activity and the 
overall lipid profile in postmenopausal women (21).  The purpose of the current investigation is 
to clarify these associations by including both specific lipoprotein subclass measures, as well as 
traditional lipid measures.  A secondary aim is to examine how HT may modify the relationship 
between leisure physical activity and lipoprotein subclass and lipid levels in postmenopausal 
women. 
4.3 METHODS 
The Women On the Move through Activity and Nutrition (WOMAN) Study is a five year 
primary CVD prevention randomized clinical trial, designed to test whether an aggressive non-
pharmacological lifestyle intervention among postmenopausal women will reduce measures of 
subclinical CVD.  This study provides a unique opportunity to explore the relationship between 
physical activity, lipids, and nuclear magnetic resonance (NMR) spectroscopy-determined 
lipoprotein subclasses in postmenopausal women currently using and not using HT.   
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 4.3.1 Study Population 
Five hundred and eight postmenopausal women were recruited for the WOMAN study, primarily 
through direct mailing from selected zip codes in Allegheny County, Pennsylvania from April 
2002 to October 2003.  Eligibility criteria for enrollment into the study included waist 
circumference ≥ 80 centimeters (cm), body mass index (BMI) between 25 – 39.9 kilograms per 
meters squared (kg/m2), not currently taking lipid lowering drugs and having a low density 
lipoprotein cholesterol (LDL-C) level between 100 - 160 milligrams per deciliter (mg/dL), no 
physical limitations that would preclude walking, no known diabetes, and no diagnosed 
psychotic disorder or depression.  All participants provided written informed consent and all 
protocols were approved by the institutional review board at the University of Pittsburgh.  
Results were based on data collected prior to randomization at the baseline clinic visit (2002-
2003).   
4.3.2 Physical Activity 
Physical activity was measured using the Modifiable Activity Questionnaire (MAQ), an 
interviewer-administered, past-year questionnaire (22).  This questionnaire assesses current 
leisure and occupational activities, as well as extreme levels of inactivity due to disability.  
Physical activity levels were calculated as the product of the duration and frequency of each 
activity (in hours per week), weighted by an estimate of the metabolic equivalent (MET) of that 
activity and summed for all activities performed.  For the purposes of this investigation, only 
leisure physical activity estimates were used.  Leisure physical activity data were expressed as 
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 metabolic equivalent hours per week (MET hr-wk).  The MAQ has been shown to be both 
reliable (22, 23) and valid (22-24). 
4.3.3 Hormone Therapy Status 
HT status was obtained through self-report in addition to a medication inventory that was 
completed at the baseline clinic visit.  Participants were classified as being either current HT 
users or non-users.   
4.3.4 Lipid and Lipoprotein Subclass Measures 
Total cholesterol, HDL-C, and triglycerides were determined by conventional methods from 
fasting (12 hour) blood samples.  LDL-C was estimated by the Friedewald equation.  Lipoprotein 
subclass particle concentrations and mean particle diameters were measured using an automated 
nuclear magnetic resonance (NMR) spectroscopic assay (LipoScience, Inc., NC) as previously 
described (25) in detail.  Unlike conventional lipid measures, which quantify lipoproteins 
according to the amounts of lipid (cholesterol or triglyceride) carried by all of the particles in the 
major class, the NMR spectroscopy assay determines concentrations of lipoprotein particles 
according to particle size (diameter).  Results are then grouped into small, medium, and large 
subclasses for HDL-P and VLDL-P.  For LDL, the particle concentrations are reported for small 
and large LDL-P in addition to intermediate density lipoprotein particles (IDL-P).  Subclasses 
are summed to provide total LDL-P, HDL-P, and VLDL-P.  Mean LDL and HDL particle sizes 
are calculated as weighted-averages (i.e. the diameter of each subclass multiplied by its relative 
mass percentage).  
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 4.3.5 Other Measures 
Demographic factors, such as age, saturated fat and cholesterol intake (fat intake index), body 
mass index (BMI) were considered confounding variables.  BMI was calculated from height and 
weight measured with a stadiometer and calibrated balance beam scale, respectively.  Fat intake 
index was assessed using the Connor Diet Habit Survey, which has been shown to be both a 
reliable and valid measure for the rapid assessment of eating habits and diet composition (26). 
4.3.6 Analytic Procedures 
Descriptive statistics were used to describe demographic, anthropometric measures, physical 
activity, and lipoprotein subclass levels in the entire cohort and stratified by HT use.  Normally 
distributed variables were reported as mean ± standard deviation; non-normally distributed 
variables were reported as median with 25th and 75th percentiles.  Depending upon the 
characteristics of the variable, t-tests, Wilcoxon Rank Sum, or Chi Square (χ2) tests were used to 
compare HT users and non-users.   
For each lipoprotein subclass, we evaluated four multivariate linear regression models.  
The first model examined the association between physical activity and lipoprotein subclasses 
after controlling for age and saturated fat/cholesterol intake.  The second model added BMI.  The 
third model added HT status.  The fourth model evaluated the addition of a physical activity*HT 
interaction term to the models.  For graphic representation, we evaluated the lipoprotein subclass 
levels across leisure physical activity quartiles by HT status.  Activity quartiles represented the 
distribution of leisure physical activity levels reported in the WOMAN study.  Jonckheere-
  62
 Terpstra tests were used estimate the linear trend in mean lipoprotein subclass levels across 
physical activity quartiles by HT status.   
4.4 RESULTS 
Twenty-six women (5.1%) had incomplete data and were excluded from these analyses.  Of the 
remaining 482 WOMAN study participants with complete data, 59.3% (n = 286) reported taking 
HT and 40.7% (n = 196) of the women reported not taking HT at the baseline assessment.  Of 
those women who reported taking HT at baseline, 120 (42% of HT users) women took estrogen 
therapy (ET), while the remaining 166 (58% of HT users) took estrogen plus progestogen 
therapy (EPT).  The mean age of the participants was 56.9 ± 2.9 years, and 11.6% were African 
American (Table 4.1).  Study participants had a mean BMI of 30.7 ± 3.8 kg/m2 and waist 
circumference of 105.7 ± 11.2 centimeters.  Only 6.2% of women reported being current 
smokers.  The median physical activity levels reported in the WOMAN study cohort at baseline 
were similar to those recommended by the  Surgeon General for physical activity and health21  
Compared to non users, HT users were significantly younger (p<0.05), were less likely to 
be African American, and reported higher levels of physical activity (Table 4.1).  In addition, HT 
users had significantly higher large VLDL particles (VLDL-P), and medium HDL-P levels.  HT 
users also had a significantly larger mean HDL particle size, and lower levels of total cholesterol, 
LDL-C, small HDL-P and small VLDL-P than non-users.  No additional significant differences 
were found between HT groups for the remaining lipid or lipoprotein levels (Table 4.1).   
In separate multivariable linear regression models in the entire cohort, after adjustment 
for age and fat intake index, leisure physical activity was significantly related to higher levels of 
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 HDL-C (p=0.001) and large HDL-P (p=0.02) and lower total and medium VLDL-P (p=0.001; 
p=0.003 respectively), and triglycerides (p=0.03).  However, for the entire cohort, after 
adjustment for age and fat intake, leisure physical activity was not significantly related to mean 
HDL or LDL particle size, total, small LDL-P, total cholesterol, total, medium, or small HDL-P, 
IDL-P, LDL-C, large LDL-P, or large or small VLDL-P (data not shown).   
When BMI was added to the model results were similar.  BMI was a significant covariate 
in most models (p<0.01 to <0.001).  Although BMI attenuated the relationship between leisure 
physical activity and HDL-C, large HDL-P, and triglycerides, physical activity remained a 
statistically significant covariate for each of these lipid and lipoprotein subclass variables.  It 
should be noted that results were similar when waist circumference was substituted in the model 
for BMI (data not shown).   
Similarly when HT was added to the multivariate model, results were similar.  Activity 
levels were significantly related to higher levels of HDL-C (p=0.01) and large HDL-P (p=0.008) 
and lower levels of total and medium VLDL-P (p=0.003, p=0.005 respectively), and 
triglycerides (p=0.006), (Table 4.2).  Physical activity was not significantly related to mean HDL 
or LDL particle size, total, small LDL-P, total cholesterol, total, medium, or small HDL-P, IDL-
P, LDL-C, large LDL-P, or large or small VLDL-P (data not shown).  HT was a significant 
covariate only for lower HDL-C levels (p<0.01), but not for other lipoproteins.  Moderate 
alcohol intake was also considered as a possible confounding factor.  However, the addition of 
this factor to the models did not significantly change the results; therefore, it was not included in 
final multivariate models.   
After adjusting for potential confounders, the physical activity*HT interaction term was 
only statistically significant for mean HDL and LDL particle size, total and small LDL-P.  
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 Therefore, we further evaluated the relationship between leisure physical activity and those four 
key lipoprotein subclass measures after stratifying by HT use (Figure 4.1).  Among HT users, 
there was no significant association between physical activity and these lipoprotein subclasses 
(Figure 1).  In contrast, among HT non-users, higher leisure physical activity was significantly 
associated with lower total and small LDL-P and larger mean LDL and HDL particle sizes.  
Furthermore, among HT non-users, these relationships remained statistically significant after 
adjustment for age, body mass index, and saturated fat/cholesterol intake (Table 4.3).   
 
4.5 DISCUSSION 
The present investigation was the first to investigate the associations between lipids, physical 
activity, and HT using specific lipoprotein subclasses.  In this large cohort of overweight 
postmenopausal women, we found that leisure physical activity was significantly related to a 
favorable lipid and lipoprotein subclass profile (i.e., higher levels of HDL-C and large HDL-P, 
and lower levels of triglycerides, and total and medium VLDL-P), regardless of HT use.  
However, we saw no association between leisure physical activity and LDL-C, which agrees 
with previous reports.  The beneficial association that was observed in our study between leisure 
physical activity and higher large HDL-C and lower total and medium VLDL-P levels are 
congruent with the higher HDL-C and lower triglyceride levels, since those are the primary 
lipids carried by those particles, respectively.  Generally, past investigations in postmenopausal 
women have shown that physical activity levels are beneficially related to both HDL-C and 
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 triglyceride levels, and these associations remained after adjustment for factors such as body 
mass index and HT status (28, 29).   
Findings from the current investigation also suggest that for several key lipoprotein 
subclass measures, the relationship with physical activity differed by HT use.  After stratification 
by HT use, physical activity was independently related to larger mean HDL and LDL particle 
size, and lower levels of total and small LDL-P among non-HT users, but not among women 
currently taking HT.  As we and others have shown, these particular lipoprotein subclass 
measures, particularly total LDL-P, are independently associated with coronary calcification (16) 
and predict incident CVD (14, 15) among postmenopausal women.  Furthermore, in a study of 
healthy postmenopausal women, we have previously shown that higher levels of total and small 
LDL-P and small mean LDL particle size are associated with coronary artery calcification, for 
both HT users and non-users (17).  Therefore, the results of the current study, showing that 
among HT users, higher levels of leisure physical activity was not associated with any 
improvements in these specific lipoprotein subclasses are particularly important.  In HT users, 
the pharmacological effects of the hormones appears to have masked or interfered with the 
potential benefits of leisure physical activity levels on important facets of the lipoprotein 
subclass profile.   
Past research exploring the relationship between physical activity and lipids in 
postmenopausal women has generated contradictory results (21).  As previously mentioned, it 
has been suggested that estrogen may mask the response of lipid levels to participation in 
physical activity in postmenopausal women taking HT (30).  Therefore, one possible reason for 
the divergent results of previous studies investigating the relationship between physical activity 
and lipid levels among postmenopausal women may be explained by the inconsistent selection of 
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 the study population with regard to HT use.  Results of the present investigation illustrate that the 
independent relationship between physical activity and certain lipoprotein subclasses, such as 
mean HDL and LDL particle size, total, and small LDL-P, may only become evident after 
stratification by HT status.  It is, therefore, imperative for future work to consider HT use when 
examining the relationship between physical activity and lipids in postmenopausal women.   
The present analysis utilized a questionnaire that assessed structured physical activity 
levels and demonstrated that leisure physical activity was related to many lipid and lipoprotein 
subclasses. Although questionnaires have been shown to accurately assess higher intensity, 
structured physical activities, they typically do a poor job when measuring lower intensity, 
unstructured lifestyle physical activities, such as household chores, childcare, and housework 
(22, 31).  Future work should examine whether total physical activity levels, including both 
structured and unstructured activities as measured by an objective assessment tool, follows the 
same trends as what was observed in the present investigation.  Also, the addition of an objective 
physical activity measure would allow investigators the opportunity to validate activity estimates 
obtained through subjective measures. 
When interpreting the findings of the present investigation, a number of limitations need 
to be considered.  Data from only one point in time, the baseline visit, was used in the analyses.  
Although informative, this cross-sectional study analysis is limited in that it does not provide 
information pertaining to the direction of association or allow us to determine how the 
relationship between physical activity and lipoprotein subclasses changes as a woman changes 
her physical activity levels, HT status, or both.  In addition, the results were adjusted for lifestyle 
factors (age, BMI, dietary saturated fat and cholesterol intake) that have been demonstrated to be 
related to both physical activity and lipid and lipoprotein subclass levels.  The adjustment of 
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 results by these lifestyle factors helps to ensure that any significant relationship that was noted 
between physical activity and lipid and lipoprotein subclass levels is not the result of 
confounding by a third factor.  Also, the results are limited by our small sample size which may 
reduce confidence in our findings.  Specifically, post-hoc power analyses revealed that the power 
to examine the interaction between physical activity levels and hormone therapy status ranged 
from 61- 75%.   However, despite having relatively low power, the results were strong enough to 
detect a statistical significant difference.  Finally, women were classified as current HT users or 
non-users; the type, dosage, and/or duration of HT usage were not considered in these analyses.  
Therefore, future work is needed to further investigate the complex relationship between HT, and 
mean lipoprotein subclass and physical activity levels.   
In conclusion, the literature has been inconsistent with regards to the relationship 
between physical activity and lipids and lipoproteins in postmenopausal women.  Findings from 
the present work confirmed earlier studies suggesting that, regardless of HT use, physical 
activity levels were directly related to HDL-C levels and indirectly related to triglyceride levels.  
However, when the results were stratified by HT use, physical activity was associated with key 
lipoprotein subclasses in HT non-users which have been shown to be related to both incident and 
subclinical CVD.  These findings raise the important question as to whether the beneficial effect 
of physical activity on the lipid profile in postmenopausal women is similar between HT users 
and non-users.  
As HT is being prescribed less frequently and for shorter periods of time, we need to be 
aware of other strategies to favorably alter the overall lipid profile in postmenopausal women.  
Despite the fact that these data are cross-sectional in nature, findings from the current 
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 investigation suggest that the promotion of physical activity may be a safe and effective 
alternative to improve lipids and reduce risk of CVD in postmenopausal women. 
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 Table 4-1: Participant Characteristics Stratifying by Current Hormone Therapy Use in the WOMAN Study 
 Entire Cohort Hormone Therapy 
Users 
Non-Hormone 
Therapy Users 
 
 n=482 n=286 (59.3%) n=196 (40.7%) p value 
Age (years) 56.9 (2.9) 56.6 (2.9) 57.3 (2.9) 0.0079 
Leisure Physical Activity (MET 
hr-wk) 
11.1 (5.3, 20.2) 12.8 (6.2, 21.5) 9.1 (4.3, 18.6) 0.0128 
Body Mass Index (kg/m2) 30.7 (3.8) 30.7 (3.6) 30.8 (4.1) 0.8054 
Waist Circumference (cm) 105.7 (11.2) 105.8 (10.6) 105.5 (12.0) 0.7489 
% High School Graduate 98.7 99.0 98.5 0.6426 
% African American 11.6 6.6 18.9 <0.0001 
% Married 66.8 69.6 62.8 0.1180 
% Current Smokers 6.2 4.9 8.2 0.1474 
Lipids 
Total Cholesterol, mg/dL 216.4 (28.1) 211.9 (26.6) 223.0 (29.1) <0.0001 
LDL Cholesterol, mg/dL 128.2 (25.0) 122.1 (22.8) 137.0 (25.5) <0.0001 
HDL Cholesterol, mg/dL 59.8 (13.9) 60.7 (13.8) 58.8 (14.0) 0.0828 
Triglyceride, mg/dL 142.2 (74.7) 146.1 (81.0) 136.6 (64.2) 0.1733 
NMR Lipoprotein Particle Measures 
Total LDL-P, nmol/L 1394.1 (310.4) 1390.1 (296.2) 1400.0 (330.6) 0.7370 
IDL, nmol/L 42.8 (36.3) 41.5 (35.7) 44.7 (37.2) 0.3423 
Large LDL-P, nmol/L 640.5 (219.9) 632.3 (213.2) 652.5 (229.3) 0.3277 
Small LDL-P, nmol/L 710.8 (419.3) 716.3 (399.4) 702.8 (447.8) 0.7326 
LDL Size, nm 21.4 (0.7) 21.4 (0.7) 21.4 (0.7) 0.7348 
Total HDL-P, μmol/L 35.0 (5.4) 35.4 (5.5) 34.6 (5.2) 0.1022 
Large HDL-P, μmol/L 7.6 (3.2) 7.7 (3.3) 7.4 (3.1) 0.2878 
Medium HDL-P, μmol/L 2.8 (3.3) 3.5 (3.6) 1.8 (2.3) <0.0001 
Small HDL-P, μmol/L 24.6 (5.3) 24.1 (5.4) 25.3 (5.2) 0.0130 
HDL Size, nm 9.1 (0.5) 9.1 (0.4) 9.0 (0.5) 0.0100 
Total VLDL-P, nmol/L 83.3 (37.3) 80.8 (37.5) 87.0 (36.9) 0.0743 
Large VLDL-P, nmol/L 4.9 (5.9) 5.3 (6.5) 4.3 (4.8) 0.0499 
Medium VLDL-P, nmol/L 31.7 (24.7) 30.9 (24.9) 32.8 (24.4) 0.3970 
Small VLDL-P, nmol/L 46.7 (17.9) 44.5 (17.5) 49.8 (18.2) 0.0016 
Age, BMI, Waist Circumference, and Lipoprotein Subclasses represented as mean (standard deviation). Leisure Physical Activity represented as 
median (25th, 75th percentile).   p value = hormone therapy users vs. non-hormone therapy users.    
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 Table 4-2: Final Multivariate Linear Regression Model for Leisure Physical Activity and Lipoprotein 
Subclasses for the Entire Cohort (n=482) 
 
Final model adjusted for age, body mass index, cholesterol/saturated fat intake, and hormone therapy.  *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001.   
 HDL-C 
(mg/dL) 
Large HDL-P 
(μmol/L) 
Total VLDL-P 
(nmol/L) 
Medium 
VLDL-P 
(nmol/L) 
Triglycerides 
(mg/dL) 
Leisure PA (MET hr-wk) 1.05 ± 
0.39** 
0.24 ± 0.08** -3.11± 1.05** -1.96 ± 
0.70** 
-5.78 ± 2.08** 
Age (years) -0.26 ± 
0.21 
-0.04 ± 0.05 0.04 ± 0.58 -0.11 ± 0.38 -0.22 ± 1.15 
Body Mass Index (kg/m2) -0.54 ± 
0.17** 
-0.14± 
0.04*** 
0.75 ± 0.46 0.23 ± 0.30 2.45 ± 0.91** 
Cholesterol/Saturated Fat 
Intake Index 
-0.09 ± 
0.05 
-0.00 ± 0.01 0.05 ± 0.14 0.07 ± 0.09 0.13 ± 0.28 
Hormone Therapy Status -1.72 ± 
1.28** 
-0.19 ± 0.30 4.97 ± 3.46 1.34 ± 2.31 -7.07 ± 6.90 
R2 0.049919 0.052433 0.33568 0.020394 0.036905 
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Table 4-3: Multivariate Linear Regression Model for Leisure Physical Activity and Lipoprotein Subclasses 
for Hormone Therapy Users and Non-Hormone Therapy Users 
  Mean HDL 
Particle Size 
(nm) 
Mean LDL 
Particle Size 
(nm) 
Total LDL-P 
(nmol/L) 
Small LDL-P 
(nmol/L) 
Model II Stratified by Hormone Therapy 
Non-Hormone 
Therapy Users 
(n=196) 
Leisure PA (MET hr-
wk) 
0.05 ± 0.02** 0.06 ± 0.03* -35.15 ± 
14.47* 
-46.41 ± 
19.45* 
 Age (years) -0.01 ± 0.01 -0.00 ± 0.02 0.72 ± 7.90 2.77 ± 10.62 
 Body Mass Index 
(kg/m2) 
-0.02 ± 0.01** -0.02 ± 0.01 10.78 ± 5.85 13.98 ± 7.86 
 Cholesterol/Saturated 
Fat Intake Index 
0.00 ± 0.00 0.01 ± 0.00 -1.02 ± 1.98 -3.54 ± 2.66 
 R2 0.097946 0.076803 0.065444 0.079416 
Hormone 
Therapy Users 
(n=286) 
Leisure PA (MET hr-
wk) 
-0.01 ± 0.02 -0.02 ± 0.03 8.38 ± 10.85 8.33 ± 14.64 
 Age (years) -0.01 ± 0.01 0.01 ± 0.01 -0.95 ± 6.03 -4.54 ± 8.13 
 Body Mass Index 
(kg/m2) 
-0.03 ± 
0.01*** 
-0.03 ± 0.01* 11.54 ± 5.01* 14.39 ± 6.76* 
 Cholesterol/Saturated 
Fat Intake Index 
-0.00 ± 0.00 0.00 ± 0.00 -0.16 ± 1.44 -0.63 ± 1.95 
 R2 0.053346 0.022870 0.020586 0.019779 
Multivariate models adjusted for age, BMI, and cholesterol/saturated fat intake.  *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.   
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 Quartile 1 Quartile 2 Quartile 3 Quartile 4Quartile 1 Quartile 2 Quartile 3 Quartile 4
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1: Mean Lipoprotein Subclass Levels by Leisure Physical Activity, stratified by Current Homone 
Therapy Use. Quartile 1: <5.3 MET hr-wk; Quartile 2: >5.3 to <11.3 MET hr-wk; Quartile 3: >11.3-20.4 
MET hr-wk; Quartile 4: >20.4 MET hr-wk 
 
 
 
 
8.7
8.
8.
8
9
9
1
2
9.3
Non-user HT user
M
ea
n 
LD
L 
P
ar
tic
le
 S
iz
e 
(n
m
)
21
21.2
21.4
21.6
21.8
Non-User HT User
M
ea
n 
LD
L 
P
ar
tic
le
 S
iz
e 
(n
m
)9.
9.
Quartile 1 Quartile 2 Quartile 3 Quartile 4Quartile 1 Quartile 2 Quartile 3 Quartile 4
1200
1250
1300
1350
1400
1450
1500
Non-User HT User
To
ta
l L
DL
-P
 (n
m
ol
/L
)
0
200
400
600
800
1000
Non-User HT User
Sm
al
l L
D
L-
P 
(n
m
ol
/L
)
  76
 5 CAN A LIFESTYLE INTERVENTION ATTENUATE THE EFFECT OF 
DISCONTINUING HORMONE THERAPY ON CARDIOVASCULAR RISK 
FACTORS? 
For Future Publication 
 
 
 
Kelley K. Pettee PhD1, Andrea M. Kriska PhD1, Molly B. Conroy1,2 MD, B. Delia Johnson PhD1, 
Trevor J. Orchard1 MD, Bret H. Goodpaster2 PhD, Frani M. Averbach1 MPH, Lewis H. Kuller1 
MD 
 
1 Department of Epidemiology 
2Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, 
Pittsburgh, PA 
 
 
 
 
  77
 5.1 ABSTRACT 
OBJECTIVE: To determine if a lifestyle intervention consisting of physical activity and dietary 
modifications can counteract unfavorable CVD risk factor changes that are predicted to occur as 
postmenopausal women discontinue hormone therapy (HT) use.  DESIGN: Participants from the 
Woman On the Move through Activity and Nutrition (WOMAN) study were randomized at 
baseline to either a health education (HE) or lifestyle change (LC) group.  The impact of a 
lifestyle intervention on CVD risk factor reduction was examined in the 231 postmenopausal 
[mean age 58.3 (2.9 years)] women who were initially on HT at baseline and either remained on 
HT (n=106) or discontinued use (n=125) by the 18 month follow up visit.  RESULTS:  In 
general, lifestyle intervention had a beneficial impact on CVD risk factor reduction regardless of 
HT status at 18 months.  Women randomized to the LC group decreased weight, BMI, WC, 
insulin and triglyceride levels and improved glucose levels when compared to the HE group.  
Within the HE arm, women who discontinued HT had significantly (p<0.01) higher increases in 
total and LDL-C as compared to HT continuers, whereas no such differences were observed in 
the LC arm.  CONCLUSIONS: A lifestyle based intervention comprised of physical activity 
and diet was effective for CVD risk factor reduction among postmenopausal women.  Negative 
lipid consequences of discontinuing HT were noted only in the HE group and not among women 
randomized to the LC group.  These findings suggest that a lifestyle behavioral approach can 
successfully attenuate increases in total and LDL-C that result from HT discontinuation.  
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 5.2 INTRODUCTION 
After menopause, women experience an increased incidence of cardiovascular disease 
(CVD) (1).  The increase in CVD incidence is likely due to detrimental changes in related risk 
factors, such as dyslipidemia, abdominal adiposity, hypertension, and insulin resistance that 
often worsen during the menopausal transition (2, 3).  Hormone therapy (HT) use has been 
shown to favorably alter CVD risk factors (4) and, until recently, was widely prescribed for both 
the relief of menopausal symptoms and general CVD prevention in postmenopausal women (5, 
6).   
Past observational studies have consistently suggested an inverse association between 
exogenous HT use and CVD (7, 8), due in part to the beneficial impact of HT on CVD risk 
factors.  The Postmenopausal Estrogen/Progestin Interventions (PEPI) study was a randomized 
clinical trial exploring the impact of four HT regimens (placebo control vs. unopposed estrogen 
or one of three estrogen/progestin combinations) on selected CVD risk factors in healthy 
postmenopausal women (9).  Results from the PEPI trial suggest that, regardless of type of HT, 
HT users had increased HDL cholesterol (HDL-C) and decreased LDL cholesterol (LDL-C) and 
fasting glucose levels when compared to the placebo control group (9).   
In contrast to observational studies, evidence from recent clinical trials, such as the 
Women’s Health Initiative (WHI) (10, 11) and Heart and Estrogen/progestin Replacement Study 
(HERS) (12) have failed to confirm the cardio-protective benefits of hormone therapy (HT) (7, 
8).  Following the publication of the WHI results, many HT users were advised by their 
physicians to taper doses and/or discontinue use (5).  Unfortunately, there is little information 
regarding the health impact of the widespread discontinuation of HT.   
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 The Women On the Move through Activity and Nutrition (WOMAN) study is a five year 
randomized clinical trial of primary CVD prevention among postmenopausal women designed to 
test whether an aggressive non-pharmacological lifestyle intervention will modify or reduce 
measures of subclinical CVD.  Approximately midway through the WOMAN study recruitment 
process, results were publicized from the estrogen/progestin (E+P) arm of the WHI trial 
indicating adverse effects among HT users (11).  Women who had already been randomized into 
the WOMAN study were advised by their health care provider to taper and/or discontinue HT 
use according to the new guidelines based upon the WHI results.  The WOMAN study provides 
a unique opportunity to explore the impact of HT discontinuation and the possible attenuation of 
this impact by healthy lifestyle behaviors on CVD risk factors after 18 months of a behavioral 
lifestyle intervention. 
Based on results from previous studies (9), it is hypothesized that HT discontinuation will 
negatively impact certain CVD risk factors such as lipids.  The purpose of this current 
longitudinal investigation is to determine if a lifestyle intervention consisting of healthy physical 
activity and dietary practices can lessen unfavorable CVD risk factor changes that are 
hypothesized to occur as women discontinue HT use after 18 months of study participation.   
5.3 METHODS 
5.3.1 Study Population 
Five hundred and eight postmenopausal women were recruited for the WOMAN study, primarily 
through direct mailing from selected zip codes in Allegheny County, Pennsylvania from April 
  80
 2002 to October 2003.  Eligibility criteria for enrollment into the study included waist 
circumference (WC)  ≥ 80 centimeters (cm), body mass index (BMI) between 25 – 39.9 
kilograms per meters squared (kg/m2), not currently taking lipid lowering drugs and having a low 
density lipoprotein (LDL-c) level between 100 - 160 milligrams per deciliter (mg/dL), no 
physical limitations that would preclude walking, no known diabetes, and no diagnosed 
psychotic disorder or depression.  All participants provided written informed consent and all 
protocols were approved by the institutional review board at the University of Pittsburgh. Results 
from the current investigation were generated from data collected at baseline and at the 18 month 
clinic visit. 
5.3.2 Group Randomization: Intervention Design 
Eligible women were randomized to a Health Education (HE) comparison group or a Lifestyle 
Change (LC) group using a block randomized design prepared by a statistician.  Briefly, women 
in the HE group received educational lectures while women randomized to the LC group 
received group and individualized intervention which focused on body weight and WC reduction 
through healthy lifestyle changes.  The healthy lifestyle behaviors promoted in the LC included 
150 minutes per week of moderate intensity physical activity similar to brisk walking and a 
caloric intake of 1300-1500 calories per day, emphasizing an eating pattern low in total (<17%) 
and saturated fat (<7%).    
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 5.3.3 Physical Activity 
Physical activity was measured using the past year version of the Modifiable Activity 
Questionnaire (MAQ), an interviewer administered questionnaire (13).  This questionnaire 
assesses leisure and occupational activities, as well as extreme levels of inactivity due to 
disability.  For the purposes of this investigation, we will focus on the leisure physical activity 
estimate as there was little reported occupational physical activity in our study population.  Study 
participants were asked to identify if they participated in a variety of specific activities, such as 
walking for exercise, at least 10 times over the past year (12 months).  For each activity 
identified, they were asked which months they had participated in that specific activity over the 
past year and then estimated the number of times each month and length of time that they spent 
doing the specific activity.  Physical activity levels were calculated as the product of the duration 
and frequency of each activity (in hours per week), weighted by an estimate of the metabolic 
equivalent (MET) of that activity and summed for all activities performed.  One MET represents 
the energy expenditure for an individual at rest, whereas a 10-MET activity requires 10 times the 
resting energy expenditure (14).  Leisure physical activity data were expressed as metabolic 
equivalent hours per week (MET hr-wk).  The MAQ has been shown to be both reliable (13, 15) 
and valid (13, 15, 16).  In the WOMAN study, baseline and 18 month physical activity estimates 
obtained from the MAQ were positively and significantly (p<0.0001) correlated with step counts 
obtained from a pedometer step counter (rho = 0.30 and 0.36, respectively). 
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 5.3.4 Hormone Therapy Groups 
Information on HT use was obtained through self-report in addition to a medication inventory 
that was completed at both the baseline and 18 month clinic visit.  Following the publication of 
the WHI results, study participants were allowed to enter the trial after recently terminating HT 
use; however, only those who were identified as current HT users at baseline were included in 
the current report.  These women were classified into one of two HT groups: 1). HT Continuers 
(HT user at baseline and 18 months) and 2). HT Discontinuers (HT user at baseline and non-user 
at 18 months).   
5.3.5 Clinical Measures 
All clinical measures were obtained at the baseline and 18 month follow-up clinic visit.  Clinical 
measures included height, body weight, waist circumference, and a fasting (12 hour) blood draw.  
BMI was calculated from height and weight measured with a stadiometer and calibrated balance 
beam scale by dividing the participant’s weight in kilograms by the square of her height in 
meters.  Waist circumference (WC) was measured at the navel (horizontal plane at the center of 
the navel) using a fiberglass retractable tape measure.  Total cholesterol, HDL-C, triglycerides, 
and glucose were determined by conventional methods.  LDL-C was estimated by the 
Friedewald equation and insulin was measured via radioimmunoassay.   
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 5.3.6 Other Measures 
In addition to the clinical measures, a saturated fat/cholesterol intake index score was calculated 
using the Connor Diet Habit Survey, which has been shown to be both a reliable and valid 
measure for the rapid assessment of eating habits and diet composition.  The saturated fat and 
cholesterol score is generated by summing the scores for 20 questions related to cholesterol and 
saturated fat intake (17). 
5.3.7 Statistical Methods 
Descriptive statistics were used to describe baseline anthropometric measures, leisure physical 
activity levels, and CVD risk factor levels by HT use at the 18 month follow-up visit.   Normally 
distributed variables were reported as mean ± standard deviation; non-normally distributed 
variables were reported as median with 25th and 75th percentiles.  Depending upon the 
characteristics of the variable, t-tests or Wilcoxon Rank Sum tests were used to compare baseline 
CVD risk factor values between HT continuers and HT discontinuers.     
The 18 month change in anthropometric, physical activity, and CVD risk factor levels 
variables over time was calculated as the difference in values between the 18 month follow-up 
and baseline.  Change variables were compared between HT continuers and HT discontinuers, 
stratified by treatment group assignment using t-tests or Wilcoxon Rank Sum tests.  CVD risk 
factor change was also reported and compared between randomized groups, stratified by HT 
status at the 18 month clinic visit.   
Further post-hoc analyses were conducted to determine the independent effect of healthy 
lifestyle behaviors that were promoted in the lifestyle intervention on CVD risk factor reduction 
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 using multivariate linear regression models.  The multivariate model examined the longitudinal 
relationship between CVD risk factor and change in leisure physical activity, and saturated 
fat/cholesterol intake, after adjusting for HT status at 18 months and baseline levels of leisure 
physical activity, saturated fat/cholesterol intake, and relevant CVD risk factor.   
5.4 RESULTS 
Of the 508 women randomized into the WOMAN study, 455 (90%) completed the 18 month 
clinic visit.  Of these 455 women, 182 reported not using HT at baseline and were excluded from 
these analyses.  Also excluded were 16 women initiating a lipid lowering medication during the 
18 month interval and 26 with incomplete physical activity, clinical, or diet quality data.  Women 
not using HT at baseline were more likely to be African American, had lower reported leisure 
physical activity levels, and higher baseline total cholesterol, LDL-C, insulin, and glucose levels 
when compared to women who were HT users at baseline (p<0.05).   
The 231 women included in the present analyses had a mean age of 58.3 (2.9 years).  The 
mean BMI was 28.5 (4.3) kg/m2 and average WC was 98.4 (11.9) cm.  Additionally, 98.7% had 
at least a high school degree, 6.9% were African American, and 4.8% were current smokers.  
One hundred and six (106; 46%) of the 231 women were HT continuers and the remaining 125 
(54%) women were HT discontinuers at 18 months.  Of the HT discontinuers, 61% had HT 
discontinued prior to the 6 month follow-up visit.  There were no significant differences between 
HT continuers and HT discontinuers with regards to education, race, or smoking status (data not 
shown).   
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 Table 5.1 describes and compares CVD risk factor levels between HT continuers vs. HT 
discontinuers at baseline.  Women in the HT continuer group were significantly (p<0.05) 
younger than women who discontinued HT.  However, the two HT groups did not significantly 
differ in anthropometric and clinical measures, leisure physical activity, saturated fat/cholesterol 
intake, lipid, or glucose levels.  One notable exception was that women who continued HT at 18 
months had lower baseline insulin levels when compared to HT discontinuers.   
The lifestyle intervention was successful and had a positive impact on many CVD risk 
factors among both HT continuers and HT discontinuers (Table 5.2).  More specifically, when 
compared to the HE group, the LC group significantly decreased weight, BMI, average WC, and 
saturated fat and cholesterol intake and increased leisure physical activity levels (significant in 
HT discontinuers only).  With regards to CVD risk factor change, women in the LC group had 
improved insulin (significant in HT continuers only), triglyceride and glucose levels (significant 
in HT discontinuers only) when compared to the HE group.   There were no significant 
differences at 18 months between randomized groups with regards to changes in HDL-C, systolic 
and diastolic blood pressure levels in either HT continuers or HT discontinuers.   
In contrast, there was marked differences by randomized group assignment between HT 
continuers and HT discontinuers with regards to two key CVD risk factors; total cholesterol and 
LDL-C (Figure 5.1).  When comparing total cholesterol and LDL-C change within the HE arm, 
women who had discontinued HT use had significantly higher increases in these two measures as 
compared to HT continuers [total cholesterol: 21.4 vs. 3.5 mg/dL (p = 0.0063) and LDL-C: 21.7 
vs. 4.0 mg/dL (p = 0.0017)].  The significant differences in total and LDL cholesterol change 
between HT continuers and HT discontinuers were not replicated in the LC arm [total 
cholesterol: 5.8 vs. 4.7 mg/dL (p = 0.8225) and LDL-C: 6.1 vs. 7.4 mg/dL (p = 0.7572)].  There 
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 were no other differences between HT groups with regards to CVD risk factor change in either 
the HE or LC group. 
Since it appeared that lifestyle intervention had a major impact on CVD risk factors in 
postmenopausal women, post-hoc analysis was performed to begin to examine the role of the 
specific components of the lifestyle intervention on risk factor reduction.  Specifically, the effect 
of leisure physical activity and diet on CVD risk factor reduction was examined in the entire 
cohort (Table 5.3).  After adjustment for HT use at the 18 month clinic visit, baseline leisure 
physical activity, saturated fat and cholesterol intake, and relevant CVD risk factor level (i.e. 
adjustment for baseline HDL-C when exploring HDL-C change), an increase in leisure physical 
activity was significantly related (p<0.05) to decreases in triglyceride levels and increases in 
HDL-C levels as well as decreases in LDL-C and glucose levels (p<0.10).  With regards to 
dietary behavior, an improvement in saturated fat and cholesterol intake was significantly related 
to decreases in total cholesterol, LDL-C, triglyceride, insulin, and glucose levels (p<0.05).   
5.5 DISCUSSION 
The present investigation explored the effect of lifestyle intervention on CVD risk factors in 
postmenopausal women that were on HT at baseline and either continued or discontinued use 
after 18 months of study participation.  Prior to the WOMAN study, the beneficial effect of a 
lifestyle intervention for CVD risk factor reduction had not been examined in women who had 
recently discontinued HT.  When considering the current controversies regarding HT use, the 
findings from the present report are timely.   
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 Regardless of HT status at 18 months, women randomized to the LC group increased 
leisure physical activity levels, improved saturated fat and cholesterol intake and glucose levels, 
and decreased weight, BMI, WC, insulin and triglyceride levels when compared to the HE group.  
The overall success of the WOMAN study lifestyle intervention was in line with the findings 
from previous reports suggesting the efficacy of lifestyle based approaches for risk factor 
reduction and chronic disease prevention in populations at risk for diabetes (18-21) and heart 
disease (22).  Specifically in older women, lifestyle intervention was demonstrated to prevent 
weight gain (23) and to determine a rise in LDL-C levels (24) during the menopausal transition.   
However, previous reports did not account for concurrent changes in HT status, an issue 
which has become particularly relevant in the post-WHI era.  The WOMAN study provided the 
unique opportunity to examine the effect of a lifestyle intervention on CVD risk factor reduction 
by change in HT status.  Based on findings from previous investigations, it was assumed that HT 
discontinuation would result in unfavorable changes to CVD risk factors (9).  As predicted, the 
WOMAN study documented that HT discontinuation at 18 months resulted in increases in total 
cholesterol and LDL-C levels in the HE group.  In contrast, in the LC group, there were no 
observed differences between HT groups with regards to these particular lipids.  These findings 
suggest that a lifestyle intervention, consisting of physical activity, dietary behavior 
modification, and weight loss can successfully attenuate unfavorable changes to CVD risk 
factors that result from HT discontinuation.  These results have important public health 
implications and suggest that a non-pharmacological approach is both a safe and effective 
strategy for CVD risk factor reduction in postmenopausal women, especially for women that 
discontinued HT use.   
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 The WOMAN study was not designed to determine the independent contribution of the 
specific intervention components on CVD risk factors.  However, post-hoc analyses were 
conducted to begin to examine the role of the specific components of the lifestyle intervention 
for CVD risk factor reduction.  Increases in leisure physical activity were independently related 
to increases in HDL-C and decreases in triglyceride levels.  Likewise, improved saturated fat and 
cholesterol intake was independently related to decreases in total cholesterol, LDL-C, 
triglyceride, insulin, and glucose levels.  The independent contribution of physical activity and 
diet on these particular lipid measures was similar in both HT continuers and discontinuers.   
CVD continues to be the leading cause of morbidity and mortality among women in 
westernized countries (1).  However, CVD in women has been underappreciated by the public 
(25) and under treated by health care providers (24, 27).  Recent public health campaigns, such 
as the American Heart Association’s “Go Red for Women” campaign (28) have raised public 
health awareness of the disease.  However, concern and confusion about the risks associated with 
HT has left women and their heath care providers searching for safe and effective means to 
reduce CVD risk factors.   
In this era of uncertainty, one potential consequence of diminished HT use for CVD risk 
factor reduction is increased use of supplementary pharmacological agents, such as statins and 
aspirin; however, both are associated with side effects (29, 30).  In addition, trial data suggests 
that aspirin does not protect women from CVD in a similar fashion to men (31).  Furthermore, 
the majority of statin research to date has been conducted in men (32, 33).  However, based on 
the promising findings of the current investigation, special attention should be paid to 
encouraging efficacious lifestyle strategies that are likely to impart more benefit and less risk 
than drug therapies.   
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 When interpreting the findings from the present investigation, a number of limitations 
need to be considered.  The present analyses utilized self-reported estimates of leisure physical 
activity levels and dietary intake which may be subject to recall bias.  Also, since this was a 
behavioral intervention, there may have been a differential reporting bias with the intervention 
group reporting what they should be doing rather than what they are doing.  However, it should 
be noted that the leisure physical activity estimates obtained via the MAQ were validated with 
pedometer step counts in the WOMAN study population.  In addition, WOMAN study 
participants were not randomized to continue or discontinue HT use at 18 months, which may 
influence the findings of the current report.  In addition, the duration of prior HT usage and/or 
time since discontinuation were not considered in these analyses.  Finally, for the purposes of 
this report, saturated fat and cholesterol intake was used as general measure of diet composition.  
Therefore, future work is needed to investigate the overall contribution of diet on CVD risk 
factor reduction.     
In conclusion, little data has been available regarding the widespread impact of the WHI 
results on CVD risk factor change in postmenopausal women.  The current report confirmed 
previous findings suggesting that a lifestyle based approach is effective for general CVD risk 
factor reduction.  In addition, lifestyle interventions incorporating physical activity and dietary 
modification can successfully attenuate negative changes to lipids that result from HT 
discontinuation.  More research and improved delivery systems are needed to facilitate 
dissemination and maintenance of healthy lifestyle programs in postmenopausal women.  
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 Table 5-1: Baseline Cardiovascular Disease Risk Factor Levels between HT Continuers and HT 
Discontinuers 
 HT Continuers 
(n=106) 
HT Discontinuers 
(n=125) 
P value 
Age, years 57.9 (2.8) 58.7 (2.9) 0.04 
Weight, lbs. 178.2 (24.7) 180.4 (25.3) 0.51 
Body Mass Index, 
kg/m2
30.4 (3.5) 30.8 (3.8) 0.41 
Waist 
Circumference, cm 
105.5 (10.1) 107.1 (11.2) 0.27 
Leisure Physical 
Activity, MET hr-
wk 
13.6 (6.7, 20.6) 10.9 (4.9, 20.2) 0.11 
Saturated 
Fat/Cholesterol 
Intake Index 
62.1 (12.5) 60.8 (12.7) 0.42 
Systolic Blood 
Pressure, mmHg 
124.7 (13.6) 122.8 (13.3) 0.28 
Diastolic Blood 
Pressure, mmHg 
76.4 (9.1) 76.0 (7.8) 0.71 
Total Cholesterol, 
mg/dL 
212.8 (23.7) 207.2 (26.0) 0.09 
LDL Cholesterol, 
mg/dL 
122.4 (21.1) 118.7 (20.8) 0.18 
HDL Cholesterol, 
mg/dL 
62.0 (14.5) 60.8 (13.1) 0.52 
Triglyceride, mg/dL 141.9 (69.0) 137.4 (74.4) 0.64 
Insulin, mg/dL 11.6 (4.6) 13.6 (7.2) 0.02 
Glucose, mg/dL 92.3 (7.7) 94.3 (9.9) 0.10 
Baseline leisure physical activity levels presented as median (25th, 75th percentile); the remaining variables as mean (SD). 
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Table 5-2: 18 Month Change in Cardiovascular Risk Factors by Hormone Therapy Group and Randomized 
Group Assignment (n=231) 
 HT Continuers 
(n=106) 
HT Discontinuers 
(n=125) 
 HE 
(n=45) 
LC 
(n=61) 
P value HE 
(n=57) 
LC 
(n=68) 
P value 
Weight, lbs. -5.3 
(13.2) 
-17.0 
(13.7) 
<0.0001 4.3 (11.8) -18.3 
(17.7) 
<0.0001
Body Mass Index, kg/m2 -0.9 (2.1) -3.0 (2.4) <0.0001 -0.9 (2.1) -3.2 (3.1) <0.0001
Waist Circumference, cm -5.3 (6.4) -10.6 (7.6) 0.0002 -3.8 (6.4) -11.0 (8.5) <0.0001
Leisure Physical Activity, 
MET hr-wk 
0.4 (-6.4, 
9.3) 
3.7 (-2.2, 
12.0) 
0.1955 0.8 (-4.8, 
6.0) 
7.2 (1.2, 
12.7) 
0.0012 
Saturated Fat/Cholesterol 
Intake Index  
8.3 (11.1) 18.4 (14.1) <0.0001 5.2 (8.6) 20.3 
(16.6) 
<0.0001
CVD Risk Factors 
Insulin, mg/dL 1.2 (4.1) -0.5 (4.0) 0.0402 1.1 (8.4) -0.1 (5.1) 0.3461 
Triglyceride, mg/dL -10.0 
(43.8) 
-11.0 
(53.5) 
0.9192 1.6 (50.9) -16.9 
(48.2) 
0.0399 
Glucose, mg/dL 5.2 (7.6) 2.2 (9.6) 0.0778 8.5 (13.0) 3.9 (9.0) 0.0264 
HDL Cholesterol, mg/dL 1.5 (11.6) 1.9 (10.1) 0.8619 -0.3 
(11.2) 
-0.2 (10.9) 0.9389 
Systolic Blood Pressure, 
mmHg 
-1.8 
(18.2) 
-2.7 (14.3) 0.7842 -2.6 
(11.9) 
-3.6 (14.3) 0.6750 
Diastolic Blood Pressure, 
mmHg 
-0.09 
(9.8) 
-0.1 (9.1) 0.9820 -1.0 (7.2) -1.9 (7.9) 0.5217 
Total Cholesterol, mg/dL 3.5 (31.5) 5.8 (25.8) 0.6871 21.4 
(32.9) 
4.7 (30.3) 0.0041 
LDL Cholesterol, mg/dL 4.0 (26.1) 6.1 (22.5) 0.6607 21.7 
(29.4) 
7.4 (25.0) 0.0045 
18 month change in leisure physical activity levels presented as median (25th, 75th percentile); the remaining 18 month change variables as mean 
(SD). 
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Table 5-3: 18 Month Change in Cardiovascular Risk Factors after Adjustment (MLR Models) (n=231) 
 Total 
Cholesterol, 
mg/dL 
LDL 
Cholesterol, 
mg/dL 
HDL 
Cholesterol, 
mg/dL 
Triglycerides, 
mg/dL 
Insulin, 
mg/dL 
 
(n=208) 
Glucose, 
mg/dL 
 
(n=230) 
Hormone 
Therapy Use at 
18 Months 
3.8 ± 3.5 5.8 ± 3.0† -2.1 ± 1.3† 1.4 ± 6.0 1.1 ± 0.7 3.1 ± 1.2** 
? Leisure 
Physical 
Activity (LPA), 
MET hr-wk 
-2.1 ± 2.0 -3.3 ± 1.7† 2.9 ± 0.7**** -9.0 ± 3.5** -0.5 ± 0.4 -1.2 ± 0.7† 
? Saturated 
Fat/Cholesterol 
Intake Score 
-0.7 ± 
0.1**** 
-0.5 ± 
0.1**** 
-0.04 ± 0.05 -0.7 ± 0.2*** -0.1 ± 
0.02**** 
-0.1 ± 
0.04** 
Baseline LPA, 
MET hr-wk 
-0.5 ± 1.1 -1.5 ± 1.0 1.6 ± 0.4**** -1.4 ± 1.9 -0.2 ± 0.2 -0.8 ± 0.4* 
Baseline 
Saturated 
Fat/Cholesterol 
Intake Score 
-0.1 ± 0.1 -0.08 ± 
0.1**** 
-0.07 ± 0.05 0.1 ± 0.2 -0.07 ± 
0.03** 
-0.05 ± 
0.05 
Baseline CVD 
Risk Factor 
Level 
-0.5 ± 
0.07**** 
-0.6 ± 
0.07**** 
-0.3 ± 
0.05**** 
-0.2 ± 
0.04**** 
-0.5 ± 
0.06**** 
-0.5 ± 
0.07**** 
R2 0.317 0.318 0.274 0.212 0.349 0.252 
*All models were adjusted for HT use at 18 months, change (?) in leisure physical activity levels, ? in saturated fat/cholesterol intake score, 
baseline leisure physical activity levels, baseline saturated fat/cholesterol intake score, and baseline levels of relevant CVD risk factor.  †<0.10; 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.   
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Figure 5-1: 18 Month Change in Total Cholesterol and LDL-C by Randomized Group Assignment and HT 
group (**p<0.01) 
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6.1 ABSTRACT 
OBJECTIVE: To examine the association between the long distance corridor walk (LDCW), 
physical activity levels, and measures of subclinical cardiovascular disease (CVD) in order to 
determine the construct validity of the LDCW to estimate health and functional status in middle-
aged, postmenopausal women.  DESIGN: The cross-sectional relationships between walk time 
from the LDCW, physical activity levels, and subclinical CVD measures were examined prior to 
group randomization in 492 [mean age 57.0 (2.9 years)] Caucasian and African-American 
women from the Woman On the Move through Activity and Nutrition (WOMAN) study.  The 
WOMAN study is a randomized clinical trial involving overweight, middle-aged, 
postmenopausal women.  RESULTS: Longer walk times were significantly associated with 
higher BMI (p<0.0001) and WC (p<0.0001) and lower subjective and objective physical activity 
levels (p<0.003).  The proportion of detectable coronary artery calcification (CAC) and median 
aortic pulse wave velocity (aPWV) levels, both subclinical measures of CVD, were significantly 
higher among those with slower walk times (p<0.002 and p<0.001, respectively).  
CONCLUSIONS:  Total walk time from the LDCW was significantly associated with both 
physical activity levels and measures of subclinical CVD.  These findings support the utility of 
the LDCW to monitor patient progress in physical activity programs and/or identify those 
individuals who may warrant additional CVD screening.  
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 6.2 INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of death among women in the United States, 
claiming approximately 500,000 lives each year (1).  A large proportion of deaths attributable to 
CVD occur in women with no prior symptoms (2, 3).  Therefore, the identification of high risk, 
asymptomatic women who may benefit from primary CVD prevention would have important 
public health implications. 
Past epidemiological studies have suggested that exercise capacity and/or cardiovascular 
fitness is an independent predictor of cardiovascular events and death among asymptomatic 
women (3, 4), thereby providing a general indicator of cardiovascular health status (5).  Maximal 
oxygen uptake (VO2 max) is the most accurate assessment technique to evaluate cardiovascular 
fitness and is typically measured using treadmill based protocols (5).  However, VO2 max 
protocols may not be practical in large epidemiological studies due to time constraints, staff 
burden, high equipment costs, and safety concerns (6).  In instances where VO2 max tests are not 
feasible, tests of walking endurance have been substituted for this gold standard measure to 
estimate fitness levels and overall health status (7-9).   
Walking endurance protocols, such as the 6-minute walk test and long distance corridor 
walk (LDCW) were developed, and have been primarily used, in diseased and/or in older 
populations as a crude measure of fitness and health and functional status.  The 6-minute walk 
test has primarily been used to estimate health status in populations with debilitating conditions 
such as chronic obstructive lung disease, heart failure, and left ventricular dysfunction (10-12), 
but has also been used to estimate functional status in older adults (13).  The LDCW is a 
modification of the 6-minute walk test and uses a predetermined distance (400 meters) rather 
than duration (9).  Time based tests of walking endurance evolved into distance based protocols 
  101
 based on the notion that an individual may be more intrinsically motivated to complete a 
predetermined distance in as little time as possible, thus, providing a more maximal effort (9).   
In contrast to the 6 minute walk test which is primarily used in diseased populations, the 
LDCW has been utilized in well-functioning, healthy older individuals with promising results.  
Results from a cross-sectional investigation suggested that walking performance was influenced 
by both clinical and subclinical disease and was strongly related to anthropometric measures and 
self reported physical activity levels (14).  The usefulness of the LDCW to provide a general 
indicator of overall health in older adults was confirmed in the follow-up, longitudinal 
investigation.  Results from this report suggested that exclusion or inability to complete the 
LDCW protocol was associated with an increased risk of mortality, incident CVD, and mobility 
limitation (7).  Furthermore, among those that completed the protocol, each additional minute of 
walk time was associated with a 29% higher rate of mortality, a 20% higher rate of incident 
CVD, and 52% higher rates of mobility limitation and disability (7).  In addition, unlike the 6 
minute walk test, the LDCW has been shown to be a valid estimate of peak VO2 (8) in older 
adults.  These findings suggest that measured parameters from the LDCW, particularly walk 
time, are useful for estimating fitness levels as well as risk of mortality and/or disease among 
older adults.   
It is fairly well established in the literature that the LDCW can be used as a low cost 
alternative for estimating fitness levels, functional status, and future morbidity and/or mortality 
in older individuals; however, little is known regarding the applicability of this test in younger 
populations.  Thus, the primary purpose of the current report was to determine the construct 
validity of walk time from the LDCW against subjective and objective physical activity 
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 assessments and measures of subclinical CVD in order to determine the utility of the LDCW to 
estimate functional status in middle-aged, postmenopausal women. 
6.3 METHODS 
6.3.1 Study Population 
Five hundred and eight postmenopausal women were recruited for the Women On the Move 
through Activity and Nutrition (WOMAN) study, primarily through direct mailing from selected 
zip codes in Allegheny County, Pennsylvania from April 2002 to October 2003.  The (WOMAN) 
study is a five year primary CVD prevention randomized clinical trial, designed to test whether 
an aggressive non-pharmacological lifestyle intervention among postmenopausal women will 
reduce measures of subclinical CVD.  Eligibility criteria for enrollment into the study included 
waist circumference ≥ 80 centimeters (cm), body mass index (BMI) between 25 – 39.9 kilograms 
per meters squared (kg/m2), not currently taking lipid lowering drugs and having a low density 
lipoprotein cholesterol (LDL-C) level between 100 - 160 milligrams per deciliter (mg/dL), no 
physical limitations that would preclude walking, no known diabetes, and no diagnosed 
psychotic disorder or depression.  All participants provided written informed consent and all 
protocols were approved by the institutional review board at the University of Pittsburgh.  
Results were based on data collected prior to randomization at the baseline clinic visit (2002-
2003). 
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 6.3.2 Demographic and Clinical Measures 
Demographic factors and clinical measures were obtained at the baseline clinic visit.  Clinical 
measures included height, body weight, average waist circumference (WC), and a fasting (12 
hour) blood draw.  Body mass index (BMI) was calculated from height and weight measured 
with a stadiometer and calibrated balance beam scale by dividing the participant’s weight in 
kilograms by the square of her height in meters.  Average WC was measured at the navel 
(horizontal plane at the center of the navel) using a fiberglass retractable tape measure.  Total 
cholesterol, HDL-C, triglycerides, and glucose were determined by conventional methods.  LDL-
C was estimated by the Friedewald equation and insulin was measured via radioimmunoassay. 
 
6.3.3 Long Distance Corridor Walk 
The LDCW was a 400 meter course which consisted of 10 laps along a hallway with cones set 20 
meters apart (40 meters per lap).  Participants were instructed to walk “at a pace that you can 
maintain for the full 10 laps.”  Standard encouragement by trained staff was given at each lap.  
Heart rate was monitored with a Polar Pacer heart monitor (Model 60905; Woodbury, NY).  
Persons with elevated blood pressure (BP ≥200/110) or resting heart rate (>110 or <40) or 
reporting exacerbation of chest pain, shortness of breath, or cardiac event or procedure within the 
past three months were excluded for safety reasons.  The LDCW was stopped if the participant’s 
heart rate exceeded 135 beats per minute (bpm) or if a participant reported chest pain or dyspnea 
during the test.  Heart rate (HR) was recorded at rest before starting the walk, at completing, and 
at recovery 2 minutes later.  Systolic blood pressure (SBP) was measured while seated prior to 
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 the walk and standing at test completion.  Based on these measures, cardiovascular (CV) 
response variables were generated.  HR and SBP response were calculated by subtracting the 
resting values from those obtained immediately following completion.  HR recovery was 
calculated by subtracting the HR obtained 2 minutes after LDCW completion from the value 
measured at completion.  On average, the entire LDCW protocol takes approximately 8-10 
minutes to administer.  
6.3.4 Physical Activity Measures 
Physical activity levels were assessed using both subjective and objective measurement tools.  
Physical activity was measured subjectively using a past year and past week version of the 
Modifiable Activity Questionnaire (MAQ) and objectively with the pedometer step counter. 
In brief, the interviewer-administered, past year version of the Modifiable Activity 
Questionnaire (MAQ) questionnaire assesses current leisure and occupational activities, as well 
as extreme levels of inactivity due to disability (15).  Physical activity levels were calculated as 
the product of the duration and frequency of each activity (in hours per week), weighted by an 
estimate of the metabolic equivalent (MET) of that activity and summed for all activities 
performed.  Physical activity data were expressed as metabolic equivalent hours per week (MET 
hr-wk).  The MAQ has been shown to be both a reliable (15, 16) and valid (15-17) assessment 
measure.   
Physical activity was also assessed using a past week version of the MAQ.  This 
questionnaire measures participation in leisure activities performed over the past 7 days.  Study 
participants were given the past week MAQ during the eligibility visit and were asked to record 
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 leisure activities for the 7 days prior to their clinic assessment.  Past week leisure physical 
activity levels were calculated similar to that used for the leisure section of the past year MAQ.   
At baseline, objective assessments of physical activity were obtained with the Accusplit 
Eagle AE120 (Accusplit Inc., Pleasanton, CA) pedometer in a subgroup of WOMAN study 
participants (n=170; 33.5%).  The participants were instructed to wear the pedometer clipped to 
their waistband over the dominant hip for one week, and at the end of each day to record the 
number of steps taken in a diary.  At the end of the week the participant returned the activity 
diary to the investigator.  The number of steps recorded in the diary from the pedometer was 
averaged for the week to obtain a seven-day average of the number of steps taken per day. 
 
6.3.5 Subclinical CVD Measures 
Electron beam tomography, with an Imatron C-150 Scanner (Imatron, San Francisco, CA) was 
used to obtain 30-40 contiguous 3-mm-thick images of the heart, as previously described (18).  
Coronary artery calcification (CAC) scores were calculated according to the Agatston method.  
The reproducibility of the electron beam tomographic scans from this laboratory has an interclass 
correlation of 0.99 (18). 
Detailed B-mode images of the right and left common carotid artery (CCA), carotid 
bifurcation, and the first 1.5 cm of the internal carotid artery (ICA) were obtained using a 
Toshiba SSA-270A ultrasound scanner (Toshiba America Inc., New York, New York) equipped 
with a 5-MHz linear array imaging probe.  To measure the average intima-media thickness 
(IMT) of each segment, lines were electronically drawn along 1-cm segments of the lumen-
intima interface and the media-adventitia interface of the near and far walls of the distal CCA 
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 and along the far walls of the carotid bulb and ICA.  The average of these was recorded for each 
location.  The mean of all average readings across the eight locations (four on each side) was 
calculated.   
Stiffness of the aorta was measured using the gold standard, carotid-femoral (or aortic) 
pulse wave velocity (aPWV), as previously described in detail (19, 20). Briefly, for each 
participant, 20 seconds of carotid and femoral pulse waveforms were collected simultaneously 
with non-directional Doppler probes and recorded to data files. Files were “scored’ using 
software developed by the Laboratory of Cardiovascular Science, Gerontology Research Center, 
National Institute on Aging.    For each file, the trained reader selected all clear waveforms for 
averaging into composite carotid and femoral waveforms, to determine the “foot” (or upstroke) 
of each.   The transit time of the pulse wave was calculated as the foot-to-foot delay between the 
averaged carotid and femoral waveforms.  The distance traveled by the pulse waveform between 
the carotid and femoral measurement sites was measured manually with a metal tape measure, 
above the surface of the participant’s torso.  Aortic pulse wave velocity was calculated by 
dividing the distance traveled by the time differential between the two waveforms and was 
expressed as distance/transit time (cm/sec).  Results from all usable data collection runs (n = 3) 
for each participant were averaged. In our lab this measure has been demonstrated to have good 
reproducibility with an intraclass correlation of 0.72-0.83 (19).  
6.3.6 Statistical Methods 
Univariate analyses were conducted on measured parameters from the LDCW, demographics, 
physical activity levels, and measures of subclinical CVD.  Normally distributed variables were 
reported as mean ± standard deviation, non-normally distributed variables were reported as 
  107
 median with 25th and 75th percentile, and proportions were noted for categorical variables.  
Spearman rank order correlation coefficients were used to assess the bivariate associations 
between walk time and CV response measures from the LDCW, demographics, physical activity 
levels, and CVD risk factors.  Partial Spearman rank order correlations were used to further 
examine these relationships adjusted for age, age and BMI, and past year leisure physical activity 
levels.  Descriptive statistics were used to illustrate demographics, physical activity levels, and 
CVD risk factors across quartiles of LDCW time.  Depending upon the characteristics of the 
variable, ANOVA, Kruskal-Wallis, or Chi Square Test of Proportions was used to compare 
demographic factors, physical activity levels, clinical and subclinical CVD measures across 
quartiles of LDCW time in those who completed the 400-meter walk.  Jonckheere-Terpstra tests 
were used estimate the linear trend in continuous variables and Cochran-Armitage Trend test 
were used to determine linear trend for categorical variables.  Due to the high number of planned 
comparisons across quartiles of walk time, a p value of <0.002 will be used to denote statistical 
significance using the Bonferonni correction method.   
6.4 RESULTS 
Of the 508 women, 3 had missing walk time, 1 had an invalid walk time, and 1 woman did not 
complete the 10 laps due to elevated HR.  Of those 503 (99%) women that completed the entire 
protocol, 11 (2%) had incomplete physical activity and/or coronary artery calcium (CAC) data 
and were excluded from the present analyses [8 of the 11 were missing past year leisure physical 
activity, 2 were missing past week leisure physical activity, and 1 woman had a missing CAC 
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 score].  The current report will focus on the remaining 492 WOMAN study participants with 
complete data.  
At baseline, the mean age of the participants was 57.0 (range: 52 - 62.8) years, 11.8% 
were African American, and 59.4% (n = 292) reported taking HT at baseline.  Study participants 
had a mean BMI of 30.8 (range: 23.3 – 41.3) kg/m2 and waist circumference of 106.0 (range: 
80.8 – 138.5) centimeters.  Only 6.1% of women reported being current smokers at baseline.  
With regards to the measured parameters from the LDCW, on average the WOMAN study 
participants completed the walk in 301.2 seconds (approximately 5 minutes).  Mean HR and SBP 
increased from resting by 36.8 bpm and 4.3 mmHg, respectively.  At the end of the 2 minute 
recovery period, HR decreased by 20.4 bpm, which was approximately 55% of the HR response 
(Table 6.1).   
Correlations between walk time and demographics, physical activity levels, CV response 
measures from the LDCW, and CVD risk factors are presented in table 6.2.   Longer walk times 
were significantly (p<0.05) associated with older age and higher BMI and average WC levels.  
Walk time was inversely related to both subjective and objective assessments of physical activity 
levels as well as the CV response (HR and SBP) to the 400 meter walk.  Longer walk times were 
related to higher resting HR and SBP, triglyceride, insulin, glucose, CAC score (continuous) and 
aPWV levels and lower HDL-C levels.  The results were similar when the associations with walk 
time were adjusted for age alone (data not shown).  However, when the results were adjusted for 
age and BMI, higher walk time was no longer significantly correlated with higher resting SBP, 
triglyceride, insulin levels or CAC score nor was walk time related to lower HDL-C levels.  
Adjusting for past year leisure physical activity levels did not substantially change the 
relationship between walk time and CVD risk factors (data not shown).    
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 Table 6.3 describes the characteristics of the study population across quartiles of LDCW 
time.  With regards to demographic factors, mean age, BMI, and WC significantly increased as 
time to complete the 400 meter course increased.  In addition, the proportion of African 
American women was significantly higher in the slower walk time categories.  The relationship 
between current HT use and walk time was not statistically significant.  Regardless of whether 
activity was measured subjectively or objectively, median physical activity levels decreased 
across increasing walk time quartiles.  Finally, relationships between walk time and CVD risk 
factors were investigated.  The SBP and HR response to the LDCW and HR recovery decreased 
as mean walk time increased.  Resting HR and SBP, LDL-C, insulin, and glucose levels 
increased as time to complete the 400 meter walk increased (significant at p<0.002 for resting 
HR, glucose, and insulin only).  With regards to subclinical CVD measures, the proportion of 
detectable CAC (>0) was significantly higher among those with slower walk times.  Median 
aortic PWV levels also significantly increased across increasing walk time quartiles.  The 
association between walk time and IMT levels was not statistically significant.   
 
6.5 DISCUSSION 
In this large cohort of healthy postmenopausal women, 99% of study participants completed the 
LDCW testing protocol without complications.  The high completion rate that was achieved in 
the current investigation confirms previous work suggesting that the LDCW protocol is practical 
to administer in large population studies.  Furthermore, the significant trends that were observed 
between walk time and physical activity levels and measures of subclinical CVD indicate that the 
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 LDCW has important psychometric properties among healthy, middle-aged, postmenopausal 
women. 
In a practical sense, the LDCW protocol may be appealing in primary care settings due to 
the relative cost and time effectiveness, lack of required medical supervision, space and/or 
equipment, and patient familiarity of the activity mode (walking).   Based on the findings from 
the current report, total walk time from the LDCW could be considered both a proxy measure for 
physical activity as well as an objective assessment of physical function and performance.  The 
use of the LDCW protocol in clinical practice may allow health care providers to more 
effectively prescribe physical activity for their patients and/or monitor progress in healthy 
lifestyle based programs.  In addition, when screening for CVD risk factors, poor performance 
during the LDCW could potentially identify those individuals who may warrant follow-up 
(cardiac) testing and evaluation. 
In the current report, total walk time from the LDCW was inversely associated with 
physical activity levels as determined by the pedometer as well as past year and past week 
versions of the MAQ (15).  Unlike past studies that estimated physical activity levels using 
subjective questionnaires, the present investigation also included an objective measure of 
physical activity, the pedometer step counter.  Although subjective physical activity measures 
have been shown to accurately assess higher intensity, structured leisure physical activities, they 
typically do a poor job when measuring lower intensity, unstructured lifestyle physical activities, 
such as household chores, childcare, and housework (15, 21).  In contrast, objective measures 
have the ability to capture both structured and unstructured activities thus providing a complete 
picture of an individual’s total physical activity levels (22).  The decrease in physical activity 
levels that was observed across increasing walk times was similar regardless of the method that 
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 was used to collect activity data (ie. subjective vs. objective assessment).  Finally, when 
comparing the subjective activity assessments (past year vs. past week MAQ), the relationship 
with walk time was stronger with the past year measure as it may reflect more typical activity 
when compared to the past week estimate which may be subject to acute changes in health status.    
When interpreting the findings of the present investigation, a number of limitations need 
to be considered.  Data from only one point in time, the baseline visit, was used in the analyses.  
Although informative, this cross-sectional study analysis is limited in that it does not provide 
information pertaining to the direction of association or allow us to determine how the 
relationship between walking performance, physical activity, and CVD risk factors may change 
over time.  In addition, maximal oxygen uptake (max VO2) was not measured in the current 
investigation; therefore, the usefulness of the LDCW to estimate fitness levels in this population 
cannot be assumed.  Finally, the ability to complete the LDCW and timed performance were 
found to be important prognostic factors for total mortality, CVD, and functional ability in older 
adults (7).  Future work is needed to determine the predictive value of the LDCW for future 
morbidity and mortality in middle-aged, postmenopausal women.     
As we move towards promoting physical activity for primary CVD prevention, quick and 
inexpensive tools are needed in order to ensure safe participation and/or evaluate progress in 
healthy lifestyle based programs.  The evidence from the current report supports the utility of the 
LDCW to estimate the functional status of middle-aged, postmenopausal women.  The 
information obtained during the LDCW protocol may allow health care providers to identify 
those individuals who may necessitate additional CVD screening. 
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 Table 6-1: Baseline Characteristics of the WOMAN Study Cohort (n=492) 
Corridor Walk Variables   
Corridor Walk Time, sec 301.2 (37.5) 
HR at End of LDCW, bpm 107.0 (12.5) 
SBP at End of LDCW, mmHg 128.5 (18.0) 
2 Minute Recovery HR, bpm 86.6 (13.0) 
SBP Response, mmHg 4.3 (13.1) 
HR Response, bpm 36.8 (12.0) 
2 Minute HR Recovery, bpm 20.4 (10.2) 
Demographics  
Age, years 57.0 (2.9) 
BMI, kg/m2 30.8 (3.8) 
Average WC, cm 106.0 (11.3) 
% African American 11.8% 
% HS Education 98.6% 
% Hormone Therapy Use 59.4% 
% Current Smokers 6.1% 
Physical Activity Measures  
Past Year Leisure Activity, MET hr-wk 11.5 (5.2, 20.5) 
Past Week Leisure Activity, MET hr-wk 11.2 (5.3, 19.3) 
Pedometer, steps/day (n=170) 6446.9 (4801.4, 8721.6) 
CVD Risk Factors  
Resting Heart Rate, bpm 70.2 (9.2) 
Systolic Blood Pressure, mmHg 124.2 (16.3) 
Diastolic Blood Pressure, mmHg 76.8 (8.3) 
Total Cholesterol, mg/dL 216.4 (28.1) 
LDL-C, mg/dL 128.0 (25.1) 
HDL-C, mg/dL 60.0 (14.2) 
Triglycerides 142.1 (74.3) 
Insulin, mg/dL (n=432) 13.6 (6.7) 
Glucose, mg/dL (n=486) 95.4 (9.3) 
% Coronary Artery Calcification  
0 
0-10 
11-100 
101+ 
 
49% 
32.1% 
13.6% 
5.3% 
IMT (n=485) 0.71 (0.65, 0.76) 
Pulse Wave Velocity, cm/sec (n=467) 846.2 (737.6, 988.8) 
Normally distributed variables presented as mean (SD); non-normally distributed variables presented as median (25th, 75th percentile). 
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 Table 6-2: Spearman Rank Order Correlations Between Walk Time from the Long Distance Corridor Walk 
(LDCW) and Related Factors 
Walk Time (sec) Unadjusted Adjusted for age 
and BMI 
 Demographics Age, yrs 0.13** -- 
  BMI, kg/m2 0.36**** -- 
  Average WC 0.29**** -- 
 Physical Activity (PA) 
Levels 
Past Year Leisure 
Activity 
-0.23**** -- 
  Past Week Leisure 
Activity 
-0.18**** -- 
  Pedometer Steps 
(n=170) 
-0.25*** -- 
 Cardiovascular 
Response to LDCW 
SBP Response, 
mmHg 
-0.13**** -0.22****
  HR Response, bpm -0.31** -0.38****
  HR Recovery, bpm -0.44**** -0.48****
 CVD Risk Factors Resting Heart Rate, 
bpm 
0.17*** 0.15***
  Systolic Blood 
Pressure (BP), 
mmHg 
0.10* 0.01 
  Diastolic BP, mmHg 0.01 -0.04 
  Total Cholesterol, 
mg/dL 
0.08† 0.06 
  LDL-C, mg/dL 0.08† 0.06 
  HDL-C, mg/dL -0.11** -0.06 
  Triglycerides, 
mg/dL 
0.09* 0.04 
  Insulin, mg/dL 
(n=432) 
0.26**** 0.15**
  Glucose, mg/dL 
(n=486) 
0.13** 0.05 
  CAC 0.16*** 0.01 
  IMT (n=485) 0.04 -0.04 
  Pulse Wave 
Velocity (n=467) 
0.16*** 0.12**
†<0.10; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
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 Table 6-3: Characteristics of Study Participants by Quartiles of Walk Time (n=492). 
 Quartiles of Walk Time (sec)   
 Quartile 1 
(n=120) 
Quartile 2 
(n=123) 
Quartile 3 
(n=124) 
Quartile 4 
(n=125) 
p value p for linear 
trend 
 
Demographics 
Age, yrs 56.6 (2.8) 56.6 (3.0) 57.3 (2.9) 57.3 (2.8) 0.04 0.01 
% African 
American 
7.5 4.1 15.3 20 0.0003 0.0002 
% Hormone 
Therapy users 
43.3 31.7 42.7 44.8 0.14 0.42 
Body Mass Index, 
kg/m2
29.3 (3.3) 30.1 (3.2) 30.7 (3.6) 32.9 (4.1) <0.0001 <0.0001 
Average Waist 
Circumference, cm 
102.4 (10.5) 104.1 (10.0) 106.7 (10.8) 110.5 (12.2) <0.0001 <0.0001 
Physical Activity (PA) 
Past Year Leisure 
PA, MET hr-wk 
15.7 (7.5, 
27.0) 
11.6 (5.5, 
23.2) 
10.6 (4.2, 
17.5) 
8.7 (4.0, 
16.4) 
<0.0001 <0.0001 
Past Week Leisure 
PA, MET hr-wk 
13.3 (7.7, 
22.2) 
11.7 (6.4, 
22.6) 
9.8 (5.0, 
16.7) 
9.9 (3.0, 
15.5) 
0.01 0.0007 
Pedometer, 
steps/day 
7285.2 (5670.7, 
10427.6) 
n=36 
6523.1 (5112.1, 
8686.7) 
n=49 
7132.5 (4864.6, 
8426.4) 
n=42 
5482.3 (4204.3, 
6581.4) 
n=43 
0.02 0.003 
Cardiovascular Response 
Systolic Blood 
Pressure (BP) 
Response, mmHg 
6.4 (13.6) 4.6 (11.7) 4.0 (12.7) 2.5 (14.0) 0.14 0.0041 
Heart Rate 
Response, bpm 
42.6 (12.0) 37.3 (10.5) 34.6 (10.9) 32.9 (12.4) <0.0001 <0.0001 
Heart Rate 
Recovery, bpm 
27.1 (9.6) 21.0 (9.8) 18.2 (8.8) 15.6 (9.0) <0.0001 <0.0001 
CVD Risk Factors 
Heart Rate, bpm 68.1 (9.3) 69.8 (8.3) 71.3 (9.5) 71.6 (9.3) 0.01 0.0005 
Systolic BP, mmHg 122.7 (13.2) 123.8 (13.8) 123.7 (13.5) 126.6 (13.8) 0.14 0.05 
Diastolic BP, 
mmHg 
77.1 (8.0) 76.1 (8.7) 76.7 (7.7) 77.2 (8.8) 0.69 0.76 
Total Cholesterol, 
mg/dL 
213.1 (24.2) 215.5 (26.7) 218.5 (29.4) 218.5 (31.6) 0.36 0.08 
LDL-C, mg/dL 124.3 (21.7) 127.7 (24.3) 129.1 (26.2) 130.9 (27.8) 0.22 0.0510 
HDL-C, mg/dL 60.9 (13.8) 60.1 (13.7) 61.4 (14.5) 57.6 (14.7) 0.15 0.06 
Triglycerides, 
mg/dL 
137.2 (75.5) 140.6 (79.2) 139.9 (72.1) 150.3 (70.3) 0.53 0.07 
Insulin, mg/dL  12.0 (5.6) 11.7 (4.4) 14.4 (7.2) 16.1 (8.0) <0.0001 <0.0001 
Glucose, mg/dL 93.8 (7.6) 94.4 (8.3) 95.7 (9.5) 97.7 (11.0) 0.006 0.002 
% Detectable CAC 40.8 51.2 49.2 62.4 0.0008 0.002 
Intima Medial 
Thickness 
0.70 (0.65, 
0.77) 
n=115 
0.70 (0.65, 
0.77) 
n=123 
0.70 (0.65, 
0.75) 
n=123 
0.72 (0.65, 
0.78) 
n=124 
0.62 0.48 
Pulse Wave 
Velocity (cm/sec) 
834.0 
(726.7, 
958.4) 
n=112 
843.3 (721.7, 
945.0) 
n=119 
824.4 
(731.6, 
981.3) 
n=115 
916.3 
(791.0, 
1087.1) 
n=121 
0.002 0.0009 
Normally distributed variables presented as mean (SD); non-normally distributed variables presented as median (25th, 75th percentile).   
Quartile 1: <267.6 seconds; Quartile 2: ≥ 267.6 to <305.4 seconds; Quartile 3: ≥ 305.4 to <319.2 seconds; Quartile 4: ≥ 319.2 
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 7 DISCUSSION 
Heart disease is the leading cause of death among American women.  Overall, cardiovascular 
disease (CVD) claims the lives of more than ½ million women each year4.  Furthermore, nearly 
2/3 of all CVD related deaths occur in women with no previous symptoms, making early 
detection and diagnosis particularly challenging in this population1, 2.  The present investigation 
focused on non-pharmacological strategies and inexpensive screening measures to facilitate 
effective primary CVD prevention in postmenopausal women.   
7.1 SUMMARY OF FINDINGS 
The findings from the current report confirm previous studies suggesting the overall benefit of 
physical activity, either separately or as part of a lifestyle intervention, on CVD risk factor 
reduction in postmenopausal women.  However, previous investigations examining the beneficial 
role of physical activity and/or lifestyle intervention for primary CVD prevention have not 
adequately accounted for the added influence of HT, which is particularly relevant following the 
publication of the results from the Women’s Health Initiative (WHI) and Heart and 
Estrogen/progestin Replacement Study (HERS).  The WOMAN study provided the unique 
opportunity to examine the separate and combined role of physical activity as part of a lifestyle 
intervention for CVD risk factor reduction by current and varying HT use (paper 1 and 2).  The 
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 utility of the long distance corridor walk (LDCW) to estimate health status and as a crude 
measure of physical fitness was also examined using the WOMAN study cohort (paper 3).  The 
specific findings from each of the three papers included in this report are provided in the 
following sections.  
7.1.1 Paper 1 
The purpose of paper 1 was to clarify the cross-sectional associations between leisure physical 
activity and lipids in postmenopausal women using specific lipoprotein subclass measures.  In 
addition, paper 1 examined how current HT use may influence these relationships.  Results of 
paper 1 suggested that baseline leisure physical activity levels were significantly associated with 
higher levels of HDL-C and large HDL-P, and lower levels of triglycerides, and total and 
medium VLDL-P, regardless of HT use.  However, for several key lipoprotein subclass 
measures, the relationship with physical activity differed by HT use.  After stratification by HT 
use, physical activity was independently related to larger mean HDL and LDL particle size, and 
lower levels of total and small LDL-P among non-HT users, but not among women currently 
taking HT.   
7.1.2 Paper 2 
The primary purpose of paper 2 was to determine the effectiveness of a lifestyle intervention to 
attenuate unfavorable CVD risk factor changes that were hypothesized to occur as result of HT 
discontinuation.  In general, the lifestyle intervention was successful and had a positive impact 
on many CVD risk factors among both HT continuers and HT discontinuers.  When compared to 
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 the HE group, women randomized to the LC group increased leisure physical activity levels and 
improved saturated fat and cholesterol intake.  Women in the intervention also made beneficial 
improvements with regards to a number of important CVD risk factors including weight, WC, 
insulin, glucose, and triglyceride levels.  There were no significant differences at 18 months 
between randomized groups with regards to changes in HDL-C, systolic and diastolic blood 
pressure levels in either HT continuers or HT discontinuers.   
In contrast, there was marked differences by randomized group assignment between HT 
continuers and HT discontinuers with regards to two key CVD risk factors; total cholesterol and 
LDL-C.  When comparing total cholesterol and LDL-C change within the HE arm, women who 
had discontinued HT use had significantly higher increases in these two measures as compared to 
HT continuers.  The significant differences in total and LDL cholesterol change between HT 
continuers and HT discontinuers were not replicated in the LC arm, suggesting that the lifestyle 
intervention successfully attenuated an increase in total cholesterol and LDL-C that likely would 
have occurred with HT discontinuation.   
7.1.3 Paper 3 
The purpose of paper 3 was to determine the utility of the long distance corridor walk (LDCW) 
in postmenopausal women.  More specifically, paper 3 examined the associations between 
measured parameters from the LDCW and related factors such as physical activity subclinical 
CVD levels.  Results from paper 3 suggested that walking performance was related to 
demographics factors such as age and race, anthropometric measures including BMI and WC, 
and physical activity levels.  Walk time was also strongly related to detectable coronary artery 
calcification (CAC) as well as aortic pulse wave velocity (aPWV), both subclinical measures of 
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 CVD, suggesting that the LDCW protocol is a useful, inexpensive measure among 
postmenopausal women using construct validity.   
7.2 PUBLIC HEALTH SIGNIFICANCE AND CLINICAL IMPLICATIONS 
In the post-WHI era, concern and confusion about the risks associated with HT has left women 
and their health care providers searching for safe and effective means to reduce CVD risk 
factors.  There is a growing body of evidence to support that physical activity, and physical 
activity as part of a lifestyle intervention, is important for primary CVD prevention in women.  
However, prior to this report little was known regarding how the relationship between healthy 
lifestyles practices, more specifically physical activity, and CVD risk factors may be influenced 
by current (paper 1) or changing (paper 2) HT use.  Data from the WOMAN study provided the 
unique opportunity to clarify these relationships.  The public health significance and clinical 
implications that are specific to each of the three papers included in this report are provided in 
the following sections. 
7.2.1 Paper 1 
Paper 1 was the first to investigate the associations between lipids, physical activity, and 
hormone therapy (HT) using specific lipoprotein subclasses in postmenopausal women.  The 
findings from paper 1 suggested that leisure physical activity was associated with favorable 
lipoprotein and lipid levels, regardless of HT use.  However, some relationships were found to 
vary by HT.  When the results were stratified by current HT use, physical activity was associated 
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 with key lipoprotein subclasses in HT non-users which have been shown to be related to both 
incident and subclinical CVD.  The results from paper 1 raise the important question as to 
whether the beneficial effect of physical activity on the lipid profile in postmenopausal women is 
similar between HT users and non-users.  As HT is being prescribed less frequently and for 
shorter periods of time, we need to be aware of other strategies to favorably alter the overall lipid 
profile in postmenopausal women. Findings from this report suggested that the promotion of 
physical activity may be a safe and effective alternative to improve lipids and reduce risk of 
CVD in postmenopausal women. 
 
7.2.2 Paper 2 
At 18 months, we were able to examine the effectiveness of a lifestyle intervention for CVD risk 
factor reduction in postmenopausal women who were on HT at baseline and either continued or 
discontinued use.  We were also able to investigate the additional benefit of lifestyle among 
women discontinuing HT (paper 2).  A lifestyle intervention was shown to attenuate increases in 
total and LDL-C levels that resulted from HT discontinuation.  In this era of uncertainty, one 
potential consequence of diminished HT use for CVD risk factor reduction is increased use of 
supplementary pharmacological agents, such as statins and aspirin; however, both are associated 
with side effects183, 184.  In addition, trial data suggests that aspirin does not protect women from 
CVD in a similar fashion to men185.  Furthermore, the majority of statin research to date has been 
conducted in men 186, 187.  Based on the promising findings of paper 2, special attention should be 
paid to encouraging efficacious lifestyle strategies that are likely to convey more benefit and less 
risk than drug therapies.  To date, few data was available regarding the widespread impact of the 
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 WHI results on CVD risk factor change in postmenopausal women.  The findings from the 
current report suggest that a lifestyle based approach is effective for general CVD risk factor 
reduction and can effectively attenuate negative changes to lipids that result from HT 
discontinuation.  
7.2.3 Paper 3 
As we move towards promoting physical activity in the community for primary CVD prevention, 
quick and inexpensive tools are needed to provide objective information regarding general 
functional and/or health status that would otherwise not be captured through subjective means.  
The findings presented in paper 3 supported previous efforts suggesting the practicality of the 
LDCW in large population studies.  The direct relationship that was observed between walk time 
and subclinical CVD measures is particularly important and supports the utility of this measure 
in postmenopausal women.  Based on these promising findings, the parameters measured during 
the LDCW may provide health care providers with additional, necessary information to 
appropriately ascertain CVD risk in apparently healthy, asymptomatic postmenopausal women.    
7.3 LIMITATIONS 
The WOMAN study provided the unique opportunity to investigate the role of lifestyle, 
including physical activity, for CVD risk factor reduction in postmenopausal women by varying 
HT use.  However, several general limitations are applicable to all three papers and need to be 
considered when interpreting the findings from the current report.   
  124
  
1. Hormone Therapy: The WOMAN study participants were not randomized to HT use at 
baseline nor were they randomized to either continue or discontinue HT use at 18 
months.  Thus, the inability to randomize the HT component of the WOMAN study 
may influence the findings of papers 1 and 2.   
2. Study Population: The WOMAN study cohort consisted primarily of healthy, well-
educated, Caucasian women.  Thus, the results from the current investigation may not 
be generalizable to women of lower socio-economic status and/or women representing 
minority populations.   
3. Study Design: The WOMAN study was also not designed to investigate the 
independent contributions of the specific intervention components for CVD risk factor 
reduction.  Therefore, the independent effect of physical activity, diet, and/or weight 
loss on CVD risk factors would be difficult to separate out from the overall effect of the 
lifestyle intervention. 
4. Sample Size: A larger and more diverse study cohort would have provided more 
statistical power to perform more detailed subgroup analyses.   
5. Assessment of Physical Activity: Although both subjective and objective physical 
activity assessments were included in the WOMAN study, the findings from the current 
report were based primarily from leisure physical activity estimates obtained from the 
past year version of the Modifiable Activity Questionnaire (MAQ)144.  Self-reported 
physical activity estimates are subject to response bias which may influence the 
precision in measures of physical activity and related energy expenditure188, 189.  While 
subjective measures accurately assess moderate to higher intensity activities, focusing 
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 solely on higher intensity activities may not be valid among women who may acquire 
the bulk of their physical activity in lower intensity activities144, 190.  Thus, the lack of 
incorporating the objective measure of physical activity (pedometer) into the analyses 
may affect the findings of paper 1 and 2.   
The limitations that are specific to each of the three papers included in this report are provided in 
the following sections: 
7.3.1 Paper 1 
When interpreting the findings from paper 1, a number of limitations need to be considered.  
Data from only one point in time, the baseline visit, was used in the analyses.  Although 
informative, this cross-sectional study analysis is limited in that it does not provide information 
pertaining to the direction of association or allow us to determine how the relationship between 
physical activity and lipoprotein subclasses changes as a woman changes her physical activity 
levels, HT status, or both.  In addition, the results were adjusted for lifestyle factors (age, BMI, 
dietary saturated fat and cholesterol intake) that have been demonstrated to be related to both 
physical activity and lipid and lipoprotein subclass levels.  Finally, women were classified as 
current HT users or non-users; the type, dosage, and/or duration of HT usage were not 
considered in these analyses.   
7.3.2 Paper 2 
The limitations of paper 2 should also be recognized.  Given that this was a behavioral 
intervention, there may be a differential reporting bias with the intervention group reporting what 
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 they should have been doing rather than what they were actually doing.  For the purposes of 
paper 2, women were classified as HT continuers or HT discontinuers at 18 months; therefore, 
the duration of prior HT usage and/or time since discontinuation were not considered in these 
analyses.  Finally, saturated fat and cholesterol intake was used as general measure of diet 
composition; therefore, other diet quality data was not considered in these analyses.   
 
7.3.3 Paper 3 
Paper 3 was a cross-sectional investigation and was; therefore, subject to the same study design 
limitations that were previously described for paper 1.  In addition, VO2 max, the current gold 
standard for assessing cardiovascular fitness, was not measured in this population.  Therefore, 
the validity (convergent) of the LDCW to estimate fitness levels cannot be assumed.  Finally, the 
LDCW was a tool developed to assess fitness levels and physical function in an older population.  
In younger individuals the time taken to complete the 400 meter course may be overestimated 
due to the fact that those walking at higher speeds may need to slow down in order to navigate 
around turns.  In a previous investigation, it was suggested that walk time was not accurate in 
estimating peak VO2  in individuals who walked at speeds of 3.75 mph (<240 seconds) and 
higher172.  However, it should be noted that only two of the 492 (0.4%) women included in the 
present investigation completed the test protocol in less than 240 seconds.  
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 7.4 FUTURE RESEARCH 
The limitations that were identified in the previous section can be used to guide future research 
efforts.  Although the WOMAN study cohort included women representing minority 
populations, 88% of the participants were of Caucasian descent.  In addition, over 98% had 
achieved at least a high school degree, indicating that the cohort was of higher socio-economic 
status.  Therefore, future efforts need to focus on translating the WOMAN lifestyle intervention 
into more diverse community settings with less manpower and a smaller budget.  Future work 
should also examine whether total physical activity levels, including both structured and 
unstructured activities as measured by an objective assessment tool, follows the same trends as 
what was observed in the current report.  An objective measure of physical activity would also 
provide the opportunity to validate the activity estimates that were obtained via subjective 
questionnaires.  Finally, the ability to complete the LDCW and timed performance were found to 
be important prognostic factors for total mortality, CVD, and functional ability in older adults.  
Future work is needed to determine the predictive value of the LDCW for future morbidity and 
mortality in middle-aged, postmenopausal women.   
7.5 CONCLUSION 
In the current report, strategies for primary CVD prevention in postmenopausal women were 
examined.  At baseline, leisure physical activity levels were shown to be beneficially related to 
improved lipid and lipoprotein subclass levels with many of these associations influenced by 
current HT use.  Physical activity, as part of a lifestyle intervention, was also shown to be 
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 effective for general CVD risk factor reduction regardless of HT continuation or discontinuation 
at 18 months.  In addition, the lifestyle based intervention attenuated increases in total and LDL-
C levels that apparently resulted from HT discontinuation.  Finally, findings from the current 
report also suggested that a simple test of walking endurance may provide supplemental 
information when ascertaining CVD risk in women.   
In conclusion, the development of primary CVD prevention strategies to decrease the 
burden from incident CVD in women has important public health implications.  Currently, there 
is much concern and confusion about the risks associated with HT use and discontinuation of 
use.  The findings from the current report suggest that a non-pharmacological, healthy lifestyle 
approach for CVD risk factor reduction is a safe and effective strategy for primary CVD 
prevention in healthy, middle-aged, postmenopausal women.    
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 APPENDIX A: WOMAN STUDY PARTICIPANT INFORMATION FORM 
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 WOMAN Study 
Participant Information  
Please only complete lines where there are changes from last visit. 
ID:_________________       
Date:_____/_____/_____(MM/DD/YY)     
Staff:_______________ 
Name:_______________________________________________________________________________ 
Address:_____________________________________________________________________________ 
 ______________________________________________________________________________ 
Phone #: (Home)_(____)______________________ 
  (Work)_(____)______________________ 
  (Other)_(____)______________________ 
Email:  ___________________________________ 
 
Alternative Contact:___________________________________Phone  (Home): _(____)___________ 
(Preferably somebody who does not live with you) 
Relation to Participant:_________________________________ (Work):  _(____)___________ 
 
Emergency Contact:___________________________________Phone  (Home): _(____)___________ 
Relation to Participant:_________________________________ (Work):  _(____)___________ 
Primary Physician’s Name:______________________________________________________________ 
Address:_____________________________________________________________________________ 
              _____________________________________________________________________________ 
PCP Phone #:_(____)_______________________________ 
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           ID ____________ 
          Date___________ 
The WOMAN on the Move Study 
HEIGHT, WEIGHT, AND WAIST  MEASUREMENTS:  
      
1. Standing Height- Record to nearest half-inch 
 (round up) without shoes:      ____. ____inches 
          ____._____cm 
2. Weight - record to nearest half-pound, (round up) 
 clothed, without shoes:       _____. ____lbs. 
_____._____kg.  
 
WAIST MEASUREMENTS (cm) - Record to nearest (.1) cm 
1st reading_______________           2nd reading_______________ 3rdreading_______________ 
 
If first 2 readings are within 2 cm, average the 2.  If not, do a third measurement and average the 2 
measures within range (2 cm). If even after 3 measures there are no matches, take the average of the 2 
closest measurements. 
 
 
 
3. Average waist circumference _____. ___cm       
 (> 80 cm–eligible)  
 
 
HEART RATE 
4.   Beats in 30 seconds: __________X2 = __________ 
 
 
BLOOD PRESSURE MEASUREMENTS: 
 
Cuff Size: ____ Regular  ____Large    ____Pediatric  _____Thigh 
Arm: _____Left _____Right 
 
 
5. First Reading     __________/___________ 
                                  Systolic         Diastolic 
6.   Second Reading __________/___________ 
       Systolic Diastolic 
7. Average of blood pressure Readings__________/___________ 
       Systolic    Diastolic 
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          ID ______________ 
BLOOD DRAW (12 HOUR FAST) 
8.      When did you last have anything other than water to eat or drink?  _________ a.m./p.m. 
Note:If less than 10 hours from clinic appointment, participant should be rescheduled for the blood draw. 
Time Blood Drawn: __________ a.m./p.m. 
 
 Difficult blood draw?  1. □Yes  2.  □No 
 
 Was blood sample collected? 1.  □Yes 2. □ No, specify reason 
 
 Tubes collected: (T if completed) 
EDTA 10mL:    _______ 
  Serum 15 mL:   _______ 
  Serum 10 mL:   _______ 
  Na Nitrate 5mL:_______ 
 
MEDICATION(S) LIST       Office Use Only 
9.   Over the past 2 weeks have you taken any prescribed medications? # meds ______ 
 1. □Yes     2. □ No 
 
Medication 1:    Medication 2:   Medication 3:  
 
Type _________________          Type _________________ Type_________________                   
      
Date began________mo/yr          Date began________mo/yr Date began________mo/yr 
  
Dose_______________mg          Dose_______________mg  Dose_______________mg 
      
Freq._________________x /day         Freq.________________x /day Freq._______________x /day 
      
Reason___________________          Reason__________________        Reason__________________     
 
 
Medication 4:    Medication 5:   Medication 6:  
 
Type _________________          Type _________________ Type_________________                   
      
Date began________mo/yr          Date began________mo/yr Date began________mo/yr 
  
Dose_______________mg          Dose_______________mg  Dose_______________mg 
      
Freq._________________x /day         Freq.________________x /day Freq._______________x /day 
      
Reason___________________          Reason__________________        Reason__________________     
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 Medication 7:    Medication 8:   Medication 9:  
Type _________________          Type _________________ Type_________________                   
      
Date began________mo/yr          Date began________mo/yr Date began________mo/yr 
  
Dose_______________mg          Dose_______________mg  Dose_______________mg 
      
Freq._________________x /day         Freq.________________x /day Freq._______________x /day 
      
Reason___________________          Reason__________________        Reason__________________     
 
9a. Do you take aspirin (not Tylenol): (0) □ daily 
      (1) □ 1-6 times/week 
      (2) □ less than once/week 
      (3) □ rarely 
      (4) □ never (go to blood results) 
 
9b. When you take aspirin, how many on the average do you take per day?_______per day 
 
9c. How many aspirin have you taken in the last 48 hours  ______aspirin 
        (00 if none) 
HORMONE REPLACEMENT USE 
10.   Are you currently taking hormone therapy?  1.  □ Yes (if yes, proceed to #11)  2.  □ No 
 
10a. If no, what was the date that you stopped taking HRT? _______(MM/YY) (proceed to #13) 
 
11. What are the hormones that you are taking? 
 
Hormone 1: (Please circle one)   Hormone 2: (Please circle one) 
Oral Patch Injection Other   Oral  Patch  Injection Other 
 
Name__________________________  Name_______________________________ 
Date Began_____________(MM/YY)  Date Began__________________(MM/YY) 
Dose________________________mg  Dose_____________________________mg 
Days/Month____________________  Days/Month_________________________ 
Months Taken___________________  Months Taken________________________ 
 
 
Hormone 3: (Please circle one)   Hormone 4: (Please circle one) 
Oral Patch Injection Other   Oral  Patch  Injection Other 
 
Name__________________________  Name_______________________________ 
Date Began_____________(MM/YY)  Date Began__________________(MM/YY) 
Dose________________________mg  Dose_____________________________mg 
Days/Month____________________  Days/Month_________________________ 
Months Taken___________________  Months Taken________________________ 
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 12.   Have you stopped taking your hormones in the past year for more than 1 week? 
    1.  □ Yes        2.  □ No | Go to #14 
            a. If yes, how many occasions did you stop taking your hormones? _____ (Proceed to #14) 
 
13.   What were the primary reasons you stopped taking hormone replacement therapy?  (Check all 
that apply) 
  □ Directed by physician 
  □ Needed second opinion from another doctor 
  □ Felt like I didn’t need it 
  □ Thought the medication was harmful 
  □ The cost of the medication  
  □ Developed a new health problem 
  □ Heard about the Women’s Health Initiative HRT results and decided to stop  
   because of health risks 
  □ Had undesirable side effects (check all that apply below): 
    ___ Weight gain   ___ Depression/mood swings 
    ___ Bleeding    ___ Flu-like symptoms 
    ___ Breast lumps   ___ Headaches 
    ___ Breast tenderness  ___ Other______________ 
  □ Other (please specify)_________________________________________ 
 
14.       Have you experienced any side effects while on HRT?  
  1.  □ Yes      2.  □ No 
 (if yes, „ check all that apply below) 
 
____Weight gain  ____Depression/mood swings 
____Bleeding   ____Flu-like symptoms 
____Breast lumps  ____Headaches 
____Breast tenderness  ____Other_________________ 
 
15. Do you currently smoke? 
1. □ Yes 2. □ No 
 
16. Have you had a mammogram in the last year? 
1. □ Yes 2. □ No      1a.   If yes, Date: _____/_____mo/yr  
If no, explain importance of mammography and where to have them done 
 
17. Have you ever been diagnosed by a physician with cancer? 
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1. □ Yes 2. □ No (If no, proceed to #18) 
       17a.   If yes, Date: _____/_____mo/yr 
 17b.   If yes, which type? 
  □ Breast 
  □ Uterine (Endometrium) 
  □ Ovary 
  □ Other, describe _________  
 
18. Have you had a cardiovascular event since the start of your participation in this study?   
1. □ Yes 2. □ No (If no, questionnaire, go to #19) 
18a.   If yes, which type of event? 
 □  Myocardial infarction; Date:______/______mo/yr 
 □  Stroke; Date:______/______mo/yr 
 □  Venous thrombosis: Date:______/______mo/yr 
 □  Aneurysm, in what location (e.g.,aortic)?__________; Date:_____/____mo/yr 
 □  Other?, describe_________________________; Date:______/______mo/yr 
 
19. Has your doctor ever told you that you have: 
 Arthritis   1. □ Yes 2. □ No 
 Diabetes (Sugar)  1. □ Yes 2. □ No 
 Lung Disease   1. □ Yes 2. □ No 
 Kidney Disease  1. □ Yes 2. □ No 
 Pancreatitis   1. □ Yes 2. □ No 
 Gallstone   1. □ Yes 2. □ No 
 Thyroid Disease  1. □ Yes 2. □ No 
 
20. Have you ever had gastric bypass surgery? 
1. □ Yes 2. □ No   
 If yes; Date:________/________mo/yr 
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                  ID_____________                                   
Corridor Walk 
Exclusion Questions 
Script: “The following tests will assess your physical fitness by having you walk 1/4 mile at a steady pace.  
First I need to ask you a few questions to see if you should try the test.” 
 
a.  Does the participant use a walking aid, such as a cane?   Yes   No 
 
b.  Within the past 3 months, have you had a heart attack?     Yes   No 
 
c.  Within the past 3 months, have you had angioplasty?    Yes   No 
 
d.  Within the past 3 months, have you had heart surgery?   Yes   No 
 
e.  Within the past 3 months, have you had any new or 
     worsening heart pain or angina?      Yes   No 
 
Demonstration   
a.  Attachment for heart rate monitor: 
Script: “This device measures your pulse, or how often your heart beats.” 
 
400-Meter Walk Test Performance 
Script: “You will be walking 10 complete laps around the course, about 1/4 mile.  We would like 
you to walk at a normal pace you can maintain over the 10 laps.  After you complete the 10 laps I will tell 
you to stop, and measure your blood pressure and heart rate.  “STOP” symptoms Script: “Please tell me 
if you fell any chest pain, tightness or pressure in your chest, if you become short of breath or if you feel 
faint, lightheaded or dizzy, or if you feel knee, hip, calf, or back pain.  If you feel any of these symptoms, 
you may slow down or stop.  Do you have any questions?”  (Start walking when I say ‘GO’ and try to 
complete 10 laps at a pace you can maintain.  Ready, go.”) 
 
a.  Baseline heart rate:                                                            ____________bpm 
 
b.  Cross off as each lap is completed:                                   1 2 3 4 5 6 7 8 9 10   
 
c.  Number of laps completed:                                                ___________laps 
 
d.  Did participant complete all 10 laps                                  1. Yes      2.   No 
 
e.  Record time at 400m or at stop:                                        ____:_____.____ 
       (Min:sec.hundreths/sec) 
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ID_______________ 
 
 f.  Did the heart rate exceed 135 bpm at any time   1.   Yes     2.  No 
     during the 400-meter walk? 
 
 g.  Heart rate at 400m or at stop:     _____________bpm 
 
h.  Blood pressure at 400m or at stop:                                      ______/______mmHg 
 
 i.  Heart rate 2 minutes after completion of 400m walk:    _____________bpm 
 
 j.  Did the participant complete the 400-meter walk?    1.   Yes      2.   No  
  Reason walk was incomplete or not done: 
   Excluded based on criteria 
   Refused 
   Heart rate > 135 bpm during 2-minute walk 
   Heart rate < 40 bpm 
   Symptoms reported during walk: 
   Specify reason_________________________ 
   Stopped by technician: 
   Specify reason_________________________ 
   Other:  
   Specify reason_________________________ 
 
While you were walking, did you have any of the following symptoms? 
 
Chest pain?   Yes  No  Don’t Know 
Shortness of breath?  Yes  No  Don’t Know  
Knee pain?   Yes  No  Don’t Know 
Hip pain?   Yes  No  Don’t Know 
Calf pain?   Yes  No  Don’t Know 
Foot pain?   Yes  No  Don’t Know 
Numbness or tingling    
in your legs or feet?  Yes  No  Don’t Know 
Leg cramps?   Yes  No  Don’t Know 
Back pain?   Yes  No  Don’t Know 
Other symptoms*?  Yes  No  Don’t Know 
 *Please specify: _________________________________________________ 
      _________________________________________________ 
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 APPENDIX B: WOMAN STUDY PHLEBOTOMY FORM 
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 WOMAN Phlebotomy/Processing Form  
DATE__________   Phlebotomist ID: _______                             ID: ____________      
PHLEBOTOMY 
Participant Questions: 
1.  Do you bleed or bruise easily? 
 No: ______ Yes: _______  Don’t Know: _________ 
2.  Have you ever been told you have a disorder related to blood clotting or coagulation? 
 No: ______   Yes: _______  Don’t Know: _________ 
3.  Have you ever experienced fainting spells while having blood drawn? 
 No: ______ Yes: _______  Don’t Know: _________ 
4.  Do you have diabetes? 
 No: ______ Yes: _______  Don’t Know: _________ 
5.  Are you fasting? 
 No: ______ Yes: _______  If yes, how long? ________________ 
Was any blood drawn: (circle one) Yes No   Time Drawn: _______________ 
 If no, reason not drawn: _________________________________________________ 
Venipuncture:   
Venipuncture time elapsed: _________________________minutes 
Time elapsed until tourniquet released: ____________________(2 min optimum) 
Quality of venipuncture: C (Clean) T (Traumatic - please specify) 
A.  Vein collapse B. Hematoma  C. Vein Hard to get D. Multiple sticks 
 E. Excessive duration of draw F. Leakage at venipuncture site 
Site of venipuncture: ________________________________________________________ 
Position of participant during blood drawing: supine  sitting 
Blood drawing: 
Blood Volume per Tube:  Fill (?)    Other (specify volume) 
1.  EDTA 10mL  ________________   __________________ 
2.  Serum 15mL   ________________   __________________ 
3.  Serum 10mL   ________________   __________________ 
4.  Na citrate 5mL  ________________   __________________ 
5.  Li Heparin 4mL  ________________   __________________ 
************************************************************************************* 
PROCESSING       Processor ID: ________________ 
Centrifuge after 30 minutes: 
Indicate after centrifugation complete whether plasma is Lipemic (L), Icteric (I), Hemolyzed (H), or clotted (C). 
Tube  (?) *   Suggested Aliquot  Blind 
  Done Lab Number vol(ml)  Tube  dupl. (?)  Comment  
#1 NMR EDTA (  ) L ______  2ml  Cryovial (  )            _________ 
#2 DNA EDTA (  ) S ______  1ml  Cryovial (  )            _________ 
#3 Extra EDTA (  ) S ______  1ml  Cryovial (  )            _________ 
#4 Extra EDTA (  ) S ______  1ml  Cryovial (  )            _________ 
#5 Na citrate (  ) V ______  1ml  Cryovial (  )            _________ 
#6 Na citrate (  ) V ______  1ml  Cryovial (  )            _________ 
#7 Serum (  ) H ______  3ml  Cryovial (  )            _________ 
#8 Serum L(a) (  ) H ______  1ml  Cryovial (  )            _________ 
#9 Serum CRP (  ) V ______  1ml  Cryovial (  )            _________ 
#10 Serum IL-6 (  ) V ______  1ml  Cryovial (  )            _________ 
#11 Serum Est. Met.(  ) I ______  1ml  Cryovial (  )            _________ 
#12 Serum TSH (  ) I ______  1ml  Cryovial (  )            _________ 
#13 Extra Serum(  ) S ______  1ml  Cryovial (  )            _________ 
#14 Extra Serum(  ) S ______  1ml  Cryovial (  )            _________ 
*L=Lipomed           V=University of Vermont               H=Heinz Lab  S=Storage 
                                                                             CBAL Use Only 
Received Date: _________________        Time: __________________         Frozen: _____________  
Comment: _________________________________________________________________________ 
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 APPENDIX C: WOMAN STUDY PHYSICAL ACTIVITY MEASURES 
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 THE MODIFIABLE ACTIVITY QUESTIONNAIRE (MAQ) 
 
1. Please circle all activities listed below that you have done more than 10 times in the past year 
from _________________________ to _________________________. 
 
1  Jogging (outdoor, treadmill) 14 Football/Socer 27 Stair Master 
2  Swimming (laps, snorkeling) 15 Raquetball/Squash 28 Fencing 
3  Bicycling (indoor, outdoor) 16 Horseback Riding 29 Hiking 
4  Softball/Baseball 17 Hunting 30 Tennis 
5  Volleyball 18 Fishing 31 Golf 
6  Bowling 19 Aerobic Dance/Step Aerobic 32 Canoeing/Rowing Kayaking 
7  Basketball 20 Water Aerobics 33 Water Skiing 
8  Skating (roller, ice, blading) 21 Dancing (square, line, ballroom) 34 Jumping Rope 
9  Martial Arts (karate, judo, kendo) 22 Gardening or Yardwork 35 Snow Skiing (x-country) 
10 Tai Chi 23 Badminton 36 Snow Skiing (downhill) 
11 Calisthenics/Toning Exercises 24 Strength/Weight Training 37 Snow Shoeing 
12 Wood Chopping 25 Rock Climbing 38 Yoga 
13 Elliptical Trainer 26 Scuba Diving 39 Other 
40 Walking for Exercise (outdoor, indoor at a mall or fitness center, treadmill) 
 
List each activity that you circled in the “activity” box below, check the months that you did each activity over the past year and then estimate the 
average amount of time spent in that activity.  If participant did not participate in any activities, please check the box below marked none.  
None ? 
ACTIVITY 
A
ct
iv
ity
  #
 
JA
N
 
FE
B
 
M
A
R
 
A
PR
 
M
A
Y
 
JU
N
 
JU
L 
A
U
G
 
SE
PT
 
O
C
T 
N
O
V
 
D
EC
 
Average 
# of 
Times 
per 
Month 
Average 
# of 
Months 
Each 
Time 
                
                
                
                
                
                
                
                
                
                
                
2. Excluding time at work, in general how many HOURS per DAY do you usually spend 
watching television or walking on the computer? ________ hours 
 
3. Over this past year, have you spent more than one week confined to a bed or chair as a result 
of an injury, illness, or surgery? Yes _______  No _______ 
 If yes, how many weeks over the past year were you confined to a  
bed or chair? _______ weeks 
 
4. Do you have difficulty doing any of the following activities? 
 a. getting in or out of a bed or chair?   Yes _______  No _______ 
 b. walking across a small room without resting? Yes _______  No _______ 
c. walking for 10 minutes without resting?  Yes _______  No _______  
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 5. Did you ever compete in an individual or team sport (not including any time spent in sports 
performed during school physical education classes)? Yes _______  No _______ 
 If yes, how many total years did you participate in competitive sports? _______ years 
 
6. Have you had a job for more than one month over the past year, from last _____ to this_____? 
 
List all JOBS that the individual held over the past 12 months for more than one month.        
Account for all 12 months of the past year.  IF unemployed/disabled/homemaker/student during 
all or part of the past 12 months, list as such and probe for job activities of a normal 8 hour day, 
5 day week. 
 
 Out of the total # of “hrs/day” the individual reported working at this “job”, how much of this time was 
usually spent sitting?  Enter this # in “hrs sitting” 
column, then place a check in the category that best 
describes their job activities when they are not sitting.  
Average Job Schedule Hrs. 
spent 
sitting at 
work 
Check the category that best 
describes job activities when not 
sitting 
 
 
 
 
 
 
 
 
 
Job 
Name 
 
 
 
 
 
 
 
 
Job 
Code 
 
 
Walk or 
bicycle 
to/from 
work 
 
 
 
Min/Day 
 
 
 
 
Mos/Yr 
 
 
 
 
Days/Wk 
 
 
 
 
Hrs/Day 
 
 
 
Hrs 
Sitting 
 
 
 
 
A 
 
 
 
 
B 
 
 
 
 
C 
          
          
          
          
 
 
Category A 
(Includes all sitting activities) 
Category B 
(Includes most indoor activities) 
Category C 
(heavy industrial work, outdoor 
construction, farming) 
Sitting Carrying light loads Carrying moderate to heavy loads 
Standing still w/o heavy lifting Continuous walking Heavy construction 
Light cleaning Heavy cleaning Farming 
Driving a bus, taxi, tractor Gardening Digging ditches, shoveling 
Jewelry making/weaving Painting/Plastering Chopping (ax), sawing wood 
General Office Work Plumbing/Welding Tree/pole climbing 
Occasional/short distance walking Sheep Herding Water/Coal/Wood Hauling 
 
 
JOB CODES 
Not employed outside of the home: Employed (or volunteer): 
1. Student 6. Armed Services 
2. Home Maker 7. Office Worker 
3. Retired 8. Non-Office Worker 
4. Disabled  
5. Unemployed  
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Seven Day 
Physical Activity Diary 
ID______________________ 
 
Dates Recorded 
_____ / _____ / _____  to 
_____ / _____ / _____ 
 
Phone  (____)______________ 
Reviewer Initials __________ 
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Directions 
 
Please complete your log the week following your 
clinic visit.  This log consists of two parts 1). the 
pedometer and 2). activity diary.  We are asking you to 
wear the pedometer and record your activities every 
day for a full seven-day period.  For each of the seven 
days, please check the day of the week (ex. Monday) 
and write in the date.  Each of the seven days is to be 
recorded on a separate sheet. 
 
 
Pedometer Instructions: The monitor is to be clipped 
snuggly to your clothes or on a belt at the waist.  First 
thing every morning, just before you put on the 
monitor, push the reset button and make sure the 
monitor reads “zero”.    Record the time you put on the 
monitor in your activity log and circle am or pm.  Keep 
the monitor on all day, except when swimming or 
bathing.  Remove the monitor at night just before 
bedtime and record the number of steps per day along 
with the time that it was removed in the activity log 
and circle am or pm.  Please repeat these steps for the 
next seven days. 
 
 
Activity Diary Instructions: Only include activities or 
exercises you do for 10 minutes or longer*.  Please 
include only  the time that you are actually active.  
Examples of physical activity includes brisk walking, 
gardening or yardwork, aerobics, swimming,  
stairclimbing,  dancing,  golf,  weight training, etc.  List 
each activity that you did during the day as well as the 
amount of time you spent doing that particular 
activity. 
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Day 1: c c c c c c c 
                    Sunday           Monday          Tuesday         Wednesday       Thursday          Friday                Saturday 
 
Date: _ _
           (month)             (day)                (year) 
_ __ /__ __ / __ _   
 
Time you put the monitor on in the morning: __ __ : __ __ am or pm 
 
Time you took the monitor off in the evening: __ __ : __ __ am or pm 
 
The number of steps taken today from the pedometer: ________________ 
 
Did you remove the monitor for longer than 30 minutes for any 
reason today such as bathing, swimming, or water aerobics?  If 
YES, please fill in the time that the monitor was taken off and 
the time it was put back on.   
Activity YES NO 
 
 
 
 
 
 
 
Time 
Monitor 
Removed 
Time 
Monitor 
Put Back 
On 
Bathing ? ? __ __ : __ __ 
am or pm 
__ __ : __ 
__ 
am or pm 
Swimming/Water 
Aerobics 
? ? __ __ : __ __ 
am or pm 
__ __ : __ 
__ 
am or pm 
 
Leisure Physical Activity Done Today for 10 minutes or more  
       
Activity/Exercise        Total Minutes/                 Activity  
                                       Day                              Code 
 
WALKING   ________  ________ 
 
2.  ___________________ ________  ________ 
 
3.  ___________________ ________  ________ 
 
4. ___________________ ________  ________ 
 
5. ___________________ ________  ________ 
 
6. ___________________ ________  ________ 
 
*NOTE: This form is replicated for an additional 6 days to obtain 7 days of 
pedometer step counts and reported leisure physical activity levels.   
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 APPENDIX D: WOMAN STUDY DIETARY MEASURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  147
 CONNOR DIET HABIT SURVEY 
 
Meat, Fish, and Poultry 
Consider your eating habits during the last month.  
For each question, circle all numbers that apply. 
 
1. Which type of ground meat do you usually eat? 
1. Regular hamburger (30% fat) 
2. “Lean” ground beef (25-27% fat) 
3. Ground chuck (20% fat) 
4. Ground round or ground sirloin, other than Giant Eagle’s ground sirloin, ground turkey (15% fat) 
5. “Extra lean”, “Ultra lean” or “93/7” (4-10% fat), Giant Eagle’s ground sirloin (7-10% fat), ground 
turkey breast, ground chicken breast 
6. Eat no ground meat 
 
2. Which best describes your typical lunch? “Lunch meat” means ham, bologna, salami, 
pastrami, etc. 
1. Cheeseburger, pizza, typical cheeses, egg dishes (egg salad, quiche, frittata, etc.) 
2. Sandwich (regular lunch meat, hamburger, grilled cheese), meat/fried chicken entrée, regular hot 
dog 
3. Skip lunch or sandwich (tuna, fish, peanut butter, chicken or turkey lunch meat/light mayo, etc), 
turkey hot dog, vegetarian dishes 
4. Tuna sandwich (w/mayo: 1 gm fat or less/Tbsp), veggie burger (e.g. Harvest, Garden, Boca), 
entrée (fish [not fried], small bits of chicken or meat), low-fat yogurt 
5. Salad (low cal dressing), low-fat vegetarian dishes, low fat or fat-free hot dog (0-2 gm fat), deli 
meats/fat free sandwich (w/mayo: 1 gm fat or less/Tbsp), bagel (light cream cheese) 
6. Fat free vegetarian dishes, salad (fat free dressing), veggie dog, garden vegan (fat free soy burger), 
nonfat yogurt, dry cereal (skim milk), bagel (fat free cream cheese) 
 
3. Circle all of the choices that reflect your entrée at your main meal. 
1. Cheese (cheddar, jack, etc.), eggs, organ meats (liver, etc), pizza, regular (not low fat) vegetarian 
dishes once a week or more. 
2. Beef, lamb, pork, or ham once a week or more 
3. Very lean red meat (top round or flank steak), rabbit, veal, or venison once a week or more 
4. Chicken, turkey, crab, lobster or shrimp twice a week or more 
5. Fish, scallops, oysters, clams, low-fat vegetarian dishes twice a week or more 
6. Fat free vegetarian dishes, fat free seafood dishes every day 
 
4. Estimate the number of ounces of meat, cheese, fish and poultry you eat in a typical day.  
Include all meals and snacks. 
To guide you in your estimate (a piece the size of a deck of cards = 3 oz) 
1 hot dog = 1 ½ oz  1 chicken thigh = 2-3 oz  1 slice cheese = 1 oz 
4 strips of bacon = 1 oz  ½ chicken breast = 3 oz  1-inch cute cheese = 1 oz 
1 sm. burger patty = 3-4 oz average T-bone steak = 8 oz most sandwich meat = 2-3 oz 
1. eleven or more ounces a day 
2. nine to 10 ounces a day 
3. six to 8 ounces a day 
4. four to 5 ounces a day 
5. up to 1 ounce cheese or 3 oz lean meat, poultry, shrimp, crab, lobster or 6 oz fish, clams, oysters, 
scallops a day 
6. none or up to 3 oz shrimp, crab, lobster or 6 oz fish, clams, oysters, scallops a day 
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 5. Which of these have you eaten in the past month? 
1. bacon, sausage 
2. Canadian bacon, turkey, or chicken sausage 
4. vegetarian sausage (e.g. Morningstar links or patties, other soy sausage) 
6.   none 
 
 
Dairy Products and Eggs 
Consider your eating habits during the last month.  
For each question, circle all numbers that apply 
 
6. Which do you usually use for drinking (don’t forget lattes/mochas) or cooking?  (most 
lattes/mochas contain whole milk unless you request otherwise). 
1. whole milk 
2. two percent milk 
4. one percent milk, buttermilk, nondairy beverages (edensoy, rice dream, etc) 
5. none or skim (non-fat) milk, light nondairy beverages (edensoy light, rice dream light, etc) 
 
7. Which toppings do you use? 
1. sour cream (real or imitation), whipped cream 
2. ligh/lowfat sour cream, cool whip, redid-whip aerosol dairy topping 
3. cool whip light, regular cottage cheese, whole milk yogurt 
4. low fat yogurt, 2% lowfat cottage cheese, reddi-whip aerosol nondairy 
5. 1% fat cottage cheese, cool whip free, soy yogurt 
6. none or nonfat sour cream, nonfat yogurt, nonfat cottage cheese 
 
8. Which frozen desserts are you most likely to eat at least once a month? 
1. ice cream (5 to 18 g fat per ½ cup) 
2. light ice cream (4 g fat per ½ cup) 
3. ice milk, most soft ice cream, frozen yogurt (cream added), tofutti 
4. sherbet, lowfat frozen yogurt, soy delicious 
5. none or nonfat frozen yogurt, sorbets, popsicles 
 
9. Which kind of cheese do you use? 
2. cheddar, swiss, jack, brie, feta, montrachet, blue, jarisbert, whole milk mozzarella, Neufchatel or 
regular cream cheese, processed cheese (velveeta, American, cheese whiz), kraft deluxe slices, 
parmesan 
6. part skim mozzarella, light cream cheese, light cheddar, light jack, (kraft light naturals, alpine 
lace-lo, velveeta light, or other part-skim cheeses), string cheese 
8. jarlsberg light, athenos reduced fat feta cheese, 2% milk processed cheese slices 
10.  light part skim mozzarella, low fat and light ricotta, lite line, nonfat parmesan, soy/rice cheese 
(cheddar, mozzarella) 
12. none or fat free cheeses (cheddar, jack, ricotta, cream cheese, healthy choice, alpine lace, etc), 
soy(tofu rella) 
 
10. Circle the type and number of “visible” eggs you eat (scrambled, fried, etc). 
1. six or more whole eggs a week 
2. three to five whole eggs a week 
3. one to two whole eggs a week 
4. one whole egg a month 
5. none or egg whites, egg substitute (nulaid, egg beaters, scramblers, second nature, etc.) 
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 11. Circle the type of eggs usually used in food prepared at home or bought in a grocery 
stores. 
1. whole eggs or mixes containing whole eggs (complete pancake mix, slice and bake cookies, etc) 
3. combination of egg whites, egg substitute and whole eggs 
5. none or egg whites, egg substitute 
 
Fats and Oils 
Consider your eating habits during the last month.  
For each question, circle all numbers that apply 
 
12. Which kinds of fats are used most often to cook your food (vegetables, meats, etc)? 
1. butter, shortening (with animal fat), lard, bacon grease, chicken fat 
2. shortening (with vegetable fat), vegetable oil (cottonseed) 
3. tub or stick margarine (all except those made from canola oil), vegetable oil (soybean, olive) 
4. vegetable oil (sunflower, corn), tub or stick margarine (made from canola oil) 
5. vegetable oil (canola, safflower) 
6. non or use nonstick cooking spray 
 
Margarine brand(s) used most often: 1) ___________________ 2) ________________________ 
 
13. How much of these “added” fats do you eat in a typical day: peanut butter, margarine, 
mayonnaise, or salad dressing (including those made with olive oil)? Do not count fat 
free products. 
Examples of amounts people often use (None: 3 tsp = 1 Tbsp) 
 
1. ten teaspoons or more  on toast: 2 tsp margarine 
2. eight to 9 teaspoons  on salads: 12 tsp (=½ cup) salad dressing 
3. six to 7 teaspoons   on sandwiches: 6 tsp mayonnaise, 2 tsp margarine 
4. four to 5 teaspoons  on potatoes: 3 tsp margarine 
5. three teaspoons   on vegetables: 3 tsp margarine 
6. none    on pasta, rice: 3 tsp margarine or oil or 6 tsp pesto 
 
14. How often do you eat potato chips, corn or tortilla chips, fried chicken, fish sticks, French 
fries, doughnuts, croissants or Danish pastries, or other foods?  Do not count fat free 
products.  
1. two or more times a day 
2. once a day 
3. two to 4 times a week 
4. once a week 
5. less than twice a month 
6. never 
 
15. Which best describes the amount of margarine, butter, peanut butter, mayonnaise or 
cream cheese that you put on bread, muffins, bagels, etc?  Do not count fat free products 
1. average 
2. lightly spread (can see the bread through it) 
4. “scrape” (can barely see the spread) 
5. none 
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 16. Which kind of salad dressings do you use? 
1. real mayonnaise 
2. miracle whip, light mayonnaise (5 gm fat per Tbs), Caesar dressing, thousand island dressing 
3. ranch, French, blue cheese or Roquefort, vinegar and oil, Italian, Russian, low fat mayonnaise 
dressing, miracle whip light dressing and Italian dressings 
4. Ranch dressing (mix and light mayo) 
5. low cal salad dressing, ranch dressing (mix and low fat yogurt), low fat mayonnaise (1 gm fat per 
Tbs) 
6. Use no salad dressing or fat free mayonnaise, miracle whip fat free, fat free salad dressings, ranch 
dressing (mix and nonfat  dairy or yogurt/sour cream, vinegar, lemon juice 
 
Sweets and Snacks 
Consider your eating habits during the last month.  
For each question, circle all numbers that apply 
 
17. How often do you eat desserts or baked goods (sweet rolls, doughnuts, muffins, scones, 
cookies, cakes)? 
1. once a day 
2. five to 6 times a week 
3. three to 4 times a week 
4. two times a week 
5. one time a week or less 
6. never 
 
18. Which of the following desserts or snacks have you eaten in the last month? 
1. croissants, cheesecake, typical cakes with frosting 
2. pies, cookies, cupcakes, muffins, scones, frosted doughnuts 
3. granola bars (nature valley, quaker chewy) 
4. low fat muffins, desserts made using lowfat recipes, lowfat cookies (fig bars, ginger snaps, 
snackwell’s) low fat granola bars (power bar, quaker chewy) 
5. fat free desserts including angel food cake, fat free cookies 
6. never eat baked goods listed above or eat fruit for dessert 
 
19. Which of the following snacks have you eaten in the last month? 
1. chocolate, commercial (movie) popcorn, poppy cock popcorn, caramel corn 
2. nuts, potato chips, corn chips, Doritos chips, microwave popcorn, homemade popcorn with butter, 
cracker jack, French fries, peanut butter, party/snack crackers (ritz) 
4. tortilla chips, baked potato chips, pretzels, light microwave popcorn, lightly buttered popcorn 
(1tsp margarine for 3 cups popcorn), low fat crackers (soda, graham) 
5. baked tortilla chips, homemade popcorn with no fat, fat free soda crackers and other fat free 
crackers 
6. do not eat snacks or eat fruits and vegetables as snacks 
 
Grains, Beans, Fruits and Vegetables 
 
Consider your eating habits during the last month.  For this part of the survey, note that the time frame 
varies for the foods listed; some questions ask you to think about how much per day, others per week. 
 
20. How many pieces of fruit or cups of fruit juice do you consume a day (do not include 
“fruit flavored” drinks) __________ cups or pieces 
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 21. How many cups of vegetables do you eat a day (tossed salad, cooked vegetables, soups, 
casseroles, etc)?  (A typical serving size for tossed salad is 1 to 1 ½ cups) 
__________ cups  
 
22. How many cups of legumes do you eat a week (refried beans, split peas, white beans, 
black beans, black-eyed peas, lentils, chili, etc)? __________ cups  
 
23. How much of the following do you eat a week?  (A typical cereal bowl holds 1 to 2 cups; 
people typically eat 9 to12 cups of popcorn, which is about what is in one full bag of 
microwave popcorn) 
Amounts eaten per week 
 
Cooked cereal    __________ bowls/week 
Ready to eat cereal   __________ bowls/week 
English muffin    __________ number/week 
Hamburger bun    __________ number/week 
Bagel (plain or flavored)   __________ number/week 
Pita or pocket bread   __________ number/week 
Eight inch tortilla    __________ number/week 
Plain popcorn    __________ servings/week  
Fat free or lowfat muffin   __________ muffins/week 
Cornbread     __________ pieces/week 
 
Amounts eaten per week 
 
Bread or toast    __________ slices/week 
Dinner or hard roll   __________ rolls/week 
French/sourdough bread   __________ slices/week 
Four inch pancake   __________ pancakes/week 
Lowfat crackers such as soda, graham __________ servings/week 
Regular sized rice cakes   __________ servings/week 
Mini sized rice cakes   __________ servings/week 
Pretzels (1 cup or 1 large soft)  __________ cups or number/week  
 
24. How much of the following do you eat a week?  Be sure to count these foods when they 
are in a mixed dish (casserole, pierogies, burrito, etc).  This includes breakfast, lunch, and 
dinner. 
 Number of servings eaten per week 
  
Macaroni, spaghetti and other pastas (½ cup/serving)   __________ 
Mashed potato (½ cup/serving)     __________ 
Baked potato (1 medium/serving)     __________ 
Cooked rice, corn, bulger, barley, other grains (½ cup/serving)  __________ 
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 Beverages 
Consider your eating habits during the last month.  
For each question, circle all numbers that apply 
 
25. Which of the following reflects your habits regarding alcohol beverages? 
 
1 drink =   12 ounce beer 
    1 ½ ounces whiskey, gin, rum, etc. 
    4 ounces of wine 
         1 ounce liquor 
 
1. one or more drinks a day 
2. four to 6 drinks a week 
3. three drinks a week 
4. one to 2 drinks a week 
5. one to 3 drinks a month 
6. do not drink alcohol beverages 
 
26. Which of the following reflects your habits regarding soda pop, sweetened selzers, sports 
drinks, fruit punch, etc?  Do not count sugar free (diet drinks) 
 
1 can = 12 ounces 
big gulp = 32 ounces 
1 liter = 33 ounces 
2 liters = 67 ounces 
 
1. more than 48 ounces 
2. 33-48 ounces 
3. 25-32 ounces 
4. 12-24 ounces 
5. none or less than 12 ounces a week 
 
27. How much coffee do you drink?  This includes espressos, lattes, mochas, etc. 
 
Guidelines for Espresso Drinks 
“short”    = 8 – 10 ounces 
small “tall”   = 12 ounces 
medium “grande” = 16 ounces 
large “venti”   = 20 ounces 
 
1. more than 40 ounces (more than 5 cups) a day 
3. 25-40 ounces (4 to 5 cups) a day 
4. 6 – 24 ounces (1 to 3 cups) a day 
5. none or less than 1 cup a day 
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 Salt 
Consider your eating habits during the last month.  
For each question, circle all numbers that apply 
 
28. Which type of salt do you normally use? 
1. regular salt, sea salt, flavoring salts (seasoned, garlic, onion, celery salt, lemon pepper etc), regular 
soy sauce 
3. combination of regular and lite salt 
4. lite salt, lower sodium soy sauce, reduced sodium flavoring salts 
5. none or salt substitute (100% potassium chloride), salt free products (Mrs. Dash, etc) 
 
29. How often do you add salt to your food at the table? 
1. always 
2. frequently 
4. occasionally 
5. never 
 
30. Which type of salt and how much do you use in cooking potatoes, rice, pasta, vegetables, 
meat, casseroles, hot cereals, and soups 
1. regular salt (typical amount) or eat in restaurants 4 or more times a week 
2. regular salt (½ typical amount) or lite salt (typical amount) 
4. lite salt (½ typical amount) 
5. none or salt free products (Mrs. Dash, etc) salt substitute 
 
31. Which type of cereals do you use? 
1. typical dry cereals (sweetened or unsweetened) or cereals cooked with regular salt (typical 
amount) 
3. combination of typical dry cereals and salt-free dry cereals (shredded wheat, puffed wheat, puffed 
rice) or cereals cooked with regular salt (½ typical amount) or lite salt (typical amount) 
5. do not eat cereal or eat salt-free dry cereals (shredded wheat, puffed wheat, puffed rice, ec) or 
cereals cooked without salt. 
 
32. How often do you use typical canned, bottled, or packaged foods such as: 
salsa   salad dressing   boxed noodle entrees 
Picante sauce  soups (chicken broth)  frozen entrees 
BBQ sauce  chili    canned beans 
ketchup  cured meats (lunch meat) canned vegetables 
1. more than 15 times a week or eat in restaurants 4 or more times a week 
2. ten to 14 times a week 
3. six to 9 times a week 
5. five times a week or less 
 
Restaurants and Recipes 
Consider your eating habits during the last month.  
For each question, circle all numbers that apply 
 
33. How often do you eat breakfast at a restaurant or cafeteria (this includes coffee shops)? 
1. more than twice a week 
2. once or twice a week 
3. once a week and you eat low fat (unbuttered toast or English muffin, oatmeal) 
4. less than once a month 
5. never 
  154
 Where do you eat breakfast out most frequently?  
1) ___________________   2) _____________________ 
 
34. How often do you eat lunch at a restaurant or cafeteria or eat “take out”? 
1. daily 
2. five days a week 
3. two to 4 days a week 
4. once a week 
5. less than once a month 
6. never 
 
Where do you eat lunch out most frequently?  
1) _____________________   2) _____________________ 
 
35. How often do you eat dinner at a restaurant or cafeteria or eat “take out”? 
1. more than 3 times a week 
2. two to 3 times a week 
3. once a week 
4. once or twice a month 
5. less than once a month 
6. never 
 
Where do you eat dinner out most frequently?  
1) _____________________   2) _____________________ 
 
36. Check the choices you make when eating in restaurants or cafeterias (you may check 
more than one) 
? Select restaurants that offer low-fat choices and order these choices 
? Order toast, muffins, cereal, pancakes, waffles for breakfast 
? Order soup (not cream), salad or other meatless, cheeseless entrees for lunch 
? Order vegetarian pizzas with half the cheese 
? Avoid cheese, eggs, bacon on salads and avoid potato and macaroni salads 
? Put garbanzo or kidney beans on salad at the salad bar 
? Use a very small amount of salad dressing 
? Order a fish, shellfish, chicken, or lean red meat entrée (but not fried) 
? Use no more than 1 pat of margarine at any meal 
? Order fruit, sorbet, sherbet, frozen yogurt or skip dessert 
 
37. How often do you eat foods made using low fat recipes or cook low fat without recipes? 
1. once a month or less 
2. one to 2 times a week 
3. three to 4 times a week 
4. five to 6 times a week 
5. everyday 
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 Seafood 
Consider your eating habits during the last month.  
For each question, circle all numbers that apply 
 
38. How often do you eat fish?  (tuna, snapper, perch, sole, halibut, cod, salmon, 
shrimp/prawns, crab, lobster, scallops, clams, oysters, sardines, etc) 
1. do not eat fish or eat fish less than once a month 
2. one to 3 times a month 
3. once a week 
4. two times a week 
5. three or more times a week or eat vegetarian with no added fat 
 
39. Which fish (fresh, frozen, or canned) have you eaten in the last month?  
1. ate no fish in the last month 
2. clams, scallops, lobster, crab, perch, cod, sole, snowcrab (surimi) 
3. tuna, halibut, snapper, catfish, shrimp (prawns), squid 
4. salmon (pink, silver, coho, red), trout, steelhead, oysters 
5. salmon (Chinook or king), sardines, herring, mackerel, or eat vegetables with no added fat 
 
Where do you most often buy your fish and seafood? 
1) ________________________________ 2) ________________________________ 
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 Fiber 
Consider your eating habits during the last month.  
For each question, circle only one number 
 
**Please note change in instructions above** 
 
40. How often do you eat Rice Krispies, 
Special K, Grapenuts, and/or Corn Flakes? 
 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
41. How often do you eat Wheaties, Shredded 
Wheat, All Bran, and/or Raisin Bran? 
 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
42. How often do you eat Cheerios, Oatmeal, 
and/or Quaker Oat Flakes? 
 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
43. How often do you eat Oat Bran (cooked) 
 
 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
44. How often do you eat All Bran’s “Bran 
Buds”? 
 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
45. How often do you eat English muffins, 
white bread, white pita, cornbread, and/or 
whole wheat bread? 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
46. How often do you eat Rye and/or 
Pumpernickel bread? 
 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
47. How often do you eat melon, banana, 
blueberries, grapes, nectarines, and/or 
pineapple? 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
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48. How often do you eat prunes, fresh or 
canned peaches, kiwi, apples, mango, and/or 
canned pears? 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
49. How often do you eat dried apricot, fresh 
grapefruit, plums, and/or strawberries? 
 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
50. How often do you eat fresh apricot, orange, 
and/or fresh pears? 
 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
51. How often do you eat cauliflower, bean 
sprouts, corn, cucumber, and/or V- 8 juice? 
 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
52. How often do you eat cabbage, celery, kale, 
turnips, spinach, canned tomato, zucchini, 
and/or snow peas? 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
53. How often do you eat asparagus, carrots, 
green beans, okra, peas, broccoli, and/or sweet 
potatoes? 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
54. How often do you eat Brussel’s sprouts? 
 
 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
55. How often do you eat lentils and/or black-
eyed peas? 
 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
56. How often do you eat chick peas 
(garbanzos), white (Great Northern), lima, 
and/or butter beans? 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
57. How often do you eat broad beans, black, 
navy, and/or kidney beans? 
 
1 Never 
2 Once a week or less 
3 1-2 times a week 
4 3-4 times a week 
5 5-6 times a week 
6 Once a day or more 
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